

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 354 598 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
19.11.2003 Bulletin 2003/47

(51) Int Cl.7: **C12N 15/11, C07K 14/705,  
A61K 38/17, A61K 39/395**

(43) Date of publication A2:  
22.10.2003 Bulletin 2003/43

(21) Application number: **03016020.4**

(22) Date of filing: **07.01.2000**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **07.01.1999 US 226533**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**00902354.0 / 1 141 274**

(71) Applicant: **ZymoGenetics, Inc.**  
**Seattle, WA 98102 (US)**

(72) Inventors:

- **Gross, Jane A.**  
**Seattle, WA 98125 (US)**
- **Xu, Wenfeng**  
**Mukilteo, WA 98275 (US)**
- **Madden, Karen**  
**Seattle, WA 98102 (US)**
- **Yee, David P.**  
**Cambridge, MA 02139 (US)**

(74) Representative: **Schlich, George William et al**  
**Mathys & Squire**  
**European Patent Attorneys,**  
**100 Gray's Inn Road**  
**London WC1X 8AL (GB)**

(54) **Therapeutic uses of BR43X2 soluble receptors**

(57) The invention provides uses of polypeptides of soluble BR43x2 class receptors, and sequences substantially homologous thereto or orthologs thereof, as well as antibodies that bind to BR43x2 class soluble receptors in the manufacture of medicaments for inhibiting ztnf4 activity. The uses of the invention also extend to manufacture of medicaments for treating autoimmune diseases, such as systemic lupus erythematosus, myasthenia gravis, multiple sclerosis and rheumatoid arthritis, amongst others.

TacI	-----	-----	-----	-----	MSGLGRSRRG
BR43X1	-----	-----	-----	-----	-----GRSRRG
BR43X2	-----	-----	-----	-----	MSGLGRSRRG
BCMA	-----	-----	-----	-----	-----
TacI	GRSRVDQEEER	FPOGLWTGVA	MRSCEEEQYM	DPLL-GTQMS	CKTICNHQSQ
BR43X1	GRSRVDQEEER	FPOGLWTGVA	MRSCEEEQYM	DPLL-GTQMS	CKTICNHQSQ
BR43X2	GRSRVDQEEER	-----	-----	-----	-----
BCMA	-----	MLQM	AGDCSQNEYF	DSLL-HACIP	COLRCSSNTP
				<--- 1st cys repeat	-----
TacI	-RTCAAFCRS	L-----SC	RKEQGKFYDH	LL-RD-CISC	ASTCGQHPKQ
BR43X1	-RTCAAFCRS	L-----SC	RKEQGKFYDH	LL-RD-CISC	ASTCGQHPKQ
BR43X2	-----HS	L-----SC	RKEQGKFYDH	LL-RD-CISC	ASTCGQHPKQ
BCMA	PLTCORYCNA	SVTNSVKGTN	ATLWTCGLLS	LIISLAVFVL	MFLLRKISSE
				<--- 2nd cys repeat	-----
TacI	CAYFCENKLR	SPVNLPEELR	RORSGEVENN	SDNSGRYQGL	EHRGSEASPA
BR43X1	CAYFCENKLR	SPVNLPEELR	RORSGEVENN	SDNSGRYQGL	EHRGSEASPA
BR43X2	CAYFCENKLR	SPVNLPEELR	RORSGEVENN	SDNSGRYQGL	EHRGSEASPA
BCMA	PLKDEFKNTG	SGLLGMANID	LEKSRTGDEI	ILPRGLEITYV	EECTCEDCIK
					-----
TacI	LPGLKLSADQ	VALVYSTLGL	CLCAVLCCFL	VAVACFLKKR	GDPCSCQPRS
BR43X1	LPGLKLSADQ	VALVYSTLGL	CLCAVLCCFL	VAVACFLKKR	GDPCSCQPRS
BR43X2	LPGLKLSADQ	VALVYSTLGL	CLCAVLCCFL	VAVACFLKKR	GDPCSCQPRS
BCMA	SKPKYDSQHC	FPLPAMEEGA	TILVTTKTND	YCKSLPAALS	ATEIEKTSISA
				<--- TACI/BR43 TN	-----
TacI	RPROSPAKSS	QDHAMEAGSP	VSTSPPEVET	CSFCFPECRA	PTQESAVTPG
BR43X1	RPROSPAKSS	QDHAMEAGSP	VSTSPPEVET	CSFCFPECRA	PTQESAVTPG
BR43X2	RPROSPAKSS	QDHAMEAGSP	VSTSPPEVET	CSFCFPECRA	PTQESAVTPG
BCMA	R-----	-----	-----	-----	-----
TacI	TPDPTCAGR	GCHTRTTVLQ	PCPHIPDSGL	GIVCVPAQEG	GPGA-----
BR43X1	TPDPTCAGR	GCHTRTTVLQ	PCPHIPDSGL	GIVCVPAQEG	GPGA-----
BR43X2	TPDPTCAGR	GCHTRTTVLQ	PCPHIPDSGL	GIVCVPAQEG	GPGA-----
BCMA	-----	-----	-----	-----	-----

FIGURE 1

BEST AVAILABLE COPY

EP 1 354 598 A3

## Description

## BACKGROUND OF THE INVENTION

**[0001]** Cellular interactions which occur during an immune response are regulated by members of several families of cell surface receptors, including the tumor necrosis factor receptor (TNFR) family. The TNFR family consists of a number of integral membrane glycoprotein receptors many of which, in conjunction with their respective ligands, regulate interactions between different hematopoietic cell lineages (Smith et al., The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation and Death, 76:959-62, 1994; Cosman, Stem Cells 12:440-55, 1994).

**[0002]** One such receptor is TACI, transmembrane activator and CAML-interactor (von Bülow and Bram, Science 228:138-41, 1997 and WIPO Publication WO 98/39361). TACI is a membrane bound receptor having an extracellular domain containing two cysteine-rich pseudo-repeats, a transmembrane domain and a cytoplasmic domain that interacts with CAML (calcium-modulator and cyclophilin ligand), an integral membrane protein located at intracellular vesicles which is a co-inducer of NF-AT activation when overexpressed in Jurkat cells. TACI is associated with B cells and a subset of T cells. von Bülow and Bram (*ibid.*) report that the ligand for TACI is not known.

**[0003]** The polypeptides of the present invention, a TACI isoform having only one cysteine-rich pseudo-repeat (BR43x2), TACI and a related B cell protein, BCMA (Gras et al., Int. Immunol. 17:1093-106, 1995) were found to bind to the TNF ligand, ztnf4, now known as neutrokinine  $\alpha$  (WIPO Publication, WO 98/18921), BLyS (Moore et al., Science, 285:260-3, 1999), BAFF (Schneider et al., J. Exp. Med. 189:1797-56, 1999), TALL-1 (Shu et al., J. Leukoc. Biol. 65: 680-3, 1999) or THANK (Mukhopadhyay et al., J. Biol. Chem. 274:15978-81, 1999). As such, BR43x2, TACI, and BCMA would be useful to regulate the activity of ztnf4 in particular, the activation of B cells.

**[0004]** Towards this end, the present invention provides protein therapeutics for modulating the activity of ztnf4 or other BR43x2, TACI or BCMA ligands, related compositions and methods as well as other uses that should be apparent to those skilled in the art from the teachings herein.

## SUMMARY OF THE INVENTION

**[0005]** Within one aspect the invention provides a method of inhibiting ztnf4 activity in a mammal comprising administering an amount of a compound selected from the group consisting of: comprising administering to said mammal an amount of a compound selected from the group consisting of: a) a polypeptide comprising the extracellular domain of BR43x2; b) a polypeptide comprising the extracellular domain of TACI; c) a polypeptide comprising the extracellular domain of BCMA; d) a polypeptide comprising the sequence of SEQ ID NO:10; e) an antibody or antibody fragment which specifically binds to a polypeptide of SEQ ID NO:2; f) an antibody or antibody fragment which specifically binds to a polypeptide of SEQ ID NO:4; g) an antibody or antibody fragment which specifically binds to a polypeptide of SEQ ID NO:6; h) an antibody or antibody fragment which specifically binds to a polypeptide of SEQ ID NO:8; i) an antibody or antibody fragment which specifically binds to a polypeptide of SEQ ID NO:10; k) a polypeptide of SEQ ID NO:4; l) amino acid residues 1-166 of SEQ ID NO:6; and m) amino acid residues 1-150 of SEQ ID NO:8.

**[0006]** Within one embodiment the compound is a fusion protein consisting of a first portion and a second portion joined by a peptide bond, said first portion comprising a polypeptide selected from the group consisting of: a) a polypeptide comprising the sequence of SEQ ID NO:8; b) a polypeptide comprising amino acid residues 25-58 of SEQ ID NO:2; c) a polypeptide comprising amino acid residues 34-66 of SEQ ID NO:6; d) a polypeptide comprising amino acid residues 71-104 of SEQ ID NO:6; e) a polypeptide comprising amino acid residues 25-104 of SEQ ID NO:6; f) a polypeptide comprising amino acid residues 8-37 of SEQ ID NO:8; g) a polypeptide comprising amino acid residues 41-88 of SEQ ID NO:8; h) a polypeptide comprising amino acid residues 8-88 of SEQ ID NO:8; and said second portion comprising another polypeptide. Within another embodiment the first portion further comprises a polypeptide selected from the group consisting of: a) amino acid residues 59-120 of SEQ ID NO:2; b) amino acid residues 105-166 of SEQ ID NO:6; and c) amino acid residues 89-150 of SEQ ID NO:8. Within another embodiment the first portion is selected from the group consisting of: a) a polypeptide comprising the extracellular domain of BR43x2; b) a polypeptide comprising the extracellular domain of TACI; and c) a polypeptide comprising the extracellular domain of BCMA. Within a related embodiment the first portion is selected from the group consisting of: a) a polypeptide of SEQ ID NO:4; b) amino acid residues 1-154 of SEQ ID NO:6; and c) amino acid residues 1-48 of SEQ ID NO:8. Within another related embodiment the second portion is an immunoglobulin heavy chain constant region.

**[0007]** Within another embodiment the antibody or antibody fragment is selected from the group consisting of: a) polyclonal antibody; b) murine monoclonal antibody; c) humanized antibody derived from b); and d) human monoclonal antibody. Within a related embodiment the antibody fragment is selected from the group consisting of F(ab'), F(ab), Fab', Fab, Fv, scFv, and minimal recognition unit. Within another embodiment the mammal is a primate.

**[0008]** Within another embodiment the ztnf4 activity is associated with B lymphocytes. Within another related embodiment the ztnf4 activity is associated with activated B lymphocytes. Within yet another embodiment the ztnf4 activity

is associated with resting B lymphocytes. Within another embodiment the ztnf4 activity is associated with antibody production. Within a related embodiment the antibody production is associated with an autoimmune disease. Within a related embodiment the said autoimmune disease is systemic lupus erythematosis, myasthenia gravis, multiple sclerosis, or rheumatoid arthritis. Within another embodiment the ztnf4 activity is associated with asthma, bronchitis or emphysema. Within still another embodiment the ztnf4 activity is associated with end stage renal failure. Within yet another embodiment the ztnf4 activity is associated with renal disease. Within a related embodiment the renal disease is glomerulonephritis, vasculitis, nephritis or pyelonephritis. Within yet another embodiment the renal disease is associated with renal neoplasms, multiple myelomas, lymphomas, light chain neuropathy or amyloidosis. Within another embodiment the ztnf4 activity is associated with effector T cells. Within a related embodiment the ztnf4 activity is associated with moderating immune response. Within yet another embodiment the activity is associated with immunosuppression. Within yet another embodiment immunosuppression is associated with graft rejection, graft versus host disease or inflammation. Within another embodiment the activity is associated with autoimmune disease. Within a related embodiment the autoimmune disease is insulin dependent diabetes mellitus or Crohn's Disease. Within another embodiment the ztnf4 activity is associated with inflammation. Within a related embodiment the inflammation is associated with joint pain, swelling, anemia, or septic shock. Within another aspect the invention provides a method for inhibiting BR43x2, TACI or BCMA receptor-ligand engagement comprising administering an amount of a compound as described above. Within another embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with B lymphocytes. Within another related embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with activated B lymphocytes. Within yet another embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with resting B lymphocytes.

**[0009]** Within another embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with antibody production. Within a related embodiment the antibody production is associated with an autoimmune disease. Within a related embodiment the said autoimmune disease is systemic lupus erythematosis, myasthenia gravis, multiple sclerosis, or rheumatoid arthritis. Within another embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with asthma, bronchitis or emphysema. Within still another embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with end stage renal failure. Within yet another embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with renal disease. Within a related embodiment the renal disease is glomerulonephritis, vasculitis, nephritis or pyelonephritis. Within yet another embodiment the renal disease is associated with renal neoplasms, multiple myelomas, lymphomas, light chain neuropathy or amyloidosis. Within another embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with effector T cells. Within a related embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with moderating immune response. Within yet another embodiment the activity is associated with immunosuppression. Within yet another embodiment immunosuppression is associated with graft rejection, graft versus host disease or inflammation. Within another embodiment the activity is associated with autoimmune disease. Within a related embodiment the autoimmune disease is insulin dependent diabetes mellitus or Crohn's Disease. Within another embodiment the BR43x2, TACI or BCMA receptor-ligand engagement is associated with inflammation. Within a related embodiment the inflammation is associated with joint pain, swelling, anemia, or septic shock.

**[0010]** Within another aspect the invention provides an isolated polynucleotide molecule encoding a polypeptide of SEQ ID NO:2. Also provided is an isolated polynucleotide molecule of SEQ ID NO:1. Within a related embodiment is provided an expression vector comprising the following operably linked elements: a transcription promoter; a polynucleotide molecule as described above, and a transcription terminator. Within another embodiment the expression vector further comprises a secretory receptor-ligand engagement sequence operably linked to said polynucleotide molecule. Also provided is a cultured cell into which has been introduced an expression vector as described above, wherein said cultured cell expresses said polypeptide encoded by said polynucleotide segment. The invention further provides a method of producing a polypeptide comprising: culturing a cell into which has been introduced an expression vector as described above; whereby said cell expresses said polypeptide encoded by said polynucleotide molecule; and recovering said expressed polypeptide. The invention also provides an isolated polypeptide having the sequence of SEQ ID NO:2. Within a related embodiment the polypeptide is in combination with a pharmaceutically acceptable vehicle.

## BRIEF DESCRIPTION OF THE DRAWING

### [0011]

Figure 1 shows a multiple amino acid sequence alignment between BR43x2, TACI (von Bülow and Bram, *ibid.*) (SEQ ID NO:6), BCMA (Gras et al., *ibid.*) (SEQ ID NO:6) and BR43x1 (SEQ ID NO:7). The cysteine-rich pseudo repeats and transmembrane domain are noted.

Figure 2 shows a Scatchard plot analysis of soluble <sup>125</sup>I-ztnf4 binding to TACI and BCMA expressed by stable

BHK transfectants.

Figure 3A shows ztnf4 co-activating human B lymphocytes to proliferate and secrete immunoglobulin.

Figure 3B shows levels of IgM and IgG measured in supernatants obtained from B cells stimulated with soluble ztnf4 in the presence of IL4 or IL4+IL5 after 9 days in culture.

Figure 4 shows human peripheral blood B cells stimulated with soluble ztnf4 or control protein (ubiquitin) in the presence of IL-4 for 5 days *in vitro*. Purified TACI-Ig, BCMA-Ig and control Fc were tested for inhibition of ztnf4 specific proliferation.

Figure 5A shows results from ztnf4 transgenic animals that have developed characteristics of SLE.

Figure 5B shows lymph node, spleen and thymus cells from ztnf4 transgenic animals stained with antibodies to CD5, CD4 and CD8.

Figure 5C shows total IgM, IgG and IgE levels in serum from transgenic ztnf4 animals ranging from 6 to 23 weeks of age.

Figure 5D shows amyloid deposition and thickened mesangium of the glomeruli identified in kidney sections from ztnf4 transgenic animals.

Figure 5E shows effector T cells in ztnf4 transgenic mice.

Figures 6A and B show elevated ztnf4 levels in serum obtained from ZNBWF1 mice and MRL/lpr/lpr mice that correlates with development of SLE.

Figure 7 shows the percentage of NZBWF1 mice that develop proteinurea over the course of the study.

Figure 8 shows anti-dsDNA levels by ELISA from ztnf4 transgenic mice and control litter mates compared to serum from ZNBWF1 and MRL/lpr/lpr mice.

**[0012]** These and other aspects of the invention will become evident upon reference to the following detailed description.

## DETAILED DESCRIPTION OF THE INVENTION

**[0013]** Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms to be used hereinafter:

**[0014]** Affinity tag: is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al., *EMBO J.* 4:1075; 1985; Nilsson et al., *Methods Enzymol.* 198:3, 1991), glutathione S transferase (Smith and Johnson, *Gene* 67:31, 1988), Glu-Glu affinity tag (Grussenmeyer et al., *Proc. Natl. Acad. Sci. USA* 82:7952-4, 1985), substance P, Flag™ peptide (Hopp et al., *Biotechnology* 6:1204-10, 1988), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., *Protein Expression and Purification* 2: 95-107, 1991. DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

**[0015]** Allelic variant: Any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (i.e., no change in the encoded polypeptide), or may encode polypeptides having altered amino acid sequence. The term "allelic variant" is also used herein to denote a protein encoded by an allelic variant of a gene. Also included are the same protein from the same species which differs from a reference amino acid sequence due to allelic variation. Allelic variation refers to naturally occurring differences among individuals in genes encoding a given protein.

**[0016]** Amino-terminal and carboxyl-terminal: are used herein to denote positions within polypeptides and proteins. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide or protein to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a protein is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete protein.

**[0017]** Complement/anti-complement pair: Denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding affinity of  $<10^{-9}$  M.

**[0018]** Contig: Denotes a polynucleotide that has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences are said to "overlap" a given stretch of polynucleotide sequence either in their entirety or along a partial stretch of the polynucleotide. For example, representative contigs to the polynucleotide

sequence 5'-ATGGCTTAGCTT-3' are 5'-TAGCTTgagtct-3' and 3'-gtcgacTACCGA-5'.

**[0019] Complements of polynucleotide molecules:** Denotes polynucleotide molecules having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

**[0020] Degenerate Nucleotide Sequence or Degenerate Sequence:** Denotes a sequence of, nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).

**[0021] Expression vector:** A DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments may include promoter and terminator sequences, and optionally one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

**[0022] Isoform:** refers to different forms of a protein that may be produced from different genes or from the same gene by alternate splicing. In some cases, isoforms differ in their transport activity, time of expression in development, tissue distribution, location in the cell or a combination of these properties.

**[0023] Isolated polynucleotide:** denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, *Nature* 316:774-78, 1985).

**[0024] Isolated polypeptide or protein:** is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99%, pure. When used in this context, the term "isolated" does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

**[0025] Operably linked:** As applied to nucleotide segments, the term "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.

**[0026] Ortholog:** Denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

**[0027] Polynucleotide:** denotes a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired. Such unpaired ends will in general not exceed 20 nt in length.

**[0028] Polypeptide:** Is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides".

**[0029] Promoter:** Denotes a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

**[0030] Protein:** is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

**[0031] Receptor:** A cell-associated protein, or a polypeptide subunit of such protein, that binds to a bioactive molecule (the "ligand") and mediates the effect of the ligand on the cell. Binding of ligand to receptor results in a change in the receptor (and, in some cases, receptor multimerization, i.e., association of identical or different receptor subunits) that causes interactions between the effector domain(s) of the receptor and other molecule(s) in the cell. These interactions

in turn lead to alterations in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, cell proliferation, increases in cyclic AMP production, mobilization, of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. BR43x2 has characteristics of TNF receptors, as discussed in more detail herein.

**[0032]** Secretory signal sequence: A DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

**[0033]** Soluble receptor: A receptor polypeptide that is not bound to a cell membrane. Soluble receptors are most commonly ligand-binding receptor polypeptides that lack transmembrane and cytoplasmic domains. Soluble receptors can comprise additional amino acid residues, such as affinity tags that provide for purification of the polypeptide or provide sites for attachment of the polypeptide to a substrate. Many cell-surface receptors have naturally occurring, soluble counterparts that are produced by proteolysis or translated from alternatively spliced mRNAs. Receptor polypeptides are said to be substantially free of transmembrane and intracellular polypeptide segments when they lack sufficient portions of these segments to provide membrane anchoring or signal transduction, respectively.

**[0034]** Molecular weights and lengths of polymers determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to  $\pm 10\%$ .

**[0035]** All references cited herein are incorporated by reference in their entirety.

**[0036]** The present invention is based in part upon the discovery of a 1192 bp DNA sequence (SEQ ID NO:1) and corresponding polypeptide sequence (SEQ ID NO:2) which is an isoform of the receptor TACI. The isoform has been designated BR43x2. A soluble form of BR43x2 is disclosed in SEQ ID NO:4, the polynucleotide encoding the soluble receptor in SEQ NO: 3. As is described in more detail herein, the BR43x2 receptor-encoding polynucleotides and polypeptides of the present invention were initially identified by signal trap cloning using a human RPMI 1788 library and the N- or C-terminally FLAG-tagged, biotin- or FITC-labeled tumor necrosis factor ligand ztnf4, now known as neutrokin  $\alpha$  (WIPO WO98/18921), BLyS (Moore et al., *ibid.*), BAFF (Schneider et al., *ibid.*), TALL-1 (Shu et al., *ibid.*) or THANK (Mukhopadhyay et al., *ibid.*). Positive pools were identified by ligand binding, broken down to single clones, the cDNA isolated and sequenced. A comparison of the BR43x2 deduced amino acid sequence (as represented in SEQ ID NO:2) with known tumor necrosis factor receptors indicated that BR43x2 is an isoform of TACI, having a single, poorly conserved, cysteine-rich pseudo-repeat.

**[0037]** Structurally, the TNF receptor family is characterized by an extracellular portion composed of several modules called, historically, "cysteine-rich pseudo-repeats". A prototypical TNFR family member has four of these pseudo-repeats, each about 29-43 residues long, one right after the other. A typical pseudo-repeat has 6 cysteine residues. They are called pseudo-repeats because, although they appear to originate from a common ancestral module, they do not repeat exactly: pseudo-repeats #1, #2, #3 and #4 have characteristic sequence features which distinguish them from one another. The crystal structure of the p55 TNF receptor revealed that each pseudo-repeat corresponds to one folding domain, and that all four pseudo-repeats fold into the same tertiary structure, held together internally by disulfide bonds.

**[0038]** TACI contains two cysteine-rich pseudo-repeats (von Billow and Bram, *ibid.*), the first is conserved in structure with other members of the TNF receptor family, the second is less conserved. The BR43x2 isoform of the present invention lacks the first TACI cysteine-rich pseudo-repeat, retaining only the second, less conserved repeat.

**[0039]** Sequence analysis of a deduced amino acid sequence of BR43x2 as represented in SEQ ID NO:2 indicates the presence of a mature protein having an extracellular domain (residues 1-120 of SEQ ID NO:2) which contains one cysteine-rich pseudo-repeat (residues 25-58 of SEQ ID NO:2), a transmembrane domain (residues 121-133 of SEQ ID NO:2) and a cytoplasmic domain (residues 134-247 of SEQ ID NO:2). The cysteine-rich pseudo-repeat of BR43x2 has 6 conserved cysteine residues (residues 25, 40, 43, 47, 54 and 58 of SEQ ID NO:2), a conserved aspartic acid residue (residue 34 of SEQ ID NO:2) and two conserved leucine residues (residues 36 and 37 of SEQ ID NO:2) and shares 46% identity with the first cysteine-rich pseudo-repeat of TACI (SEQ ID NO:6) and 35% identity with the cysteine-rich pseudo-repeat of BCMA (SEQ ID NO:8) (Figure 1). The cysteine-rich pseudo-repeat can be represented by the following motif:

**CX{QEK}[QEKNRDHS][QE]X{0-2}[YFW][YFW]DXLLX{2}C[IMLV]XCX{3}  
CX{6-8}CX{2}[YF]C (SEQ ID NO:10),**

wherein C represents the amino acid residue cysteine, Q glutamine, E glutamic acid, K lysine, N asparagine, R arginine, D aspartic acid, H histidine, S serine, Y tyrosine, F phenylalanine, W tryptophan, L leucine, I isoleucine, V valine and X represents any naturally occurring amino acid residue except cysteine. Amino acid residues in square

brackets "[ ]" indicate the allowed amino acid residue variation at that position. The number in the braces "{}" indicates the number of allowed amino acid residues at that position.

[0040] The present invention also provides soluble polypeptides of from 32 to 40 amino acid residues in length as provided by SEQ ID NO:10.

[0041] The soluble BR43x2 receptor, as represented by residues 1-120 of SEQ ID NO:4, contains one cysteine-rich pseudo-repeat (residues 25-58 of SEQ ID NO:4) and lacks the transmembrane and cytoplasmic domains of BR43x2 as described in SEQ ID NO:2.

[0042] Those skilled in the art will recognize that these domain boundaries are approximate; and are based on alignments with known proteins and predictions of protein folding. These features indicate that the receptor encoded by the DNA sequences of SEQ ID NOs:1 and 3 is a member of the TNF receptor family.

[0043] Northern blot and Dot blot analysis of the tissue distribution of the mRNA corresponding to nucleotide probes to BR43x1 which are predicted to detect BR43x2 expression showed expression in spleen, lymph node, CD19+ cells, weakly in mixed lymphocyte reaction cells, Daudi and Raji cells. Using reverse transcriptase PCR BR43x1 was detected in B cells only and not in activated T cells as had been reported for TACI (von Bülow and Bram, *ibid.*). Using a BR43x2 probe that overlaps 100% with the corresponding TACI sequence, TACI and BR43x2 were detected in spleen, lymph node and small intestine, stomach, salivary gland, appendix, lung, bone marrow, fetal spleen, CD 19+ cells, and Raji cells.

[0044] Using Northern Blot analysis BCMA was detected in small intestine, spleen, stomach, colon, appendix, lymph node, trachea, and testis. BCMA was also detected in adenolymphoma, non-Hodgkins lymphoma, and parotid tumor, detected faintly in CD 8+, CD 19+, MLR cells, Daudi, Raji and Hut 78 cells.

[0045] Northern blot analysis was also done using murine ztnf4 (SEQ ID NO:19) and like human TACI, BCMA, and BR43x2, murine ztnf4 expression was detected predominately in spleen and thymus. Murine ztnf4 was also expressed in lung and faint expression was detected in skin and heart.

[0046] The present invention also provides polynucleotide molecules, including DNA and RNA molecules, that encode the BR43x2 polypeptides disclosed herein. Those skilled in the art will readily recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among these polynucleotide molecules. SEQ ID NO:11 is a degenerate DNA sequence that encompasses all DNAs that encode the soluble BR43x2 polypeptide of SEQ ID NO:4. Similarly, SEQ ID NO:12 is a degenerate DNA sequence that encompasses all DNAs that encode the BR43x2 polypeptide of SEQ ID NO:2. Those skilled in the art will recognize that the degenerate sequence of SEQ ID NO:12 also provides all RNA sequences encoding SEQ ID NO:4 by substituting U for T. Thus, BR43x2 polypeptide-encoding polynucleotides comprising nucleotide 1 to nucleotide 360 of SEQ ID NO:11, nucleotide 1 to 741 of SEQ ID NO:12 and their RNA equivalents are contemplated by the present invention. Table 1 sets forth the one-letter codes used within SEQ ID NOs:11 and 12 to denote degenerate nucleotide positions. "Resolutions" are the nucleotides denoted by a code letter. "Complement" indicates the code for the complementary nucleotide(s). For example, the code Y denotes either C or T, and its complement R denotes A or G, A being complementary to T, and G being complementary to C.

TABLE 1

Nucleotide	Resolution	Complement	Resolution
A	A	T	T
C	C	G	G
G	G	C	C
T	T	A	A
R	A G	Y	C T
Y	C T	R	A G
M	A C	K	G T
K	G T	M	A C
S	C G	S	C G
W	A T	W	A T
H	A C T	D	A G T
B	C G T	V	A C G
V	A C G	B	C G T
D	A G T	H	A C T
N	A C G T	N	A C G T

**[0047]** The degenerate codons used in SEQ ID NOs:11 and 12, encompassing all possible codons for a given amino acid, are set forth in Table 2.

TABLE 2

Acid	One Amino Letter. Code	Codons	Degenerate Codon
Cys	C	TGC TGT	TGY
Ser	S	AGC AGT TCA TCC TCG TCT	WSN
Thr	T	ACA ACC ACG ACT	ACN
Pro	P	CCA CCC CCG CCT	CCN
Ala	A	GCA GCC GCG GCT	GCN
Gly	G	GGA GGC GGG GGT	GGN
Asn	N	AAC AAT	AAY
Asp	D	GAC GAT	GAY
Glu	E	GAA GAG	GAR
Gln	Q	CAA CAG	CAR
His	H	CAC CAT	CAY
Arg	R	AGA AGG CGA CGC CGG CGT	MGN
Lys	K	AAA AAG	AAR
Met	M	ATG	ATG
Ile	I	ATA ATC ATT	ATH
Leu	L	CTA CTC CTG CTT TTA TTG	YTN
Val	V	GTA GTC GTG GTT	GTN
Phe	F	TTC TTT	TTY
Tyr	Y	TAC TAT	TAY
Trp	W	TGG	TGG
Ter	.	TAA TAG TGA	TRR
AsnIAsp	B		RAY
GlulGln	Z		SAR
Any	X		NNN

**[0048]** One of ordinary skill in the art will appreciate that some ambiguity is introduced in determining a degenerate codon, representative of all possible codons encoding each amino acid. For example, the degenerate codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding phenylalanine and leucine. Thus, some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequences of SEQ ID NOs:2 and 4. Variant sequences can be readily tested for functionality as described herein.

**[0049]** One of ordinary skill in the art will also appreciate that different species can exhibit "preferential codon usage." In general, see, Grantham, et al., *Nuc. Acids Res.* 8:1893-912, 1980; Haas, et al. *Curr. Biol.* 6:315-24, 1996; Wain-Hobson, et al., *Gene* 13:355-64, 1981; Grosjean and Fiers, *Gene* 18:199-209, 1982; Holm, *Nuc. Acids Res.* 14:3075-87, 1986; Ikemura, *J. Mol. Biol.* 158:573-97, 1982. As used herein, the term "preferential codon usage" or "preferential codons" is a term of art referring to protein translation codons that are most frequently used in cells of a certain species, thus favoring one or a few representatives of the possible codons encoding each amino acid (See Table 2). For example, the amino acid threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian cells ACC is the most commonly used codon; in other species, for example, insect cells, yeast, viruses or bacteria, different Thr codons may be preferential. Preferential codons for a particular species can be introduced into the polynucleotides of the present invention by a variety of methods known in the art. Introduction of preferential codon sequences into recombinant DNA can, for example, enhance production of the protein by making protein translation more efficient within a particular cell type or species. Therefore, the degenerate codon sequences disclosed in SEQ ID NOs:11 and 12 serve as a template for optimizing expression of polynucleotides in various cell types and species commonly used in the art and disclosed herein. Sequences containing preferential codons can be tested and optimized for expression in various species, and tested for functionality as disclosed herein..

**[0050]** The highly conserved amino acids in the cysteine-rich pseudo-repeat of BR43x2 can be used as a tool to identify new family members. For instance, reverse transcription-polymerase chain reaction (RT-PCR) can be used,



to amplify sequences encoding the extracellular ligand-binding domain, described above, from RNA obtained from a variety of tissue sources or cell lines. In particular, highly degenerate primers designed from the BR43x2 sequences are useful for this purpose.

[0051] Within preferred embodiments of the invention, isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO:3, or to a sequence complementary thereto, under stringent conditions. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typical stringent conditions are those in which the salt concentration is up to about 0.03 M at pH 7 and the temperature is at least about 60°C.

[0052] As previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for isolating DNA and RNA are well known in the art. It is generally preferred to isolate RNA from RPMI 1788 cells, PBMNCs, resting or activated transfected B cells' or tonsil tissue, although DNA can also be prepared using RNA from other tissues or isolated as genomic DNA. Total RNA can be prepared using guanidine HCl extraction followed by isolation by centrifugation in a CsCl gradient (Chirgwin et al., *Biochemistry* 18:52-94, 1979). Poly (A)<sup>+</sup> RNA is prepared from total RNA using the method of Aviv and Leder (*Proc. Natl. Acad. Sci. USA* 69:1408-12, 1972). Complementary DNA (cDNA) is prepared from poly(A)<sup>+</sup> RNA using known methods. Polynucleotides encoding BR43x2 polypeptides are then identified and isolated by, for example, hybridization or PCR.

[0053] Those skilled in the art will recognize that the sequences disclosed in SEQ ID NOs:1 and 3 represent a single allele of the human gene, and that allelic variation and alternative splicing is expected to occur. Allelic variants of the DNA sequences shown in SEQ ID NOs:1 and 3, including those containing silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of SEQ ID NOs:2 and 4. Allelic variants and splice variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals or tissues according to standard procedures known in the art.

[0054] The present invention also provides isolated BR43x2 polypeptides that are substantially homologous to the polypeptides of SEQ ID NOs:2 and 4 and their species orthologs. The term "substantially homologous" is used herein to denote polypeptides having 50%, preferably 60%, more preferably at least 80%, sequence identity to the sequences shown in SEQ ID NOs:2 and 4 or their orthologs. Such polypeptides will more preferably be at least 90% identical, and most preferably 95% or more identical to SEQ ID NO:2 or its orthologs. Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., *Bull. Math. Bio.* 48: 603-66, 1986 and Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915-9, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and Henikoff (ibid.) as shown in Table 3 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as:

$$\frac{\text{Total number of identical matches}}{\text{[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences]}} \times 100$$

Table 3

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
A	4																			
R	-1	5																		
N	-2	0	6																	
D	-2	-2	1	6																
C	0	-3	-3	-3	9															
Q	-1	1	0	0	-3	5														
E	-1	0	0	2	-4	2	5													
G	0	-2	0	-1	-3	-2	-2	6												
H	-2	0	1	-1	-3	0	0	-2	8											
I	-1	-3	-3	-3	-1	-3	-3	-4	-3	4										
L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4									
K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5								
M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5							
F	-2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-1	-2	-4	7						
S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4				
T	0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-1	-2	-1	1	5			
W	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11		
Y	-2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1	4

Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above.

[0055] Substantially homologous proteins and polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 4) and other substitutions that do not significantly affect the folding or activity of the protein or polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or an affinity tag. Polypeptides comprising affinity tags can further comprise a proteolytic cleavage site between the BR43x2 polypeptide and the affinity tag. Preferred such sites include thrombin cleavage sites and factor Xa cleavage sites.

Table 4

Conservative amino acid substitutions	
Basic:	arginine
	lysine
	histidine
Acidic:	glutamic acid
	aspartic acid
Polar:	glutamine
	asparagine
Hydrophobic:	leucine
	isoleucine
	valine
Aromatic:	phenylalanine
	tryptophan
	tyrosine
Small:	glycine
	alanine
	serine
	threonine
	methionine

**[0056]** In addition to the 20 standard amino acids, non-standard amino acids (such as 4-hydroxyproline, 6-N-methyl lysine, 2-aminoisobutyric acid, isovaline and  $\alpha$ -methyl serine) may be substituted for amino acid residues of BR43x2 polypeptides of the present invention. A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, and unnatural amino acids may be substituted for BR43x2 polypeptide amino acid residues. The proteins of the present invention can also comprise non-naturally occurring amino acid residues.

**[0057]** Non-naturally occurring amino acids include, without limitation, trans-3-methylproline, 2,4-methanoproline, cis-4-hydroxyproline, trans-4-hydroxyproline, N-methylglycine, allo-threonine, methylthreonine, hydroxy-ethylcysteine, hydroxyethyl-homocysteine, nitroglutamine, homoglutamine, pipercolic acid, tert-leucine, norvaline, 2-azaphenylalanine, 3-aza-phenylalanine, 4-azaphenylalanine, and 4-fluoro-phenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is carried out in a cell free system comprising an *E. coli* S30 extract and commercially available enzymes and other reagents. Proteins are purified by chromatography. See, for example, Robertson et al., *J. Am. Chem. Soc.* 113:2722, 1991; Ellman et al., *Methods Enzymol.* 202:301, 1991; Chung et al., *Science* 259:806-9, 1993; and Chung et al., *Proc. Natl. Acad. Sci. USA* 90:10145-9, 1993). In a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., *J. Biol. Chem.* 271:19991-8, 1996). Within a third method, *E. coli* cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluoro-phenylalanine). The non-naturally occurring amino acid is incorporated into the protein in place of its natural counterpart. See, Koide et al., *Biochem.* 33:7470-6, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by *in vitro* chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, *Protein Sci.* 2:395-403, 1993).

**[0058]** A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for BR43x2 amino acid residues.

**[0059]** Essential amino acids in the BR43x2 polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and

Wells, *Science* 244:1081-5, 1989). Single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g., providing a decrease in B cell response during the immune response, inhibition or decrease in autoantibody production) to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et al., *J. Biol. Chem.* 271:4699-708, 1996. Sites of biological interaction, ligand binding portions such as the cysteine-rich pseudo-repeats, can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., *Science* 255:306-12, 1992; Smith et al., *J. Mol. Biol.* 224:899-904, 1992; Wlodaver et al., *FEBS Lett.* 309:59-64, 1992. The identities of essential amino acids can also be inferred from analysis of homologies with related TNFR family members such as TACI and BCMA.

**[0060]** Additional amino acid substitutions can be made within the cysteine-rich pseudo-repeat of BR43x2 so long as the conserved cysteine, aspartic acid and leucine residues are retained and the higher order structure is not disturbed. It is preferred to make substitutions within the cysteine-rich pseudo-repeat of BR43x2 by reference to the sequences of other cysteine-rich pseudo-repeats. SEQ ID NO:10 is a generalized cysteine-rich pseudo-repeat that shows allowable amino acid substitutions based on such an alignment. Substitutions within this domain are subject to the limitations set forth herein.

**[0061]** Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (*Science* 241:53-7, 1988) or Bowie and Sauer (*Proc. Natl. Acad. Sci. USA* 86:2152-6, 1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., *Biochem.* 30:10832-7, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis (Derbyshire et al., *Gene* 46:145, 1986; Ner et al., *DNA* 7:127, 1988).

**[0062]** Variants of the disclosed BR43x2 DNA and polypeptide sequences can be generated through DNA shuffling as disclosed by Stemmer, *Nature* 370:389-91, 1994, Stemmer, *Proc. Natl. Acad. Sci. USA* 91:10747-51, 1994 and WIPO Publication WO 97/20078. Briefly, variant DNAs are generated by *in vitro* homologous recombination by random fragmentation of a parent DNA followed by reassembly using PCR, resulting in randomly introduced point mutations. This technique can be modified by using a family of parent DNAs, such as allelic variants or DNAs from different species, to introduce additional variability into the process. Selection or screening for the desired activity, followed by additional iterations of mutagenesis and assay provides for rapid "evolution" of sequences by selecting for desirable mutations while simultaneously selecting against detrimental changes.

**[0063]** Mutagenesis methods as disclosed above can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides in host cells. Mutagenized DNA molecules that encode active polypeptides (e.g., providing a decrease in B cell response during the immune response, inhibition or decrease in autoantibody production) can be recovered from the host cells and rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

**[0064]** Using the methods discussed above, one of ordinary skill in the art can identify and/or prepare a variety of polypeptides that are substantially homologous to residues 1 to 120 of SEQ ID NO:2 or allelic variants thereof and retain the B cell suppression properties of the wild-type protein. Such polypeptides may include additional amino acids or domains from other members of the tumor necrosis factor receptor superfamily, affinity tags or the like. BR43x2 polypeptide or fusion constructs, containing functional domains of other members of the TNFR superfamily, constitute hybrid tumor necrosis factor receptors exhibiting modified B cell suppression capabilities.

**[0065]** The present invention further provides counterpart receptors and polynucleotides from other species (orthologs). These species include, but are not limited to mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and invertebrate species. Of particular interest are BR43x2 receptors from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primate receptors. Orthologs of the human BR43x2 receptor can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses the receptor. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A receptor-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequence. A cDNA can also be cloned using PCR, using primers designed from the sequences disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to the receptor. Similar techniques can also be applied to the isolation of genomic clones.

**[0066]** The receptor polypeptides of the present invention, including full-length receptor polypeptides, soluble recep-

tors polypeptides, polypeptide fragments, and fusion polypeptides, can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, 1989; and Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987.

**[0067]** In general, a DNA sequence encoding a BR43x2 polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

**[0068]** To direct a BR43x2 polypeptide into the secretory pathway of a host cell, a secretory signal sequence (also known as a signal sequence, leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of the BR43x2 polypeptide, or may be derived from another secreted protein (e.g., t-PA) or synthesized *de novo*. The secretory signal sequence is joined to the BR43x2 DNA sequence in the correct reading frame and positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

**[0069]** Cultured mammalian cells are suitable hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 1:841-45, 1982), DEAE-dextran mediated transfection (Ausubel et al., *ibid.*), and liposome-mediated transfection (Hawley-Nelson et al., Focus 15:73, 1993; Ciccarone et al., Focus 15:80, 1993). The production of recombinant polypeptides in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134. Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977), Jurkat (ATCC No. CRL-8129), BaF3 (an interleukin-3 dependent pre-lymphoid cell line derived from murine bone marrow. See, Palacios and Steinmetz, Cell 41: 727-34; 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-5, 1986) and Chinese hamster ovary (e.g., CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978 and the adenovirus major,late promoter).

**[0070]** Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g., hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used. Alternative markers that introduce an altered phenotype, such as green fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase may be used to sort transfected cells from untransfected cells by such means as FACS sorting or magnetic bead separation technology.

**[0071]** Other higher eukaryotic cells can also be used as hosts, including plant cells, insect cells and avian cells. The use of *Agrobacterium rhizogenes* as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987. Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222 and WIPO publication WO 94/06463. Insect cells can be infected with recombinant baculovirus, commonly derived from *Autographa californica nuclear polyhedrosis virus* (AcNPV). See, King and Possee, The baculovirus Expression System: A Laboratory Guide, London, Chapman & Hall; O'Reilly

et al., Baculovirus Expression Vectors: A Laboratory Manual, New York, Oxford University Press., 1994; and Richardson, Ed., Baculovirus Expression Protocols. Methods in Molecular Biology. Totowa, NJ, Humana Press, 1995. A second method of making recombinant BR43x2 baculovirus utilizes a transposon-based system described by Luckow (Luckow, et al., J Virol 67:4566-79, 1993). This system, which utilizes transfer vectors, is sold in the Bac-to-Bac™ kit (Life Technologies, Rockville, MD). This system utilizes a transfer vector, pFastBac1™ (Life Technologies) containing a Tn7 transposon to move the DNA encoding the BR43x2 polypeptide into a baculovirus genome maintained in *E. coli* as a large plasmid called a "bacmid." See, Hill-Perkins and Possee, J. Gen. Virol. 71:971-6, 1990; Bonning, et al., J. Gen. Virol. 75:1551-6, 1994; and, Chazenbalk, and Rapoport, J. Biol. Chem. 270:1543-9, 1995. In addition, transfer vectors can include an in-frame fusion with DNA encoding an epitope tag at the C- or N-terminus of the expressed BR43x2 polypeptide, for example, a Glu-Glu epitope tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. 82:7952-4, 1985). Using a technique known in the art, a transfer vector containing BR43x2 is transformed into *E. coli*, and screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect *Spodoptera frugiperda* cells, e.g. Sf9 cells. Recombinant virus that expresses BR43x2 is subsequently produced. Recombinant viral stocks are made by methods commonly used the art.

**[0072]** The recombinant virus is used to infect host cells, typically a cell line derived from the fall armyworm, *Spodoptera frugiperda*. See, in general, Glick and Pasternak, Molecular Biotechnology: Principles and Applications of Recombinant DNA, ASM Press, Washington, B.C., 1994. Another suitable cell line is the High Five™ cell line (Invitrogen) derived from *Trichoplusia ni* (U.S. Patent #5,300,435). Commercially available serum-free media are used to grow and maintain the cells. Suitable media are Sf900 II™ (Life Technologies) or ESF 921™ (Expression Systems) for the Sf9 cells; and Ex-cellO405™ (JRH Biosciences, Lenexa, KS) or Express Five™ (Life Technologies) for the *T. ni* cells. The cells are grown up from an inoculation density of approximately 2-5 x 10<sup>5</sup> cells to a density of 1-2 x 10<sup>6</sup> cells at which time a recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to 10, more typically near 3. Procedures used are generally described in available laboratory manuals (King and Possee, *ibid.*; O'Reilly, et al., *ibid.*; Richardson, *ibid.*). Subsequent purification of the BR43x2 polypeptide from the supernatant can be achieved using methods described herein.

**[0073]** Fungal cells, including yeast cells, can also be used within the present invention. Yeast species of particular interest in this regard include *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Pichia methanolica*. Methods for transforming *S. cerevisiae* cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in *Saccharomyces cerevisiae* is the *POT1* vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., J. Gen. Microbiol. 132:3459-65, 1986 and Cregg, U.S. Patent No. 4,882,279. *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

**[0074]** For example, the use of *Pichia methanolica* as host for the production of recombinant proteins is disclosed by Raymond, U.S. Patent No. 5,716,808, Raymond, U.S. Patent No. 5,736,383, Raymond et al., Yeast 14:11-23, 1998, and in international publication Nos. WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in transforming *P. methanolica* will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in *P. methanolica*, it is preferred that the promoter and terminator in the plasmid be that of a *P. methanolica* gene, such as a *P. methanolica* alcohol utilisation gene (*AUG1* or *AUG2*). Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. To facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment of the plasmid flanked at both ends by host DNA sequences. A preferred selectable marker for use in *Pichia methanolica* is a *P. methanolica* *ADE2* gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), which allows, *ade2* host cells to grow in the absence of adenine. For large-scale, industrial processes where it is desirable to minimize the use of methanol, it is preferred to use host cells in which both methanol utilization genes (*AUG1* and *AUG2*) are deleted. For production of secreted proteins, host cells deficient in vacuolar protease genes (*PEP4* and *PRB1*) are preferred. Electroporation is used to facilitate the introduc-

tion of a plasmid containing DNA encoding a polypeptide of interest into *P. methanolica* cells. It is preferred to transform *P. methanolica* cells by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant (t) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.

**[0075]** Prokaryotic host cells, including strains of the bacteria *Escherichia coli*, *Bacillus* and other genera are also useful host cells within the present invention. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art (see, e.g., Sambrook et al., *ibid.*). When expressing a BR43x2 polypeptide in bacteria such as *E. coli*, the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea. The denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the latter case, the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need. for denaturation and refolding.

**[0076]** Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell. *P. methanolica* cells are cultured in a medium comprising adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C. Liquid cultures are provided with sufficient aeration by conventional means, such as shaking of small flasks or sparging of fermentors. A preferred culture medium for *P. methanolica* is YEPD (2% D-glucose, 2% Bacto™ Peptone (Difco Laboratories, Detroit, MI), 1% Bacto™ yeast extract (Difco Laboratories), 0.004% adenine and 0.006% L-leucine).

**[0077]** Expressed recombinant BR43x2 polypeptides (or chimeric or fusion BR43x2 polypeptides) can be purified using fractionation and/or conventional purification methods and media. It is preferred to provide the proteins or polypeptides of the present invention in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. Ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples. Exemplary purification steps. may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable anion exchange media. include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred, with DEAE Fast-Flow Sepharose (Pharmacia, Piscataway, NJ) being particularly preferred. Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties. Examples of coupling chemistries include cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries. These and other solid media are well known and widely used in the art, and are available from commercial suppliers. Methods for binding receptor polypeptides to support media are well known in the art. Selection of a particular method is a matter of routine design and is determined in part by the properties of the chosen support. See, for example, Affinity Chromatography: Principles & Methods, Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988.

**[0078]** The polypeptides of the present invention can be isolated by exploitation of their physical properties. For example, immobilized metal ion adsorption (IMAC) Chromatography can be used to purify histidine-rich proteins including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to form a chelate (Sulkowski, Trends in Biochem. 3:1-7, 1985). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other methods of purification include purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography (Methods in Enzymol., Vol. 182, "Guide to Protein Purification", M. Deutscher, (ed.), Acad. Press, San Diego, 1990, pp. 529-39). Within additional embodiments of the invention, a fusion of the polypeptide of interest and an affinity tag (e.g., maltose-binding protein, FLAG-tag (Asp Tyr Lys Asp Asp Asp Lys (SEQ ID NO:13)), Glu-Glu tag (Glu Glu Tyr Met Pro Met Glu (SEQ ID NO:14)), an immunoglobulin domain) may be constructed to facilitate purification.

[0079] Protein refolding (and optionally reoxidation) procedures may be advantageously used. It is preferred to purify the protein to >80% purity, more preferably to >90% purity, even more preferably >95%, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents. Preferably, a purified protein is substantially free of other proteins, particularly other proteins of animal origin.

[0080] BR43x2 polypeptides or fragments thereof may also be prepared through chemical synthesis. BR43x2 polypeptides may be monomers or multimers; glycosylated or non-glycosylated; pegylated or non-pegylated; and may or may not include an initial methionine amino acid residue. Exemplary BR43x2 polypeptides include polypeptides of from 32-40 residues in length having an amino acid sequence conforming to the motif :  $XXCX[QEK] [QEKNRDHS] [QE]X\{0-2\}[YFW][YFW]DXLLX\{2\} C[IMLV]XCX\{3\}CX\{6-9\},CX\{2\} [YF]CXX$  (SEQ ID NO:10), and subject to the limitations described herein.

[0081] BR43x2 polypeptides can be synthesized by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. The polypeptides are preferably prepared by solid phase peptide synthesis, for example as described by Merrifield, *J. Am. Chem. Soc.* 85:2149, 1963. The synthesis is carried out with amino acids that are protected at the alpha-amino terminus. Trifunctional amino acids with labile side-chains are also protected with suitable groups to prevent undesired chemical reactions from occurring during the assembly of the polypeptides. The alpha-amino protecting group is selectively removed to allow subsequent reaction to take place at the amino-terminus. The conditions for the removal of the alpha-amino protecting group do not remove the side-chain protecting groups.

[0082] The alpha-amino protecting groups are those known to be useful in the art of stepwise polypeptide synthesis. Included are acyl type protecting groups (e.g., formyl, trifluoroacetyl, acetyl), aryl type protecting groups (e.g., biotiny), aromatic urethane type protecting groups [e.g., benzyloxycarbonyl (Cbz), substituted benzyloxycarbonyl and 9-fluorenylmethyloxycarbonyl (Fmoc)], aliphatic urethane protecting groups (e.g., t-butyloxycarbonyl (tBoc); isopropyl-oxycarbonyl, cyclohexyloxycarbonyl] and alkyl type protecting groups (e.g., benzyl, triphenylmethyl). The preferred protecting groups are tBoc and Fmoc.

[0083] The side-chain protecting groups selected must remain intact during coupling and not be removed during the deprotection of the amino-terminus protecting group or during coupling conditions. The side-chain protecting groups must also be removable upon the completion of synthesis using reaction conditions that will not alter the finished polypeptide. In tBoc chemistry, the side-chain protecting groups for trifunctional amino acids are mostly benzyl based. In Fmoc chemistry, they are mostly tert-butyl or trityl based.

[0084] In tBoc chemistry, the preferred side-chain protecting groups are tosyl for arginine, cyclohexyl for aspartic acid, 4-methylbenzyl (and acetamidomethyl) for cysteine, benzyl for glutamic acid, serine and threonine, benzyloxymethyl (and dinitrophenyl) for histidine, 2-Cl-benzyloxycarbonyl for lysine, formyl for tryptophan and 2-bromobenzyl for tyrosine. In Fmoc chemistry, the preferred side-chain protecting groups are 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) or 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for arginine, trityl for asparagine, cysteine, glutamine and histidine, tert-butyl for aspartic acid, glutamic acid, serine, threonine and tyrosine, tBoc for lysine and tryptophan.

[0085] For the synthesis of phosphopeptides, either direct or post-assembly incorporation of the phosphate group is used. In the direct incorporation strategy, the phosphate group on serine, threonine or tyrosine may be protected by methyl, benzyl, or tert-butyl in Fmoc chemistry or by methyl, benzyl or phenyl in tBoc chemistry. Direct incorporation of phosphotyrosine without phosphate protection can also be used in Fmoc chemistry. In the post-assembly incorporation strategy, the unprotected hydroxyl groups of serine, threonine or tyrosine are derivatized on solid phase with di-tert-butyl-, dibenzyl- or dimethyl-N,N'-diisopropylphosphoramidite and then oxidized by tert-butylhydroperoxide.

[0086] Solid phase synthesis is usually carried out from the carboxyl-terminus by coupling the alpha-amino protected (side-chain protected) amino acid to a suitable solid support. An ester linkage is formed when the attachment is made to a chloromethyl, chlorotriyl or hydroxymethyl resin, and the resulting polypeptide will have a free carboxyl group at the C-terminus. Alternatively, when an amide resin such as benzhydrylamine or p-methylbenzhydrylamine resin (for tBoc chemistry) and Rink amide or PAL resin (for Fmoc chemistry) are used, an amide bond is formed and the resulting polypeptide will have a carboxamide group at the C-terminus. These resins, whether polystyrene- or polyamide-based or polyethyleneglycol-grafted, with or without a handle or linker, with or without the first amino acid attached, are commercially available, and their preparations have been described by Stewart et al., "Solid Phase Peptide Synthesis" (2nd Edition), (Pierce Chemical Co., Rockford, IL, 1984) and Bayer and Rapp, *Chem. Pept. Prot.* 3:3, 1986; and Atherton et al., *Solid Phase Peptide Synthesis: A Practical Approach*, IRL Press, Oxford, 1989.

[0087] The C-terminal amino acid, protected at the side chain if necessary, and at the alpha-amino group, is attached to a hydroxymethyl resin using various activating agents including dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIPCDI) and carbonyldiimidazole (CDI). It can be attached to chloromethyl or chlorotriyl resin directly in its cesium tetramethylammonium salt form or in the presence of triethylamine (TEA) or diisopropylethylamine (DIEA). First amino acid attachment to an amide resin is the same as amide bond formation during coupling reactions.



**[0088]** Following the attachment to the resin support, the alpha-amino protecting group is removed using various reagents depending on the protecting chemistry (e.g., tBoc, Fmoc). The extent of Fmoc removal can be monitored at 300-320 nm or by a conductivity cell. After removal of the alpha-amino protecting group, the remaining protected amino acids are coupled stepwise in the required order to obtain the desired sequence.

**[0089]** Various activating agents can be used for the coupling reactions including DCC, DIPCDI, 2-chloro-1,3-dimethylimidium hexafluorophosphate (CIP), benzotriazol-1-yl-oxy-tris-(dimethyl-amino)-phosphonium hexafluorophosphate (BOP) and its pyrrolidine analog (PyBOP), bromotris-pyrrolidino-phosphonium hexafluorophosphate (PyBrOP), O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and its tetra-fluoroborate analog (TBTU) or its pyrrolidine analog (HBPYU), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium hexafluoro-phosphate (HATU) and its tetrafluoroborate analog (TATU) or its pyrrolidine analog (HAPYU). The most common catalytic additives used in coupling reactions include 4-dimethylaminopyridine (DMAP), 3-hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine (HODhbt), N-hydroxybenzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt). Each protected amino acid is used in excess (>2.0 equivalents), and the couplings are usually carried out in N-methylpyrrolidone (NMP) or in DMF, CH<sub>2</sub>Cl<sub>2</sub> or mixtures thereof. The extent of completion of the coupling reaction can be monitored at each stage, e.g., by the ninhydrin reaction as described by Kaiser et al., *Anal. Biochem.* 34:595, 1970.

**[0090]** After the entire assembly of the desired peptide, the peptide-resin is cleaved with a reagent with proper scavengers. The Fmoc peptides are usually cleaved and deprotected by TFA with scavengers (e.g., H<sub>2</sub>O, ethanedithiol, phenol and thioanisole). The tBoc peptides are usually cleaved and deprotected with liquid HF for 1-2 hours at -5 to 0° C, which cleaves the polypeptide from the resin and removes most of the side-chain protecting groups. Scavengers such as anisole, dimethylsulfide and p-thiocresol are usually used with the liquid HF to prevent cations formed during the cleavage from alkylating and acylating the amino acid residues present in the polypeptide. The formyl group of tryptophan and the dinitrophenyl group of histidine need to be removed, respectively by piperidine and thiophenyl in DMF prior to the HF cleavage. The acetamidomethyl group of cysteine can be removed by mercury(II)acetate and alternatively by iodine, thallium(III) trifluoroacetate or silver tetrafluoroborate which simultaneously oxidize cysteine to cystine. Other strong acids used for tBoc peptide cleavage and deprotection include trifluoromethanesulfonic acid (TFMSA) and trimethylsilyl-trifluoroacetate (TMSOTf).

**[0091]** The present invention further provides a variety of other polypeptide fusions and related multimeric proteins comprising one or more polypeptide fusions. A soluble BR43x2, TACI or BCMA polypeptide can be expressed as a fusion with an immunoglobulin heavy chain constant region, typically an F<sub>c</sub> fragment, which contains two constant region domains and lacks the variable region. Methods for preparing such fusions are disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584. Such fusions are typically -secreted as multimeric molecules wherein the Fc portions are disulfide bonded to each other and two non-Ig polypeptides are arrayed in close proximity to each other. Immunoglobulin-BR43x2 (TACI or BCMA) polypeptide fusions can be expressed in genetically engineered cells to produce a variety of multimeric BR43x2 analogs. Auxiliary domains can be fused to BR43x2 (TACI or BCMA) polypeptides to target them to specific cells, tissues, or macromolecules. Fusions may also be made using toxins as discussed herein. In this way, polypeptides and proteins can be targeted for therapeutic or diagnostic purposes. A BR43x2 polypeptide can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al., *Connect. Tiss. Res.* 34:1-9, 1996. Fusions of this type can also be used, for example, to affinity purify cognate ligand from a solution, as an *in vitro* assay tool, to 'block signals *in vitro* by specifically titrating out ligand, to bind ligand on the cell surface or as a BR43x2 antagonists *in vivo* by administering them to block ligand stimulation. For use in assays, the fusion proteins may be bound to a support via the F<sub>c</sub> region and used in an ELISA format.

**[0092]** The invention also provides soluble BR43x2 receptors and polypeptide fragments used to form fusion proteins with affinity tags or labels. Soluble BR43x2-affinity tag fusion proteins are used, for example, to identify the BR43x2 ligands, as well as agonists and antagonists of the natural ligand. Using labeled, soluble BR43x2, cells expressing the ligand, agonists or antagonists are identified by fluorescence immunocytometry or immunohistochemistry. The soluble fusion proteins are useful in studying the distribution of the ligand on tissues or specific cell lineages, and to provide insight into receptor/ligand biology.

**[0093]** To purify ligand, agonists or antagonists, a BR43x2-Ig fusion protein is added to a sample containing the ligand, agonist or antagonist under conditions that facilitate receptor-ligand binding (typically near-physiological temperature, pH, and ionic strength). The receptor-ligand complex is then separated by the mixture using protein A, which is immobilized on a solid support (e.g., insoluble resin beads). The ligand, agonist, antagonist is then eluted using conventional chemical techniques, such as with a salt or pH gradient. In the alternative, the fusion protein itself can be bound to a solid support, with binding and elution carried out as above. Methods for immobilizing receptor polypeptide to a solid support, such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use are known in the art. Methods for linking polypeptides to solid supports are known in the art, and include amine chemistry, cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, and hydrazide activation. The

resulting media will generally be configured in the form of a column, and fluids containing ligand are passed through the column one or more times to allow ligand to bind to the receptor polypeptide. The ligand is then eluted using changes in salt concentration, chaotropic agents ( $MnCl_2$ ), or pH to disrupt ligand-receptor binding.

**[0094]** To direct the export of the soluble receptor from the host cell, the soluble receptor DNA is linked to a second DNA segment encoding a secretory peptide, such as a t-PA secretory peptide. To facilitate purification of the secreted receptor domain, an N- or C-terminal extension, such as an affinity tag or another polypeptide or protein for which an antibody or other specific binding agent is available, can be fused to the receptor polypeptide.

**[0095]** Cells expressing functional soluble and membrane bound receptors of the present invention are used within screening -assays. A variety of suitable assays are known in the art. These assays are based on the detection of a biological response in a target cell. A change in metabolism compared to a control value indicates a test compound that modulates BR43x2 mediated metabolism. One such assay is a cell proliferation assay. Cells are cultured in the presence or absence of a test compound, and cell proliferation is detected by, for example, measuring incorporation of tritiated thymidine or by colorimetric assay based on the metabolic breakdown of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Mosman, *J. Immunol. Meth.* 65: 55-63, 1983). An alternative assay format uses cells that are further engineered to express a reporter gene. The reporter gene is linked to a promoter element that is responsive to the receptor-linked pathway, and the assay detects activation of transcription of the reporter gene. Numerous reporter genes that are easily assayed for in cell extracts are known in the art, for example, the *E. coli lacZ*, chloroamphenicol acetyl transferase (CAT) and serum response element (SRE) (see, e.g., Shaw et al., *Cell* 56:563-72, 1989). A preferred such reporter gene is a luciferase gene (de Wet et al., *Mol. Cell. Biol.* 7:725, 1987). Expression of the luciferase gene is detected by luminescence using methods known in the art (e.g., Baumgartner et al., *J. Biol. Chem.* 269:29094-101, 1994; Schenborn and Goiffin, *Promega Notes* 41:11, 1993). Luciferase activity assay kits are commercially available from, for example, Promega Corp., Madison, WI. Target cell lines of this type can be used to screen libraries of chemicals, cell-conditioned culture media, fungal broths, soil samples, water samples, and the like. For example, a bank of cell-conditioned media samples can be assayed on a target cell to identify cells that produce ligand. Positive cells are then used to produce a cDNA library in a mammalian expression vector, which is divided into pools, transfected into host cells, and expressed. Media samples from the transfected cells are then assayed, with subsequent division of pools, re-transfection, subculturing, and re-assay of positive cells to isolate a cloned cDNA-encoding the ligand.

**[0096]** An assay system that uses a ligand-binding receptor (or an antibody, one member of a complement/anti-complement pair) or a binding fragment thereof, and a commercially available biosensor instrument (BIAcore™, Pharmacia Biosensor, Piscataway, NJ) may also may be advantageously employed. Such receptor, antibody, member of a complement/anti-complement pair or fragment is immobilized onto the surface of a receptor chip. Use of this instrument is disclosed by Karlsson, *J. Immunol. Meth.* 145:229-40, 1991 and Cunningham and Wells, *J. Mol. Biol.* 234: 554-63, 1993. For example, a BR43x2 polypeptide, fragment, antibody or member of a complement/anti-complement pair is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within the flow cell. A test sample is passed through the cell. If a ligand, epitope, or opposite member of the complement/anti-complement pair is present in the sample, it will bind to the immobilized receptor, antibody or member, respectively, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film. This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding. Ligand-binding receptor polypeptides can also be used within other assay systems known in the art. Such systems include Scatchard analysis for determination of binding affinity (see, Scatchard, *Ann. NY Acad. Sci.* 51: 660-72, 1949) and calorimetric assays (Cunningham et al., *Science* 253:545-48, 1991; Cunningham et al., *Science* 245:821-25, 1991).

**[0097]** Scatchard plot analysis for soluble  $^{125}$ -ztnf4 binding to TACI and BCMA is shown in Figure 2 and compared with the binding constants of other members of the TNFR family in Table 7.

Table 7

Ligand	Kd M	Cell source	Reference
TNFa high	7.14E-11	HL-60	a
TNFa low	3.26E-10	HEP-2	a
TNFa high	2.00E-10	HL-60	b

a Hohmann et al., *J. Biol. Chem.* 264:14927-34, 1989

b Manna and Aggarwal, *J. Biol. Chem.* 273:33333-41, 1998

Table 7 (continued)

Ligand	Kd M	Cell source	Reference
CD27L	3.70E-10	MP-1	c
CD27L	8.30E-09	MP-1	c
CD40L	5.00E-10	EL40.5	d
CD40L	1.00E-09	EBNA	d
(125I-CD40)			
4-1BBL	1.16E-09	Biacore	e
anti	41BBmab 4.14E-10	Biacore	e
ztnf4 sol.	1.11E-09	TACI-BHK	
ztnf4 sol.	1.25E-09	BCMA-BHK	

c Goodwin et al., *Cell* 73:447-56, 1993, 1997d Armitage et al., *Nature* 357:80-82, 1992e Shuford et al., *J. Exp. Med.* 186:47-55, 1997

**[0098]** As a receptor, the activation of BR43x2 polypeptide can be measured by a silicon-based biosensor microphysiometer which measures the extracellular acidification rate or proton excretion associated with receptor binding and subsequent physiologic cellular responses. An exemplary device is the Cytosensor™ Microphysiometer manufactured by Molecular Devices, Sunnyvale, CA. A variety of cellular responses, such as cell proliferation, ion transport, energy production, inflammatory response, regulatory and receptor activation, and the like, can be measured by this method. See, for example, McConnell et al., *Science* 257:1906-12, 1992; Pitchford et al., *Meth. Enzymol.* 228:84-108, 1997; Arimilli et al., *J. Immunol. Meth.* 212:49-59, 1998; Van Liefde et al., *Eur. J. Pharmacol.* 346:87-95, 1998. The microphysiometer can be used for assaying adherent or non-adherent eukaryotic or prokaryotic cells. By measuring extracellular acidification changes in cell media over time, the microphysiometer directly measures cellular responses to various stimuli, including agonists, ligands, or antagonists of the BR43x2 polypeptide. Preferably, the microphysiometer is used to measure responses of a BR43x2-expressing eukaryotic cell, compared to a control eukaryotic cell that does not express BR43x2 polypeptide. BR43x2-expressing eukaryotic cells comprise cells into which BR43x2 has been transfected, as described herein, creating a cell that is responsive to BR43x2-modulating stimuli; or cells naturally expressing BR43x2, such as BR43x2-expressing cells derived from spleen tissue. Differences, measured by a change in extracellular acidification, for example, an increase or diminution in the response of cells expressing BR43x2, relative to a control, are a direct measurement of BR43x2-modulated cellular responses. Moreover, such BR43x2-modulated responses can be assayed under a variety of stimuli. Also, using the microphysiometer, there is provided a method of identifying agonists and antagonists of BR43x2 polypeptide, comprising providing cells expressing a BR43x2 polypeptide, culturing a first portion of the cells in the absence of a test compound, culturing a second portion of the cells in the presence of a test compound, and detecting a change, for example, an increase or diminution, in a cellular response of the second portion of the cells as compared to the first portion of the cells. The change in cellular response is shown as a measurable change extracellular acidification rate. Antagonists and agonists for BR43x2 polypeptide can be rapidly identified using this method.

**[0099]** The soluble BR43x2 is useful in studying the distribution of ligands on tissues or specific cell lineages, and to provide insight into receptor/ligand biology. Application may also be made of the specificity of TNF receptors for their ligands as a mechanism by which to destroy ligand-bearing target cells. For example, toxic compounds may be coupled to BR43x2 soluble receptor or BR43x2 fusion. Examples of toxic compounds would include radiopharmaceuticals that inactivate target cells; chemotherapeutic agents such as doxorubicin, daunorubicin, methotrexate, and cytoxin; toxins, such as ricin, diphtheria, Pseudomonas exotoxin A and abrin; and antibodies to cytotoxic T-cell surface molecules.

**[0100]** Ztnf4 (5 ng/ml) was found to bind to BR43x2 (SEQ ID NO:2), TACI (SEQ ID NO:6), BCMA (SEQ ID NO:8) and BR43x1 (SEQ ID NO:9), by FACS analysis (Flow Cytometry and Sorting, Melamed et al. eds. Wiley-Liss, 1990 and Immunofluorescence and Cell Sorting, Current Protocols in Immunology, Volume 1, Coligan et al. eds. John Wiley

& Son, 1997). FITC-tagged, soluble ztnf4 was also shown to bind specifically to, among other things, B lymphocytes in PBMCs, tonsil cells, to B cell lymphoma cell lines (Raji, Burkitt's human lymphoma, ATCC CCL86), Ramos (Burkitt's lymphoma cell line, ATCC CRL-1596), Daudi (Burkitt's human lymphoma, ATCC CCL213) and RPMI 1788 <a B lymphocyte cell line, ATCC CCL-156) using FACS analysis. No binding was seen with HL-60, (ATCC a promyelocytic cell line, ATCC CCL-240). Specificity for binding to B cells from PBMC and tonsil cells was confirmed by co-staining with antibodies to B cell specific molecules including CD19, IgD, IgM, and CD20. Similarity of ztnf4 to CD40L suggested a broader tissue distribution than was seen. Affinity of ztnf4 was tested on monocytes, dendritic cells, and purified T cells using cytokine proliferation and T cell proliferation assays, for example, and could not detect binding of ztnf4 or any other biological effect on any other type of cell tested. Therefore, the specificity for B cells by the ligand and receptor suggests that they are useful for the study and treatment of autoimmunity, B cell cancers, immunomodulation, IBD and any antibody-mediated pathologies, e.g. ITCP, myasthenia gravis and the like, renal diseases, indirect T cell immune response, graft rejection, graft versus host disease.

**[0101]** Ztnf4 has been shown to activate B cells resulting in B cell proliferation, antibody production and up-regulation of activation markers *in vitro* (see examples below). These effects may require co-stimulation via IL-4 or other cytokines or stimulation through the B cell antigen receptor or other cell surface receptors which activate B cells, i.e., CD40. Other tumor necrosis factor ligands, such as gp39 and TNF $\beta$ , also stimulate B cell proliferation. Thus the polypeptides of the current invention can be targeted to specifically regulate B cell responses, inhibiting activated B cells, during the immune response without affecting other cell populations which is advantageous in the treatment of disease. Additionally, the polypeptides of the present invention could be used to modulate B cell development, development of other cells, antibody production and cytokine production. BR43x2 polypeptides can also find use in inducing apoptosis and/or anergy within cells. Polypeptides of the present invention could also modulate T and B cell communication by neutralizing the proliferative effects of ztnf4 Bioassays and ELISAs are available to measure cellular response to ztnf4 in the presence of soluble BR43x2, TACI and/or BCMA. Other assays include those which measure changes in cytokine production as a measure of cellular response (see for example, Current Protocols in Immunology ed. John E. Coligan et al., NIH, 1996). Assays to measure other cellular responses, including antibody isotype, monocyte activation, NK cell formation, antigen presenting cell function, apoptosis.

**[0102]** BR43x2 polypeptides of the present invention would be useful to neutralize the effects of ztnf4 for treating pre-B or B-cell leukemias, such as plasma cell leukemia, chronic or acute lymphocytic leukemia, myelomas such as multiple myeloma, plasma cell myeloma, endothelial myeloma and giant cell myeloma; and lymphomas such as non-Hodgkins lymphoma, for which an increase in ztnf4 polypeptides is associated. Soluble BR43x2 would be a useful component in a therapy regime for inhibiting tumor progression and survival.

**[0103]** Northern blot analysis showed ztnf4 is expressed in CD8<sup>+</sup> cells, monocytes, dendrocytes, activated monocytes. This suggests that in some autoimmune disorders, cytotoxic T-cells might stimulate B-cell production through excess production of ztnf4 Immunosuppressant proteins that selectively block the action of B-lymphocytes would be of use in treating disease. Autoantibody production is common to several autoimmune diseases and contributes to tissue destruction and exacerbation of disease. Autoantibodies can also lead to the occurrence of immune complex deposition complications and lead to many symptoms of systemic lupus erythromatosis, including kidney , failure, neuralgic symptoms and death. Modulating antibody production independent of cellular response would also be beneficial in many disease states. B cells have also been shown to play a role in the secretion of arthritogenic immunoglobulins in rheumatoid arthritis, (Korganow et al., Immunity 10:451-61, 1999). As such, inhibition of ztnf4 antibody production would be beneficial in treatment of autoimmune diseases such as myasthenia gravis and rheumatoid arthritis. Immunosuppressant therapeutics such as soluble BR43x2 that selectively block or neutralize the action of B-lymphocytes would be useful for such purposes. To verify these capabilities in BR43x2 soluble receptor polypeptides of the present invention, such BR43x2 polypeptides are evaluated using assays known in the art and described herein.

**[0104]** The invention provides methods employing BR43x2, TACI or BCMA polypeptides, fusions, antibodies, agonists or antagonists for selectively blocking or neutralizing the actions of B-cells in association with end stage renal diseases, which may or may not be associated with autoimmune diseases. Such methods would also be useful for treating immunologic renal diseases. Such methods would be useful for treating glomerulonephritis associated with diseases such as membranous nephropathy, IgA nephropathy or Berger's Disease, IgM nephropathy, Goodpasture's Disease, post-infectious glomerulonephritis; mesangioproliferative disease, minimal-change nephrotic syndrome. Such methods would also serve as therapeutic applications for treating secondary glomerulonephritis or vasculitis associated with such diseases as lupus, polyarteritis, Henoch-Schonlein, Scleroderma, HIV-related diseases, amyloidosis or hemolytic uremic syndrome. The methods of the present invention would also be useful as part of a therapeutic application for treating interstitial nephritis or pyelonephritis associated with chronic pyelonephritis, analgesic abuse, nephrocalcinosis, nephropathy caused by other agents, nephrolithiasis, or chronic or acute interstitial nephritis.

**[0105]** The methods of the present invention also include use of BR43x2, TACI or BCMA polypeptides, fusions, antibodies, agonists or antagonists in the treatment of hypertensive or large vessel diseases, including renal artery

stenosis or occlusion and cholesterol emboli or renal emboli.

**[0106]** The present invention also provides methods for diagnosis and treatment of renal or urological neoplasms, multiple myelomas, lymphomas, light chain neuropathy or amyloidosis.

**[0107]** The invention also provides methods for blocking or inhibiting activated B cells using BR43x2, TACI, or BCMA polypeptides, fusions, antibodies, agonists or antagonists for the treatment of asthma and other chronic airway diseases such as bronchitis and emphysema.

**[0108]** Also provided are methods for inhibiting or neutralizing an effector T cell response using BR43x2, TACI, or BCMA polypeptides, fusions, antibodies, agonists or antagonists for use in immunosuppression, in particular for such therapeutic use as for graft-versus-host disease and graft rejection. Additional use would be found in regulation of the immune response, in particular the activation and regulation of lymphocytes. BR43x2, TACI, or BCMA polypeptides, fusions, antibodies, agonists or antagonists would be useful in therapies for treating immunodeficiencies. BR43x2, TACI, or BCMA polypeptides, fusions, antibodies, agonists or antagonists would be useful in therapeutic protocols for treatment of such autoimmune diseases as insulin dependent diabetes mellitus (IDDM) and Crohn's Disease. Methods of the present invention would have additional therapeutic value for treating chronic inflammatory diseases, in particular to lessen joint pain, swelling, anemia and other associated symptoms as well as treating septic shock.

**[0109]** The effect of soluble BR43x2, TACI, or BCMA polypeptides and fusion proteins on immune response can be measured by administering the polypeptides of the present invention to animals immunized with antigen followed by injection of ztnf4 and measuring antibody isotype production and B and T cell responses including delayed type hypersensitivity and *in vitro* proliferation and cytokine production according to the methods known in the art.

**[0110]** The present invention therefore provides a method of inhibiting ztnf4 activity in a mammal comprising administering to said mammal an amount of a compound selected from the group consisting of: a) a polypeptide of SEQ ID NO:4; b) a polypeptide of SEQ ID NO:8; c) a fusion protein; d) a polypeptide of SEQ ID NO:6 from amino acid residue 1 to residue 166; e) a polypeptide of SEQ ID NO:8 from amino acid residue 1 to residue 150; f) an antibody or antibody fragment which specifically binds to a polypeptide of SEQ ID NO:4; and g) an antibody or antibody fragment which specifically binds to a polypeptide of SEQ ID NO:10. Examples of fusion proteins include fusions of soluble BR43x2 (SEQ ID NO:4), TACI (from amino acid residue 1 to residue 166 of SEQ ID NO:6) or BCMA (from amino acid residue 1 to residue 150 of SEQ ID NO:8) with another polypeptide, preferably an immunoglobulin heavy chain constant region F<sub>c</sub> fragment. The invention similarly provides a method for inhibiting BR43x2, TACI or BCMA receptor-ligand engagement.

**[0111]** Such methods would be particularly useful where ztnf4 activity is associated with activated B lymphocytes and for treating pre-B cell or B-cell cancers. Such methods would also be useful where ztnf4 activity is associated with antibody production. In particular, antibody production associated with autoimmune diseases such as systemic lupus erythematosus, myasthenia gravis or rheumatoid arthritis.

**[0112]** The present invention also provides BR43x2 agonists and antagonists. Compounds identified as BR43x2 agonists are useful for modifying the proliferation and development of target cells *in vitro* and *in vivo*. For example, agonist compounds are useful alone or in combination with other cytokines and hormones as components of defined cell culture media. Agonists are thus useful in specifically mediating the growth and/or development of BR43x2-bearing B lymphocytes cells in culture. Agonists and antagonists may also prove useful in the study of effector functions of B lymphocytes, in particular B lymphocyte activation and differentiation. Antagonists are useful as research reagents for characterizing ligand-receptor interaction.

**[0113]** Compounds identified as BR43x2 antagonists are also useful to boost the humoral immune response. B cell responses are important in fighting infectious diseases including bacterial, viral, protozoan and parasitic infections. Antibodies against infectious microorganisms can immobilize the pathogen by binding to antigen followed by complement mediated lysis or cell mediated attack. A BR43x2 antagonist would serve to boost the humoral response and would be a useful therapeutic for individuals at risk for an infectious disease or as a supplement to vaccination.

**[0114]** The invention also provides antagonists, which either bind to BR43x2 polypeptides or, alternatively, to a ligand to which BR43x2 polypeptides bind, thereby inhibiting or eliminating the function of BR43x2. Such BR43x2 antagonists would include antibodies; oligonucleotides which bind either to the BR43x2 polypeptide or to its ligand; natural or synthetic analogs of BR43x2 ligands which retain the ability to bind the receptor but do not result in either ligand or receptor signaling. Such analogs could be peptides or peptide-like compounds. Natural or synthetic small molecules which bind to BR43x2 polypeptides and prevent signaling are also contemplated as antagonists. As such, BR43x2 antagonists would be useful as therapeutics for treating certain disorders where blocking signal, from either a BR43x2 receptor or ligand would be beneficial. Antagonists are useful as research reagents for characterizing ligand-receptor interaction. BR43x2 is expressed on transformed B cell lines including EBV induced and spontaneous Burkitt's lymphoma and several B cell myelomas. Inhibiting the function of BR43x2 would be useful in the treatment of B cell lymphomas or multiple myelomas. BR43x2 antagonists, such as BR43x2 soluble receptors or antibodies, could be used therapeutically to mediate tumor progression.

**[0115]** The activity of agonists and antagonists can be determined by activity assays which determine the potency

of receptor/ligand engagement. Stably transfected B-cell lines, such as Baf3 (a murine pre-B cell line Palacios and Steinmetz, *ibid.* and Mathey-Prevot et al., *ibid.*), which co-express high levels of reporter gene constructs for NFkB, NFAT-1 and AP-1 were made which express BR43x2. Cell lines expressing TACI and BCMA were also be prepared in a similar manner and in Jurkat and other B lymphoma cell lines. Ztnf4 was found to signal through the reporter genes in these constructs. Soluble BR43x2 and antibodies can be used to measure binding.

[0116] An *in vivo* approach for assaying proteins of the present invention involves viral delivery systems. Exemplary viruses for this purpose include adenovirus, herpesvirus, vaccinia virus and adeno-associated virus (AAV). Adenovirus, a double-stranded DNA virus, is currently the best studied gene transfer vector for delivery of heterologous nucleic acid (for a review, see Becker et al., *Meth. Cell Biol.* 43:161-89, 1994; and Douglas and Curiel, *Science & Medicine* 4: 44-53, 1997). The adenovirus system offers several advantages: adenovirus can (i) accommodate relatively large DNA inserts; (ii) be grown to high-titer; (iii) infect a broad range of mammalian cell types; and (iv) be used with a large number of available vectors containing different promoters. Also, because adenoviruses are stable in the bloodstream, they can be administered by intravenous injection.

[0117] By deleting portions of the adenovirus genome, larger inserts (up to 7 kb) of heterologous DNA can be accommodated. These inserts may be incorporated into the viral DNA by direct ligation or by homologous recombination with a co-transfected plasmid. In an exemplary system, the essential E1 gene has been deleted from the viral vector, and the virus will not replicate unless the E1 gene is provided by the host cell (the human 293 cell line is exemplary). When intravenously administered to intact animals, adenovirus primarily targets the liver. If the adenoviral delivery system has an E1 gene deletion, the virus cannot replicate in the host cells. However, the host's tissue (e.g., liver) will express and process (and, if a signal sequence is present, secrete) the heterologous protein. Secreted proteins will enter the circulation in the highly vascularized liver, and effects on the infected animal can be determined.

[0118] The adenovirus system can also be used for protein production *in vitro*. By culturing adenovirus-infected non-293 cells under conditions where the cells are not rapidly dividing, the cells can produce proteins for extended periods of time. For instance, BHK cells are grown to confluence in cell factories, then exposed to the adenoviral vector encoding the secreted protein of interest. The cells are then grown under serum-free conditions, which allows infected cells to survive for several weeks without significant cell division. Alternatively, adenovirus vector infected 293S cells can be grown in suspension culture at relatively high cell density to produce significant amounts of protein (see Garnier et al., *Cytotechnol.* 15:145-55, 1994). With either protocol, an expressed, secreted heterologous protein can be repeatedly isolated from the cell culture supernatant. Within the infected 293S cell production protocol, non-secreted proteins may also be effectively obtained.

[0119] Well established animal models are available to test *in vivo* efficacy of soluble BR43x2, TACI, or BCMA polypeptides of the present invention in certain disease states. In particular, soluble BR43x2, TACI, or BCMA polypeptides and polypeptide fragments can be tested *in vivo* in a number of animal models of autoimmune disease, such as MRL-*lpr/lpr* or NZB x NZW F1 congenic mouse strains which serve as a model of SLE (systemic lupus erythematosus). Such animal models are known in the art, see for example *Autoimmune Disease Models A Guidebook*, Cohen and Miller eds. Academic Press. Offspring of a cross between New Zealand Black (NZB) and New Zealand White (NZW) mice develop a spontaneous form of SLE that closely resembles SLE in humans. The offspring mice, known as NZBW begin to develop IgM autoantibodies against T-cells at 1 month of age, and by 5-7 months of age, Ig anti-DNA autoantibodies are the dominant immunoglobulin. Polyclonal B-cell hyperactivity leads to overproduction of autoantibodies. The deposition of these autoantibodies, particularly ones directed against single stranded DNA is associated with the development of glomerulonephritis, which manifests clinically as proteinuria, azotemia, and death from renal failure. Kidney failure is the leading cause of death in mice affected with spontaneous SLE, and in the NZBW strain, this process is chronic and obliterative. The disease is more rapid and severe in females than males, with mean survival of only 245 days as compared to 406 days for the males. While many of the female mice will be symptomatic (proteinuria) by 7-9 months of age, some can be much younger or older when they develop symptoms. The fatal immune nephritis seen in the NZBW mice is very similar to the glomerulonephritis seen in human SLE, making this spontaneous murine model very attractive for testing of potential SLE therapeutics (Putterman and Naparstek, *Murine Models of Spontaneous Systemic Lupus Erythematosus*, *Autoimmune Disease Models: A Guidebook*, chapter-14, pp.217-34, 1994; Mohan et al., *J. Immunol.* 154:1470-80, 1995; and Daikh et al., *J. Immunol.* 159:3104-08, 1997). Administration of soluble TACI-Ig, BR43x2-Ig, BCMA-Ig or other soluble and fusion proteins to these mice to evaluate the efficacy of TACI, BR43x2, or BCMA to amelioration of symptoms and alterations to the course of disease is described below in the Example section.

[0120] Mouse models for experimental allergic encephalomyelitis (EAE) has been used as a tool to investigate both the mechanisms of immune-mediated disease, and methods of potential therapeutic intervention. The model resembles human multiple sclerosis, and produces demyelination as a result of T-cell activation to neuroproteins such as myelin basic protein (MBP), or proteolipid protein (PLP). Inoculation with antigen leads to induction of CD4+, class II MHC-restricted T-cells (Th1). Changes in the protocol for EAE can produce acute, chronic-relapsing, or passive-transfer variants of the model (Weinberg et al., *J. Immunol.* 162:1818-26, 1999; Mijaba et al., *Cell. Immunol.* 186:94-102, 1999;

and Glabinski, Meth. Enzym. 288:182-90, 1997). Administration of soluble TACI-Ig, BR43x2-Ig, BCMA-Ig or other soluble and fusion proteins to these mice to evaluate the efficacy of TACI, BR43x2, or BCMA to amelioration of symptoms and alterations to the course of disease is described below in the Example section.

**[0121]** In the collagen-induced arthritis (CIA) model, mice develop chronic inflammatory arthritis which closely resembles human rheumatoid arthritis (RA). Since CIA shares similar immunological and pathological features with RA, this makes it an ideal model for screening potential human anti-inflammatory compounds. Another advantage in using the CIA model is that the mechanisms of pathogenesis are known. The T and B cell epitopes on type II collagen have been identified, and various immunological (delayed-type hypersensitivity and anti-collagen antibody) and inflammatory (cytokines, chemokines, and matrix-degrading enzymes) parameters relating to immune-mediating arthritis have been determined, and can be used to assess test compound efficacy in the models (Wooley, Curr. Rheum. 3:407-20, 1999; Williams et al., Immunol. 89:9784-788, 1992; Myers et al., Life Sci. 61:1861-78, 1997; and Wang et al., Immunol. 92:8955-959, 1995). Administration of soluble TACI-Ig, BR43x2-Ig, BCMA-Ig or other soluble and fusion proteins to these mice to evaluate the efficacy of TACI, BR43x2, or BCMA to amelioration of symptoms and alterations to the course of disease is described below in the Example section.

**[0122]** Models for bronchial infection, such as asthma, can be created when mice are injected with ovalbumin and restimulated nasally with antigen which produces an asthmatic response in the bronchi similar to asthma. Administration of soluble TACI-Ig, BR43x2-Ig, BCMA-Ig, or other soluble and fusion proteins to these mice to evaluate the efficacy of TACI, BR43x2, or BCMA to amelioration of symptoms and alterations to the course of disease is described below in the Example section.

**[0123]** Another use for *in vivo* models includes delivery of an antigen challenge to the animal followed by administration of soluble BR43x2 (TACI) or its ligand ztnf4 and measuring the T and B cell response.

**[0124]** T cell dependent and T cell independent immune response can be measured as described in Perez-Melgosa et al., J. Immunol. 163:1123-7, 1999.

**[0125]** Immune response in animals subjected to a regular antigen challenge (for example, ovalbumin or collagen) followed by administration of BR43x2, TACI or BCMA polypeptides or soluble Ig-fusions can be done to measure effect on B cell response.

**[0126]** Pharmacokinetic studies can be used in association with radiolabeled, soluble BR43x2, TACI or BCMA polypeptides or fusions to determine the distribution and half life of such polypeptides *in vivo*. Additionally animal models can be used to determine the effects of soluble BR43x2, TACI or BCMA on tumors and tumor development *in vivo*.

**[0127]** Also provided is the use of BR43x2, TACI or BCMA polypeptides as surrogate markers for autoimmune diseases, kidney diseases, B and T cell diseases. Such patients can be bled and BR43x2, TACI or BCMA soluble receptors and their ligands can be detected in the blood.

**[0128]** The invention also provides antibodies. Antibodies to BR43x2 or peptides having an amino acid sequence of SEQ ID NO:8, can be obtained, for example, using as an antigen the product of an expression vector containing the polypeptide of interest, or a polypeptide isolated from a natural source. Particularly useful antibodies "bind specifically" with BR43x2 or peptides having an amino acid sequence of SEQ ID NO:10. Antibodies are considered to be specifically binding if the antibodies bind to a BR43x2 polypeptide or a polypeptide of SEQ ID NO:8, peptide or epitope with a binding affinity ( $K_a$ ) of  $10^6 M^{-1}$  or greater, preferably  $10^7 M^{-1}$  or greater, more preferably  $10^8 M^{-1}$  or greater, and most preferably  $10^9 M^{-1}$  or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, Ann. NY Acad. Sci. 51:660, 1949). Suitable antibodies include antibodies that bind with BR43x2, in particular the extracellular domain of BR43x2 (amino acid residues 1-120 of SEQ ID NO:2) and those that bind with polypeptides having an amino acid sequence of SEQ ID NO:10.

**[0129]** Anti-BR43x2 antibodies can be produced using antigenic BR43x2 epitope-bearing peptides and polypeptides. Antigenic epitope-bearing peptides and polypeptides of the present invention contain a sequence of at least nine, preferably between 15 to about 30 amino acids contained within SEQ ID NO:2. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of the invention, containing from 30 to 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are useful for inducing antibodies that bind with BR43x2. It is desirable that the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (*i.e.*, the sequence includes relatively hydrophilic residues, while hydrophobic residues are preferably avoided). Hydrophilic peptides can be predicted by one of skill in the art from a hydrophobicity plot, see for example, Hopp and Woods (Proc. Nat. Acad. Sci. USA 78:3824-8, 1981) and Kyte and Doolittle (J. Mol. Biol. 157: 105-142, 1982). Moreover, amino acid sequences containing proline residues may be also be desirable for antibody production.

**[0130]** Polyclonal antibodies to recombinant BR43x2 protein or to BR43x2 isolated from natural sources can be prepared using methods well-known to those of skill in the art. See, for example, Green et al., "Production of Polyclonal Antisera," in Immunochemical Protocols (Manson, ed.), pages 1-5 (Humana Press 1992), and Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in DNA Cloning 2: Expression Systems, 2nd Edition, Glover et al. (eds.), page 15 (Oxford University Press 1995). The immunogenicity

of a BR43x2 polypeptide can be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of BR43x2 or a portion thereof 'with an immunoglobulin polypeptide or with maltose binding protein. , The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "haptene-like,"

5 such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

[0131] Although polyclonal antibodies are typically raised in animals such as horses, cows, dogs, chicken, rats, mice, rabbits, hamsters, guinea pigs, goats or sheep, an anti-BR43x2 antibody of the present invention may also be derived from a subhuman primate antibody. General techniques for raising diagnostically and therapeutically useful antibodies

10 in baboons may be found, for example, in Goldenberg et al., international patent publication No. WO 91/11465, and in Losman et al., Int. J. Cancer 46:310, 1990. Antibodies can also be raised in transgenic animals such as transgenic sheep, cows, goats or pigs, and may be expressed in yeast and fungi in modified forms as will as in mammalian and insect cells.

[0132] Alternatively, monoclonal anti-BR43x2 antibodies can be generated. Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art (see, for example, Kohler et al., Nature 256: 495, 1975, Coligan et al. (eds.), Current Protocols in Immunology, Vol. 1, pages 2.5.1-2.6.7 (John Wiley & Sons 1991),

15 Picksley et al., "Production of monoclonal antibodies against proteins expressed in *E. coli*," in DNA Cloning 2: Expression Systems, 2nd Edition, Glover et al. (eds.), page 93 (Oxford University Press 1995)).

[0133] Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising a BR43x2 gene product, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

20

[0134] In addition, an anti-BR43x2 antibody of the present invention may be derived from a human monoclonal antibody. Human monoclonal antibodies are obtained from transgenic mice that have been engineered to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described, for example, by Green et al., Nat. Genet. 7:13, 1994, Lonberg et al., Nature 368:856, 1994, and Taylor et al., Int. Immun. 6:579, 1994.

25

[0135] Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography. (see, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3; Baines et al., "Purification of Immunoglobulin G (IgG)," in Methods in Molecular Biology, Vol. 10, pages 79-104 (The Humana Press, Inc. 1992)).

30

[0136] For particular uses, it may be desirable to prepare fragments of anti-BR43x2 antibodies. Such antibody fragments can be obtained, for example, by proteolytic hydrolysis of the antibody. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As an illustration, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')<sub>2</sub>. This fragment can be further cleaved using a thiol reducing agent to produce 3.5S Fab' monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that result from cleavage of disulfide linkages. As an alternative, an enzymatic cleavage using pepsin produces two monovalent Fab fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patent No. 4,331,647, Nisonoff et al., Arch Biochem. Biophys. 89:230, 1960, Porter, Biochem. J. 73:119, 1959, Edelman et al., in Methods in Enzymology Vol. 1, page 422 (Academic Press 1967), and by Coligan, *ibid*.

35

[0137] Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

40

[0138] For example, Fv fragments comprise an association of V<sub>H</sub> and V<sub>L</sub> chains. This association can be noncovalent, as described by Inbar et al., Proc. Natl. Acad. Sci. USA 69:2659, 1972. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde (see, for example, Sandhu, Crit. Rev. Biotech. 12:437, 1992).

45

[0139] The Fv fragments may comprise V<sub>H</sub> and V<sub>L</sub> chains which are connected by a peptide linker. These single-chain antigen binding proteins (scFv) are prepared by constructing a structural gene comprising DNA sequences encoding the V<sub>H</sub> and V<sub>L</sub> domains which are connected by an oligonucleotide. The structural gene is inserted into an expression vector which is subsequently introduced into a host cell, such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing scFvs are

50



described, for example, by Whitlow et al., Methods: A Companion to Methods in Enzymology 2:97, 1991, also see, Bird et al., Science 242:423, 1988, Ladner et al., U.S. Patent No. 4,946,778, Pack et al., Bio/Technology 11:1271, 1993, and Sandhu, ibid.

[0140] As an illustration, a scFV can be obtained by exposing lymphocytes to BR43x2 polypeptide *in vitro*, and selecting antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled BR43x2 protein or peptide). Genes encoding polypeptides having potential BR43x2 polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances. Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al., U.S. Patent No. 5,223,409, Ladner et al., U.S. Patent No. 4,946,778, Ladner et al., U.S. Patent No. 5,403,484, Ladner et al., U.S. Patent No. 5,571,698, and Kay et al., Phage Display of Peptides and Proteins (Academic Press, Inc. 1996)) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from Clontech (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA), and Pharmacia LKB Biotechnology Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the BR43x2 sequences disclosed herein to identify proteins which bind to BR43x2.

[0141] Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (see, for example, Larrick et al., Methods: A Companion to Methods in Enzymology 2:106, 1991), Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), page 166 (Cambridge University Press 1995), and Ward et al., "Genetic Manipulation and Expression of Antibodies," in Monoclonal Antibodies: Principles and Applications, Birch et al., (eds.), page 137 (Wiley-Liss, Inc. 1995)).

[0142] Alternatively, an anti-BR43x2 antibody may be derived from a "humanized" monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementary determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain. Typical residues of human antibodies are then substituted in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi et al., Proc. Natl. Acad. Sci. USA 86:3833, 1989. Techniques for producing humanized monoclonal antibodies are described, for example, by Jones et al., Nature 321:522, 1986, Carter et al., Proc. Nat. Acad. Sci. USA 89:4285, 1992, Sandhu, Crit. Rev. Biotech. 12:437, 1992, Singer et al., J. Immun. 150:2844, 1993, Sudhir (ed.), Antibody Engineering Protocols (Humana Press, Inc. 1995), Kelley, "Engineering Therapeutic Antibodies," in Protein Engineering: Principles and Practice, Cleland et al. (eds.), pages 399-434 (John Wiley & Sons, Inc. 1996), and by Queen et al., U.S. Patent No. 5,693,762 (1997).xxx

[0143] Polyclonal anti-idiotypic antibodies can be prepared by immunizing animals with anti-BR43x2 antibodies or antibody fragments, using standard techniques. See, for example, Green et al., "Production of Polyclonal Antisera," in Methods In Molecular Biology: Immunochemical Protocols, Manson (ed.), pages 1-12 (Humana Press 1992). Also, see Coligan, ibid. at pages 2.4.1-2.4.7. Alternatively, monoclonal anti-idiotypic antibodies can be prepared using anti-BR43x2 antibodies or antibody fragments as immunogens with the techniques, described above. As another alternative, humanized anti-idiotypic antibodies or subhuman primate anti-idiotypic antibodies can be prepared using the above-described techniques. Methods for producing anti-idiotypic antibodies are described, for example, by Irie, U.S. Patent No. 5,208,146, Greene, et. al., U.S. Patent No. 5,637,677, and Varthakavi and Minocha, J. Gen. Virol. 77:1875, 1996.

[0144] Antibodies or polypeptides herein can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. For instance, polypeptides or antibodies of the present invention can be used to identify or treat tissues or organs that express a corresponding anti-complementary molecule (receptor or antigen, respectively, for instance). More specifically, BR43x2 polypeptides or anti-BR43x2 antibodies, or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the anti-complementary molecule.

[0145] Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, Pseudomonas exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the

polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/anti-complementary pair, where the other member is bound to the polypeptide or antibody portion. For these purposes,

5 biotin/streptavidin is an exemplary complementary/anticomplementary pair.  
**[0146]** Soluble BR43x2 polypeptides or antibodies to BR43x2 can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for in vivo diagnostic or therapeutic applications. For instance, polypeptides or antibodies of the present invention can be used to identify or treat tissues or organs that "express a corresponding anti-complementary molecule (receptor or antigen, respectively, for instance). More specifically, BR43x2

10 polypeptides or anti-BR43x2 antibodies, or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the anti-complementary molecule.  
**[0147]** Suitable detectable molecules can be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules can be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, *Pseudomonas* exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or antibodies can also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or

20 cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/anticomplementary pair, where the other member is bound to the polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/anticomplementary pair.  
**[0148]** Such polypeptide-toxin fusion proteins or antibody/fragment-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Alternatively, if the polypeptide has multiple functional domains (i.e., an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain can be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the domain only fusion protein includes a complementary molecule, the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/

30 tissue-specific delivery of generic anti-complementary-detectable/cytotoxic molecule conjugates. The bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action.  
**[0149]** Antibodies can be made to soluble, BR43x2 polypeptides which are His or FLAG<sup>TM</sup> tagged. Antibodies can also be prepared to *E. coli* produced MBP-fusion proteins. Alternatively, such polypeptides could include a fusion protein with Human Ig. In particular, antiserum containing polypeptide antibodies to His-tagged, or FLAG<sup>TM</sup> tagged soluble BR43x2 can be used in analysis of tissue distribution of BR43x2 by immunohistochemistry on human or primate tissue. These soluble BR43x2 polypeptides can also be used to immunize mice in order to produce monoclonal antibodies to a soluble human BR43x2 polypeptide. Monoclonal antibodies to a soluble human BR43x2 polypeptide can also be used to mimic ligand/receptor coupling, resulting in activation or inactivation of the ligand/receptor pair. For

40 instance, it has been demonstrated that cross-linking anti-soluble CD40 monoclonal antibodies provides a stimulatory signal to B cells that have been sub-optimally activated with anti-IgM or LPS, and results in proliferation and immunoglobulin production. These same monoclonal antibodies act as antagonists when used in solution by blocking activation of the receptor. Monoclonal antibodies to BR43x2 can be used to determine the distribution, regulation and biological interaction of the BR43x2/BR43x2-ligand pair on specific cell lineages identified by tissue distribution studies.  
**[0150]** The invention also provides isolated and purified BR43x2, TACI and BCMA polynucleotide probes or primers. Such polynucleotide probes can be RNA or DNA. DNA can be either cDNA or genomic DNA. Polynucleotide probes are single or double-stranded DNA or RNA, generally synthetic oligonucleotides, but may be generated from cloned cDNA or genomic sequences and will generally comprise at least 16 nucleotides, more often from 17 nucleotides to 25 or more nucleotides, sometimes 40 to 60 nucleotides, and in some instances a substantial portion, domain or even

50 the entire BR43x2 gene or cDNA. Probes and primers are generally synthetic oligonucleotides, but may be generated from cloned cDNA or genomic sequences or its complements. Analytical probes will generally be at least 20 nucleotides in length, although somewhat shorter probes (14-17 nucleotides) can be used. PCR primers are at least 5 nucleotides in length, preferably 15 or more nt, more preferably 20-30 nt. Short polynucleotides can be used when a small region of the gene is targeted for analysis. For gross analysis of genes, a polynucleotide probe may comprise an entire exon or more. Probes can be labeled to provide a detectable signal, such as with an enzyme, biotin, a radionuclide, fluorophore, chemiluminescer, paramagnetic particle and the like, which are commercially available from many sources, such as Molecular Probes, Inc., Eugene, OR, and Amersham Corp., Arlington Heights, IL, using techniques that are well known in the art. Preferred regions from which to construct probes include the ligand binding region, cysteine-rich

pseudo repeats, signal sequences, and the like. Techniques for developing polynucleotide probes and hybridization techniques are known in the art, see for example, Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1991.

[0151] BR43x2, TACI and BCMA polypeptides and antibodies may be used within diagnostic systems to detect the presence of BR43x2, TACI, and BCMA and BR43x2, TACI, and BCMA ligand polypeptides, such as ztnf4. The information derived from such detection methods would provide insight into the significance of BR43x2 polypeptides in various diseases, and as a would serve as diagnostic tools for diseases for which altered levels of BR43x2 are significant. Altered levels of BR43x2, TACI and BCMA receptor polypeptides may be indicative of pathological conditions including cancer, autoimmune disorders and infectious diseases.

[0152] In a basic assay, a single-stranded probe molecule is incubated with RNA, isolated from a biological sample, under conditions of temperature and ionic strength that promote base pairing between the probe and target BR43x2, TACI or BCMA RNA species. After separating unbound probe from hybridized molecules, the amount of hybrids is detected.

[0153] Well-established hybridization methods of RNA detection include northern analysis and dot/slot blot hybridization (see, for example, Ausubel *ibid.* and Wu et al. (eds.), "Analysis of Gene Expression at the RNA Level," in Methods in Gene Biotechnology, pages 225-239 (CRC Press, Inc. 1997)). Nucleic acid probes can be detectably labeled with radioisotopes such as <sup>32</sup>P or <sup>35</sup>S. Alternatively, BR43x2 RNA can be detected with a nonradioactive hybridization method (see, for example, Isaac (ed.), Protocols for Nucleic Acid Analysis by Nonradioactive Probes, Humana Press, Inc., 1993). Typically, nonradioactive detection is achieved by enzymatic conversion of chromogenic or chemiluminescent substrates. Illustrative nonradioactive moieties include biotin, fluorescein, and digoxigenin.

[0154] BR43x2, TACI, and BCMA oligonucleotide probes are also useful for *in vivo* diagnosis. As an illustration, <sup>18</sup>F-labeled oligonucleotides can be administered to a subject and visualized by positron emission tomography (Tavitian *et al.*, Nature Medicine 4:467, 1998).

[0155] Numerous diagnostic procedures take advantage of the polymerase chain reaction (PCR) to increase sensitivity of detection methods. Standard techniques for performing PCR are well-known (see, generally, Mathew *led.*), Protocols in Human Molecular Genetics (Humana Press, Inc. 1991), White (ed.), PCR Protocols: Current Methods and Applications (Humana Press, Inc. 1993), Cotter (ed.), Molecular Diagnosis of Cancer (Humana Press, Inc. 1996), Hanausek and Walaszek (eds.), Tumor Marker Protocols (Humana Press, Inc. 1998), Lo (ed.), Clinical Applications of PCR (Humana Press, Inc. 1998), and Meltzer (ed.), PCR in Bioanalysis (Humana Press, Inc. 1998)). PCR primers can be designed to amplify a sequence encoding a particular BR43x2 domain or motif, such as the BR43x2, TACI or BCMA cysteine rich pseudo repeat.

[0156] One variation of PCR for diagnostic assays is reverse transcriptase-PCR (RT-PCR). In the RT-PCR technique, RNA is isolated from a biological sample, reverse transcribed to cDNA, and the cDNA is incubated with BR43x2 primers (see, for example, Wu et al. (eds.), "Rapid Isolation of Specific cDNAs or Genes by PCR," in Methods in Gene Biotechnology, CRC Press, Inc., pages 15-28, 1997). PCR is then performed and the products are analyzed using standard techniques.

[0157] As an illustration, RNA is isolated from biological sample using, for example, the guanidinium-thiocyanate cell lysis procedure described above. Alternatively, a solid-phase technique can be used to isolate mRNA from a cell lysate. A reverse transcription reaction can be primed with the isolated RNA using random oligonucleotides, short homopolymers of dT, or BR43x2, TACI, or BCMA anti-sense oligomers. Oligo-dT primers offer the advantage that various mRNA nucleotide sequences are amplified that can provide control target sequences. BR43x2, TACI, or BCMA sequences are amplified by the polymerase chain reaction using two flanking oligonucleotide primers that are typically at least 5 bases in length.

[0158] PCR amplification products can be detected using a variety of approaches. For example, PCR products can be fractionated by gel electrophoresis, and visualized by ethidium bromide staining. Alternatively, fractionated PCR products can be transferred to a membrane, hybridized with a detectably-labeled BR43x2 probe, and examined by autoradiography. Additional alternative approaches include the use of digoxigenin-labeled deoxyribonucleic acid triphosphates to provide chemiluminescence detection, and the C-TRAK colorimetric assay.

[0159] Another approach is real time quantitative PCR (Perkin-Elmer Cetus, Norwalk, Ct.). A fluorogenic probe, consisting of an oligonucleotide with both a reporter and a quencher dye attached, anneals specifically between the forward and reverse primers. Using the 5' endonuclease activity of Taq DNA polymerase, the reporter dye is separated from the quencher dye and a sequence-specific signal is generated and increases as amplification increases. The fluorescence intensity can be continuously monitored and quantified during the PCR reaction.

[0160] Another approach for detection of BR43x2, TACI, or BCMA expression is cycling probe technology (CPT), in which a single-stranded DNA target binds with an excess of DNA-RNA-DNA chimeric probe to form a complex, the RNA portion is cleaved with RNase H, and the presence of cleaved chimeric probe is detected (see, for example, Beggs *et al.*, J. Clin. Microbiol. 34:2985, 1996 and Bekkaoui *et al.*, Biotechniques 20:240, 1996). Alternative methods for detection of BR43x2, TACI or BCMA sequences can utilize approaches such as nucleic acid sequence-based

amplification (NASBA), cooperative amplification of templates by cross-hybridization (CATCH), and the ligase chain reaction (LCR) (see, for example, Marshall et al., U.S. Patent No. 5,686,272 (1997), Dyer et al., J. Virol. Methods 60: 161, 1996; Ehrlich et al., Eur. J. Biochem. 243:358, 1997 and Chadwick et al., J. Virol. Methods 70:59, 1998). Other standard methods are known to those of skill in the art.

5 [0161] BR43x2, TACI, and BCMA probes and primers can also be used to detect and to localize BR43x2, TACI, or BCMA gene expression in tissue samples. Methods for such *in situ* hybridization are well-known to those of skill in the art (see, for example, Choo (ed.), In Situ Hybridization Protocols, Humana Press, Inc., 1994; Wu et al. (eds.), "Analysis of Cellular DNA or Abundance of mRNA by Radioactive *In Situ* Hybridization IRISH), in Methods in Gene Biotechnology, CRC Press, Inc., pages 259-278, 1997 and Wu et al. (eds.), "Localization of DNA or Abundance of mRNA by Fluorescence *In Situ* Hybridization IRISH), in Methods in Gene Biotechnology, CRC Press, Inc., pages 279-289, 1997).

10 [0162] Various additional diagnostic approaches are well-known to those of skill in the art (see, for example, Mathew (ed.), Protocols in Human Molecular Genetics Humana Press, Inc., 1991; Coleman and Tsongalis, Molecular Diagnostics, Humana Press, Inc., 1996 and Elles, Molecular Diagnosis of Genetic Diseases, Humana Press, Inc., 1996).

15 [0163] In addition, such polynucleotide probes could be used to hybridize to counterpart sequences on individual chromosomes. Chromosomal identification and/or mapping of the BR43x2 gene could provide useful information about gene function and disease association. Many mapping techniques are available to one skilled in the art, for example, mapping somatic cell hybrids, and fluorescence *in situ* hybridization (FISH). A preferred method is radiation hybrid mapping. Radiation hybrid mapping is a somatic cell genetic technique developed for constructing high-resolution, contiguous maps of mammalian chromosomes (Cox et al., Science 250:245-50, 1990). Partial or full knowledge of a  
20 gene's sequence allows the designing of PCR primers suitable for use with chromosomal radiation hybrid mapping panels. Commercially available radiation hybrid mapping panels which cover the entire human genome, such as the Stanford G3 RH Panel and the GeneBridge 4 RH Panel (Research Genetics, Inc., Huntsville, AL), are available. These panels enable rapid, PCR based, chromosomal localizations and ordering of genes, sequence-tagged sites (STSs), and other non-polymorphic- and polymorphic markers within a region of interest. This includes establishing directly  
25 proportional physical distances between newly discovered genes of interest and previously mapped markers. The precise knowledge of a gene's position can be useful in a number of ways including: 1) determining if a sequence is part of an existing contig and obtaining additional surrounding genetic sequences in various forms such as YAC-, BAC- or cDNA clones, 2) providing a possible candidate gene for an inheritable disease which shows linkage to the same chromosomal region, and 3) for cross-referencing model organisms such as mouse which may be beneficial in helping  
30 to determine what function a particular gene might have.

[0164] Chromosomal localization can also be done using STSs. An STS is a DNA sequence that is unique in the human genome and can be used as a reference point for a particular chromosome or region of a chromosome. An STS can be defined by a pair of oligonucleotide primers that can be used in a polymerase chain reaction to specifically detect this site in the presence of all other genomic sequences. Since STSs are based solely on DNA sequence they  
35 can be completely described within a database, for example, Database of Sequence Tagged Sites (dbSTS), GenBank, (National Center for Biological Information, National Institutes of Health, Bethesda, MD <http://www.ncbi.nlm.nih.gov>), they can be searched with a gene sequence of interest for the mapping data contained within these short genomic landmark STS sequences.

40 [0165] The present invention also provides reagents for additional diagnostic applications. For example, the BR43x2 gene, a probe comprising BR43x2 DNA or RNA, or a subsequence thereof can be used to determine if the BR43x2 gene is present on a particular chromosome or if a mutation has occurred. Detectable chromosomal aberrations at the BR43x2 gene locus include, but are not limited to, aneuploidy, gene copy number changes, insertions, deletions, restriction site changes and rearrangements. These aberrations can occur within the coding sequence, within introns, or within flanking sequences, including upstream promoter and regulatory regions, and may be manifested as physical  
45 alterations within a coding sequence or changes in gene expression level.

[0166] In general, these diagnostic methods comprise the steps of (a) obtaining a genetic sample from a patient; (b) incubating the genetic sample with a polynucleotide probe or primer as disclosed above, under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence, to produce a first reaction product; and (iii) comparing the first reaction product to a control reaction product. A difference between the first reaction product and the control reaction product is indicative of a genetic abnormality in the patient. Genetic samples for use within the present invention include genomic DNA, cDNA, and RNA. The polynucleotide probe or primer can be RNA or DNA, and will comprise a portion of SEQ ID NO:3, the complement of SEQ ID NO:1, or an RNA equivalent thereof. Suitable assay methods in this regard include molecular genetic techniques known to those in the art, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, ligation chain reaction (Barany, PCR Methods and Applications 1:5-16, 1991), ribonuclease protection assays, and other genetic linkage analysis techniques known in the art (Sambrook et al., *ibid.*; Ausubel et al., *ibid.*; Marian, Chest 108: 255-65, 1995). Ribonuclease protection assays (see, e.g., Ausubel et al., *ibid.*, ch. 4) comprise the hybridization of an RNA probe to a patient RNA sample, after which the reaction product (RNA-RNA hybrid) is exposed to RNase. Hy-

bridized regions of the RNA are protected from digestion. Within PCR assays, a patient's genetic sample is incubated with a pair of polynucleotide primers, and the region between the primers is amplified and recovered. Changes in size or amount of recovered product are indicative of mutations in the patient. Another PCR-based technique that can be employed is single strand conformational polymorphism (SSCP) analysis (Hayashi, PCR Methods and Applications 1: 34-8, 1991).

**[0167]** Antisense methodology can be used to inhibit BR43x2, TACI, or BCMA gene transcription, such as to inhibit B cell development and interaction with other cells. Polynucleotides that are complementary to a segment of a BR43x2, TACI, or BCMA-encoding polynucleotide (e.g., a polynucleotide as set forth in SEQ ID NO:3 are designed to bind to BR43x2, TACI, or BCMA-encoding mRNA and to inhibit translation of such mRNA. Such antisense polynucleotides are used to inhibit expression of BR43x2, TACI, or BCMA polypeptide-encoding genes in cell culture or in a subject.

**[0168]** Mice engineered to express BR43x2, TACI, or BCMA, referred to as "transgenic mice," and mice that exhibit a complete absence of BR43x2, TACI, or BCMA function, referred to as "knockout mice," may also be generated (Snouwaert et al., Science 257:1083, 1992; Lowell et al., Nature 366:740-42, 1993; Capecchi, Science 244: 1288-92, 1989; Palmiter et al. Annu Rev Genet. 20: 465-99, 1986). For example, transgenic mice that over-express BR43x2, TACI, or BCMA either ubiquitously or under a tissue-specific or tissue-restricted promoter can be used to ask whether over-expression causes a phenotype. For example, over-expression of a wild-type BR43x2, TACI, or BCMA polypeptide, polypeptide fragment or a mutant thereof may alter normal cellular processes, resulting in a phenotype that identifies a tissue in which BR43x2, TACI, or BCMA expression is functionally relevant and may indicate a therapeutic target for BR43x2, TACI, BCMA or their agonists or antagonists. For example, a preferred transgenic mouse to engineer is one that over-expresses soluble BR43x2, TACI or BCMA. Moreover, such over-expression may result in a phenotype that shows similarity with human diseases.. Similarly, knockout BR43x2, TACI, or BCMA mice can be used to determine where BR43x2 is absolutely required *in vivo*. The phenotype of knockout mice is predictive of the *in vivo* effects that a BR43x2, TACI, or BCMA antagonist, such as those described herein, may have. The human BR43x2, TACI, or BCMA cDNA can be used to isolate murine BR43x2, TACI, or BCMA mRNA, cDNA and genomic DNA, which are subsequently used to generate knockout mice. These mice may be employed to study the BR43x2, TACI, or BCMA gene and the protein encoded thereby in an *in vivo* system, and can be used as *in vivo* models for corresponding human diseases. Moreover, transgenic expression of BR43x2, TACI, or BCMA antisense polynucleotides or ribozymes directed against BR43x2, TACI, or BCMA, described herein, can be used analogously to transgenic mice described above.

**[0169]** Pharmaceutically effective amounts of BR43x2, TACI, or BCMA polypeptides of the present invention can be formulated with pharmaceutically acceptable carriers for parenteral, oral, nasal, rectal, topical, transdermal administration or the like, according to conventional methods. Formulations may further include one or more diluents, fillers, emulsifiers, preservatives, buffers, excipients, and the like, and may be provided in such forms as liquids, powders, emulsions, suppositories, liposomes, transdermal patches and tablets, for example. Slow or extended-release delivery systems, including any of a number of biopolymers (biological-based systems), systems employing liposomes, and polymeric delivery systems, can also be utilized with the compositions described herein to provide a continuous or long-term source of the BR43x2 polypeptide or antagonist. Such slow release systems are applicable to formulations, for example, for oral, topical and parenteral use. The term "pharmaceutically acceptable carrier" refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the active ingredients and which is not toxic to the host or patient. One skilled in the art may formulate the compounds of the present invention in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington: The Science and Practice of Pharmacy, Gennaro, ed., Mack Publishing Co., Easton PA, 19th ed., 1995.

**[0170]** As used herein a "pharmaceutically effective amount" of a BR43x2, TACI, or BCMA polypeptide, agonists or antagonist is an amount sufficient to induce a desired biological result. The result can be alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an effective amount of a BR43x2, TACI, or BCMA polypeptide is that which provides either subjective relief of symptoms or an objectively identifiable improvement as noted by the clinician or other qualified observer. For example, such an effective amount of a BR43x2, TACI, or BCMA polypeptide or soluble fusion would provide a decrease in B cell response during the immune response, inhibition or decrease in autoantibody production, inhibition of diminution of symptoms associated with SLE, MG or RA. Effective amounts of BR43x2, TACI, or BCMA will decrease the percentage of B cells in peripheral blood. Effective amounts of the BR43x2, TACI, or BCMA polypeptides can vary widely depending on the disease or symptom to be treated. The amount of the polypeptide to be administered and its concentration in the formulations, depends upon the vehicle selected, route of administration, the potency of the particular polypeptide, the clinical condition of the patient, the side effects and the stability of the compound in the formulation. Thus, the clinician will employ the appropriate preparation containing the appropriate concentration in the formulation, as well as the amount of formulation administered, depending upon clinical experience with the patient in question or with similar patients. Such amounts will depend, in part, on the particular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art. Typically a dose will be in the range of 0.1-100 mg/kg of subject. Doses for specific compounds may be determined from *in vitro* or *ex vivo* studies in combination with

studies on experimental animals. Concentrations of compounds found to be effective *in vitro* or *ex vivo* provide guidance for animal studies, wherein doses are calculated to provide similar concentrations at the site of action.

[0171] The invention is further illustrated by the following non-limiting examples.

## 5 EXAMPLES

### Example 1 Identification of BR43x2

[0172] The TACI isoform was cloned from RPMI array library using secretion trap approach. An RPMI 1788 (activated B-cell line) library was arrayed using twenty 96-well plates. Each well contained about 100 *E. coli* colonies, with each colony containing one cDNA clone. DNA minipreps were prepared in 96-well format using the TomTech Quadra 9600. The isolated DNA was then pooled into 120 pools which represent 1600 clones each. These pools were transfected into Cos-7 cells and plated into 12-well plates. Three microliters of pool DNA and 5  $\mu$ l LipofectAMINE were mixed in 92  $\mu$ l serum-free DMEM media (55 mg sodium pyruvate, 146 mg L-glutamine, 5 mg transferrin, 2.5 mg insulin, 1  $\mu$ g selenium and 5 mg fetuin in 500 ml DMEM), incubated at room temperature for 30 minutes, followed by addition of 400  $\mu$ l serum-free DMEM media. The DNA-LipofectAMINE mix was added onto 220,000 Cos-7 cells/well plated on 12-well tissue culture plates and incubated for 5 hours at 37°C. Following incubation, 500  $\mu$ l of 20% FBS DMEM media (100 ml FBS, 55 mg sodium pyruvate and 146 mg L-glutamine in 500 ml DMEM) was added to each well and the cells were incubated overnight.

[0173] The secretion trap screen was performed using biotinylated, FLAG-tagged ztnf4. The cells were rinsed with PBS and fixed for 15 minutes with 1.8% formaldehyde in PBS. The cells were then washed with TNT (0.1 M Tris-HCl, 0.15 M NaCl, and 0.05% Tween-20 in H<sub>2</sub>O). Cells were permeated with 0.1% Triton-X in PBS for 15 minutes followed by a wash in TNT. The cells were blocked for 1 hour with TNB (0.1 M Tris-HCl, 0.15 M NaCl and 0.5% Blocking Reagent) using a NEN Renaissance® TSA-Direct Kit (NEN, Boston, MA) according the manufacturer's instruction. The cells were washed with TNT and blocked for 15 minutes with avidin and then biotin (Vector Labs Cat# SP-2001) washing in-between with TNT. The cells were incubated for 1 hour with 1  $\mu$ g/ml ztnf4/Flag/Biotin in TNB followed by a TNT wash. The cells were then incubated for one hour with a 1:300 dilution of streptavidin-HRP (NEN) in TNB, and washed with TNT. Hybridizations were detected with fluorescein tyramide reagent diluted 1:50 in dilution buffer (NEN) and incubated for 4.4 minutes and washed with TNT. Cells were preserved with Vectashield Mounting Media (Vector Labs, Burlingame, CA) diluted 1:5 in TNT.

[0174] The cells were visualized by fluorescent microscopy using a FITC filter. Twelve pools were positive for ztnf4 binding. Pool D8 (representing 1600 clones) was broken down and a single clone (D8-1), positive for ztnf4 binding, was isolated. Sequencing analysis revealed clone, D8-1, contained a polypeptide sequence which encoded an isoform of TACI, in which the Phe21-Arg67 first cysteine-rich pseudo repeat of TACI was replaced by a single amino acid residue, tryptophan. This isoform was designated BR43x2, the polynucleotide sequence of which is presented in SEQ ID NO:1.

### Example 2 Localization of BR43x1 in Lymphocytes and Monocytes

[0175] Reverse transcriptase PCR was used to localize BR43x1 expression in T and B cells and monocytes. Oligonucleotide primers ZC19980 (SEQ ID NO:15) and ZC19981 (SEQ ID NO:16) were used to screen CD19<sup>+</sup>, CD3<sup>+</sup> and monocyte cDNA for BR43. The reverse transcriptase reaction was carried out at 94°C for 3 minutes, followed by 30 cycles at 94°C for 30 seconds, 68°C for 2 minutes and 72°C for 1 minute, followed by a 7 minute extension at 72°C. A band of the expected size, 720 bp, was detected in B cells only and not in activated T cells as had been reported for TACI using antibodies (von Bülow and Bram, *ibid.*).

### Example 3 B cell Proliferation Assay using the BR43 Ligand Ztnf4

[0176] A vial containing 1 x 10<sup>8</sup> frozen, apheresed peripheral blood mononuclear cells (PBMCs) was quickly thawed in 37°C water bath and resuspended in 25 ml B cell medium (Iscove's Modified Dulbecco's Medium, 10% heat inactivated fetal bovine serum, 5% L-glutamine, 5% Pen/Strep) in a 50 ml tube. Cells were tested for viability using Trypan Blue (GIBCO BRL, Gaithersburg, MD). Ten milliliters of Ficoll/Hypaque Plus (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) was layered under cell suspension and spun for 30 minutes at 1800 rpm and allowed to stop with the brake off. The interphase layer was then removed and transferred to a fresh 50 ml tube, brought up to a final volume of 40 ml with PBS and spun for 10 minutes at 1200 rpm with the brake on. The viability of the isolated B cells was tested using Trypan Blue. The B cells were resuspended at a final concentration of 1 x 10<sup>6</sup> cells/ml in B cell medium and plated at 180  $\mu$ l/well in a 96 well U bottom plate (Falcon, VWR, Seattle, WA).

[0177] To the cells were added one of the following stimulators to bring the final volume to 200  $\mu$ l/well:

[0178] Soluble, FLAG-tagged ztnf-4sCF or ztnf-4sNF, at 10 fold dilutions from 1 mg-1 ng/ml either alone, with 10 ug/ml anti-IgM (goat anti Human IgM) diluted in NaH<sub>2</sub>CO<sub>3</sub>, pH 9.5, (Southern Biotechnology Associates, Inc., Birmingham, AL); or with 10 µg/ml anti-IgM, and 10 ng/ml recombinant human IL4 (diluted in PBS and 0.1% BSA). Additionally, other cytokines such as IL-3 and IL-6 as well as a soluble CD40 (sCD40) antibody (Pharmingen, San Diego, CA) were tested as well. As a control the cells incubated with 0.1% bovine serum albumen (BSA) and PBS, 10 µg/ml anti-IgM or 10 ug/ml anti-IgM and 10 ng/ml IL4 (or other cytokines). The cells were then incubated at 37°C in a humidified incubator for 72 hours. Sixteen hours prior to harvesting, 1 µCi <sup>3</sup>H thymidine was added to all wells. The cells were harvested into a 96 well filter plate (UniFilter GF/C, Packard, Meriden, CT) where they were harvested using a cell harvester (Packard) and collected according to manufacturer's instructions. The plates were dried at 55°C for 20-30 minutes and the bottom of the wells were sealed with an opaque plate sealer. To each well was added 0.25 ml of scintillation fluid (Microscint-O, Packard) and the plate was read using a TopCount Microplate Scintillation Counter (Packard).

[0179] To measure induction of IgG production in response to various B cell mitogens following stimulation of purified B cells, cells were prepared as described and incubated for 9 days. The cell supernatant was collected to determine IgG production.

[0180] To measure cell surface marker activation in response to various B cell mitogens following stimulation of purified B cells, cells were prepared as described above but incubated only 48 hours. Cell surface markers were measured by FACS analysis.

[0181] Proliferation of human purified B cells stimulated with the various B cell mitogens is summarized in Table 5:

Table 5

Stimulus	Proliferative Index'
ztnf4	1.5
ztnf4 + IL4	9.9
ztnf4 + anti-IgM + IL4	15.8

[0182] A synergistic affect of ztnf4 with IL4, IL3 (10 µg/ml) and IL6 (10 µg/ml) was seen on B cell proliferation. A two fold increase in B cell signaling was seen when using sCD40.

[0183] Induction of IgG production (ng/ml) in response to various B cell mitogens following stimulation of purified B cells is summarized in Table 6.

Table 6

Stimulus	Control	Ztnf4
anti-IgM	3	7.5
anti-IgM + IL-4	13	32
anti-IgM + IL-4 + IL-5	10	45

[0184] An increase in cell surface activation markers after stimulation of purified B cells with ztnf4 alone, or with anti-IgM or anti-IgM + IL-4 was seen. There was no effect on the proliferation of PBMCs in the presence of optimal or suboptimal T cell mitogens. Also, no affect on TNFα production was seen in purified monocytes in response to LPS stimulation.

[0185] Figure 3 shows soluble ztnf4 co-activation of human B lymphocytes to proliferate and secrete immunoglobulin. Figure 3A shows purified human peripheral blood B cells proliferation in response to stimulation with soluble ztnf4 (25 ng/ml) in the presence of IL-4 alone, and IL-4 with anti-IgM, anti-CD40, or anti-CD19, after five days in culture. Figure 3B shows the levels of IgM and IgG measured in the supernatants obtained from human B cells stimulated with soluble ztnf4 in the presence of IL-4 or IL-4 + IL-5, after nine days in culture.

[0186] These results suggest that soluble ztnf4 is a B cell activation molecule which acts in concert with other B cell stimuli and weakly by itself. Soluble ztnf4 promotes B cell proliferation and Ig production. The up regulation of adhesion molecules, costimulatory molecules and activation receptors suggests a role for promoting APC function of B cells.

[0187] Figure 4 shows stimulation of human peripheral blood B cells with soluble ztnf4 (25 ng/ml) or a control protein (ubiquitin) in the presence of 10 ng/ml IL-4 for 5 days in vitro. Purified TACI-Ig, BCMA-Ig, or control Fc were tested for inhibition of soluble ztnf4 specific proliferation.

#### Example 4 Selecting TACI and BCMA Transformed BHK Cells using Ztnf4 Binding

[0188] BHK cells expressing a high level of TACI protein were selected by dilution cloning of a transfectant pool.

Transfectant cells ( $2 \times 10^5$ ) were incubated on ice for 30 minutes with biotinylated ztnf4 at 1  $\mu\text{g/ml}$  in binding buffer (PBS, 2% BSA, 0.02%  $\text{NaN}_3$ ). Cells were washed 2X with binding buffer, then incubated with SA-PE (Caltag) (1:1000 dilution in binding buffer) on ice for 30 minutes. Cells were then washed 2X in binding buffer, resuspended in binding buffer, and read by FACS (FACS Vantage, Becton Dickinson). Clones with the highest binding of TNF4 are selected.

**[0189]** BHK cells expressing a high level of BCMA protein were selected by surface labeling the BCMA-expressing transfectant pool with biotinylated ztnf4. This was followed by streptavidin-Phyco-Erythrin (SA-PE Caltag Burlingame, CA) and sterile sorting for bright cells in FL2 on the FACS Vantage (Becton Dickinson). The single colonies were then screened for ztnf4 binding.

## Example 5

### Tissue Distribution

**[0190]** Human Multiple Tissue Northern Blots (MTN I, MTN II and MTN III; Clontech) were probed to determine the tissue distribution of human BR43x2 and TACI expression. An approximately 500 bp PCR derived probe (SEQ ID NO: 21) was amplified using BR43x2 (SEQ ID NO:1) as templates and oligonucleotide ZC20061 (SEQ ID NO:22 and ZC20062 (SEQ ID NO:23) as primers. This sequence is identical to the homologous region of TACI. The amplification was carried out as follows: 1 cycle at 94°C for 1.0 minutes, 30 cycles of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 seconds, followed by 1 cycle at 72°C for 10 minutes. The PCR products were visualized by agarose gel electrophoresis and the 500 bp PCR product was purified using a Gel Extraction Kit (Qiagen, Chatsworth, CA) according to manufacturer's instructions. The probe was radioactively labeled using the MULTIPRIME DNA labeling kit (Amersham, Arlington Heights, IL) according to the manufacturer's instructions. The probe was purified using a NUCTRAP-push column (Stratagene). EXPRESSHYB (Clontech) solution was used for prehybridization and as a hybridizing solution for the Northern blots. Hybridization took place overnight at 65°C using  $10^6$  cpm/ml of labeled probe. The blots were then washed in 2X SSC and 0.1% SDS at room temp, followed by 2 washes in 0.1X SSC and 0.1% SDS at 50°C. A transcript of approximately 1.5 kb was detected in spleen, lymph node and small intestine.

**[0191]** Human Multiple Tissue Northern Blots (MTN I, MTN II and MTN III; Clontech) were probed to determine the tissue distribution of human BCMA expression. An approximately 257 bp PCR derived probe (SEQ ID NO:24) was amplified using Daudi cell cDNA as a template and oligonucleotide ZC21065 (SEQ ID NO:25) and ZC21067 (SEQ ID NO:26) as primers. The amplification was carried out as follows: 1 cycle at 94°C, for 1.0 minutes, 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 seconds, followed by 1 cycle at 72°C for 10 minutes. The PCR products were visualized by agarose gel electrophoresis and the 257 bp PCR product was purified using a Gel Extraction Kit (Qiagen, Chatsworth, CA) according to manufacturer's instructions. The probe was radioactively labeled using the MULTIPRIME DNA labeling kit (Amersham, Arlington Heights, IL) according to the manufacturer's instructions. The probe was purified using a NUCTRAP push column (Stratagene). EXPRESSHYB (Clontech) solution was used for prehybridization and as a hybridizing solution for the Northern blots. Hybridization took place overnight at 65°C using  $10^6$  cpm/ml of labeled probe. The blots were then washed in 2X SSC and 0.1% SDS at room temp, followed by 2 washes in 0.1X SSC and 0.1% SDS at 50°C. A transcript of approximately 1.2 kb was detected in stomach, small intestine, lymph node, trachea, spleen and testis.

**[0192]** RNA Master Dot Blots (Clontech) that contained RNAs from various tissues that were normalized to 8 house-keeping genes was also probed with either the TACI probe (SEQ ID NO:21) or the BCMA probe (SEQ ID NO:24) and hybridized as described above. BR43x2/TACI expression was seen in spleen, lymph node, small intestine, stomach, salivary gland, appendix, lung, bone marrow and fetal spleen. BCMA expression was detected in small intestine, spleen, stomach, colon, lymph node and appendix.

**[0193]** A human Tumor Panel Blot V (Invitrogen Inc., San Diego, CA) and a human lymphoma blot (Invitrogen) were probed as described above either with a Br43x2/TACI probe (SEQ ID NO:21) or a BCMA probe (SEQ ID NO:24). A 1.5 kb transcript corresponding to TACI was found in non-Hodgkin's lymphoma and parotid tumor. A 1.2 kb transcript corresponding to BCMA was found in adenolymphoma, non-Hodgkins lymphoma, and parotid tumor.

**[0194]** Total RNA from CD4+, CD8+, CD19+ and mixed lymphocyte reaction cells (CellPro, Bothell, WA) was prepared using guanidine isothiocyanate (Chirgwin et al., *Biochemistry* 18:52-94, 1979), followed by a CsCl centrifugation step. Poly(A)+ RNA was isolated using oligo d(T) cellulose chromatography (Aviv and Leder, *Proc. Natl. Acad. Sci. USA*, 69:1408-12, 1972). Northern blot analysis was then performed as follows.

**[0195]** About 2 mg of each of the poly A+ RNAs was denatured in 2.2 M formaldehyde/phosphate buffer (50mM  $\text{Na}_2\text{HPO}_4$ , 50 mM  $\text{NaH}_2\text{PO}_4$ , 50 mM  $\text{NaOAc}$ , 1 mM EDTA and 2.2 M formaldehyde) and separated by 1.5% agarose mini gel (Stratagene Cloning Systems, La Jolla, CA) electrophoresis in formaldehyde/phosphate buffer. The RNA was blotted overnight onto a nytran filter (Schleicher & Schuell, Keene, NH), and the filter was UV crosslinked (1,200 mJoules) in a STRATALINKER<sup>®</sup> UV crosslinker (Stratagene Cloning Systems) and then baked at 80°C for 1 hour.

**[0196]** The blots were probed with either a TACI (SEQ ID NO:21) or BCMA (SEQ ID NO: 24) probe. A 1.5 kb band



representing TACI was detected only in CD 19<sup>+</sup> cells. A 1.2 kb transcript representing BCMA was detected faintly in CD 8<sup>+</sup>, CD 19<sup>+</sup> and MLR cells.

**[0197]** Additional Northern Blot analysis was carried out on blots made with poly(A) RNA from K-562 cells (erythroid, ATCC CCL 243), HUT78 cells (T cell, ATCC TIB-161), Jurkat cells (T cell), DAUDI (Burkitt's human lymphoma, Clontech, Palo Alto, CA), RAJI (Burkitt's human lymphoma, Clontech) and HL60 (Monocyte) as described above. The blots were probed with either a TACI (SEQ ID NO:21) or BCMA (SEQ ID NO:24) probe. A transcript of 1.5 kb corresponding to TACI was detected in Raji cells. A transcript of 1.2 kb corresponding to BCMA was detected in Daudi, Raji and Hut 78 cells.

**[0198]** A PCR-based screen was used to identify tissues which expressed human or murine TACI and human BCMA. Human and Murine Rapid-Scan<sup>TM</sup> Gene Expression Panels (OriGene Technologies, Inc., Rockville, MD), were screened according to manufacturer's instructions. Oligonucleotide primers ZC24200 (SEQ ID NO:27) and ZC24201 (SEQ ID NO:28) were designed to span an exon junction and produce a 272 bp fragment corresponding to murine TACI. Expression was detected in spleen, thymus, lung, breast, heart, muscle, skin, adrenal gland, stomach, small intestine, brain, ovary, prostate gland and embryo. Additional bands of ~500 and 800bp were detected in many tissues.

**[0199]** Oligonucleotide primers ZC24198 (SEQ ID NO:29) and ZC24199 (SEQ ID NO:30) were designed to span an exon junction and produce a 204 bp fragment corresponding to human TACI. Expression was detected in spleen, brain, heart, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, adrenal gland, pancreas, prostate, peripheral blood lymphocytes and bone marrow.

**[0200]** Oligonucleotide primers ZC24271 (SEQ ID NO:31) and ZC24272 (SEQ ID NO:32) were designed to span an exon junction and produce a 329 bp fragment corresponding to human BCMA. Expression was detected in brain, spleen, colon, lung, small intestine, stomach, ovary, testis, salivary gland, adrenal gland, prostate, peripheral blood lymphocytes, bone marrow and fetal liver.

**[0201]** Oligonucleotide primers ZC24495 (SEQ ID NO:33) and ZC24496 (SEQ ID NO:34) were designed to span an exon junction and produce a 436 bp fragment corresponding to murine BCMA. Expression was detected in liver.

#### Example 6 Preparation of TACI-Ig and BCMA-Ig Fusion Vectors

##### Ig Gammal Fc4 Fragment Construction

**[0202]** To prepare the TACI-Ig fusion protein, the Fc region of human IgG1 (the hinge region and the CH2 and CH3 domains) was modified so as to remove Fc receptor (FcγRI) and complement (C1q) binding functions. This modified version of human IgG1 Fc was called Fc4.

**[0203]** The Fc region was isolated from a human fetal liver library (Clontech) by PCR using oligo primers ZC10,134 (SEQ ID NO:43) and ZC10,135 (SEQ ID NO:44). PCR was used to introduce mutations within the Fc region to reduce FcγRI binding. The FcγRI binding site (Leu-Leu-gly-Gly) was mutated to Ala-Glu-gly-Ala (amino acid residues 38-41 of SEQ ID NO:45) according to Baum et al. (EMBO J. 13:3992-4001, 1994), to reduce FcR1 binding (Duncan et al., Nature 332:563-4, 1988). Oligonucleotide primers ZC15,345 (SEQ ID NO:46) and ZC15,347 (SEQ ID NO:47) were used to introduce the mutation. To a 50 μl final volume was added 570 ng IgFc template, 5 μl 10x Pfu reaction Buffer (Stratagene), 8 μl of 1.25 mM dNTPs, 31 μl dH<sub>2</sub>O, 2 μl 20 mM ZC15,345 (SEQ ID NO:46) and ZC15,347 (SEQ ID NO:47). An equal volume of mineral oil was added and the reaction was heated to 94°C for 1 minute. Pfu polymerase (2.5 units, Stratagene) was added followed by 25 cycles at 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 1 minute followed by a 7 minute extension at 72°C. The reaction products were electrophoresed and the band corresponding to the predicted size of ~676 bp was detected. The band was excised from the gel and recovered using a QIAGEN QIAquick<sup>TM</sup> Gel Extraction Kit (Qiagen) according to the manufacturers instructions.

**[0204]** PCR was also used to introduce a mutation of Ala to Ser (amino acid residue 134 of SEQ ID NO:45) and Pro to Ser (amino acid residue 135 of SEQ ID NO:45) to reduce complement C1q binding and/or complement fixation (Duncan and Winter, Nature 332:788, 1988) and the stop codon TAA. Two, first round reactions were done using the FcγRI binding site-mutated IgFc sequence as a template. To a 50 μl final volume was added 1 μl FcγRI binding site mutated IgFc template, 5 μl 10X Rfu Reaction Buffer (Stratagene), 8 μl 1.25 mM dNTPs, 31 μl dH<sub>2</sub>O, 2 μl 20 mM ZC15,517 (SEQ ID NO:48), a 5' primer beginning at nucleotide 26 of SEQ ID NO:45 and 2 μl 20 mM ZC15,530 (SEQ ID NO:49), a 3' primer beginning at the complement of nucleotide 405 of SEQ ID NO:45. The second reaction contained 2 μl each of 20 mM stocks of oligonucleotide primers ZC15,518 (SEQ ID NO:50), a 5' primer beginning at nucleotide, 388 of SEQ ID NO:45 and ZC15,347 (SEQ ID NO:47), a 3' primer, to introduce the Ala to Ser mutation, Xba I restriction site and stop codon. An equal volume of mineral oil was added and the reactions were heated to 94°C for 1 minute. Pfu polymerase (2.5 units, Stratagene) was added followed by 25 cycles at 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 2 minutes followed by a 7 minute extension at 72°C. The reaction products were electrophoresed and bands corresponding to the predicted sizes, ~370 and ~395 bp respectively, were detected. The bands were excised from the gel and extracted using a QIAGEN QIAquick<sup>TM</sup> Gel Extraction Kit (Qiagen) according to the manufacturers in-

structions. A second round reaction was done to join the above fragments and add the 5' Bam HI restriction site. To a 50 µl final volume was added 30 µl dH<sub>2</sub>O, 8 µl 1.25 mM dNTPs, 5 µl 10X Pfu polymerase reaction buffer (Stratagene) and 1 µl each of the two first two PCR products. An equal volume of mineral oil was added and the reaction was heated to 94°C for 1 minute. Pfu polymerase (2.5 units, Stratagene) was added followed by 5 cycles at 94°C for 30 seconds, 55 °C for 30 seconds, and 72°C for 2 minutes. The temperature was again brought to 94°C and 2 µl each of 20 mM stocks of ZC15,516 (SEQ ID NO:51), a 5' primer beginning at nucleotide 1 of SEQ ID NO:45, and ZC15,347 (SEQ ID NO:47) were added followed by 25 cycles at 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 2 minutes, and a final 7 minute extension at 72°C. A portion of the reaction was visualized using gel electrophoresis. A 789 bp band corresponding the predicted size was detected.

#### TACI-Fc4 and BCMA-Fc4 Expression Vector Construction

**[0205]** Expression plasmids containing TACI-Fc4 and BCMA-Fc4 fusion proteins were constructed via homologous recombination in yeast. A fragment of TACI cDNA was isolated using PCR that included the polynucleotide sequence from nucleotide 15 to nucleotide 475 of SEQ ID NO:5. The two primers used in the production of the TACI fragment were: (1) a primer containing 40 bps of the 5' vector flanking sequence and 17 bps corresponding to the amino terminus of the TACI fragment (SEQ ID NO:52); (2) 40 bps of the 3' end corresponding to the flanking Fc4 sequence and 17 bp corresponding to the carboxyl terminus of the TACI fragment (SEQ ID NO:53). To an 100 µl final volume was added 10 ng TACI template, 10 µl 10X Taq polymerase Reaction Buffer (Perkin Elmer), 8 µl 2.5 mM dNTPs, 78 µl dH<sub>2</sub>O, 2 µl each of 20 mM stocks of oligonucleotide primers SEQ ID NO:52 and SEQ ID NO:53, and taq polymerase (2.5 units, Life Technology). An equal volume of mineral oil was added and the reaction was heated to 94°C for 2 minutes, followed by 25 cycles at 94°C for 30 seconds, 65 °C for 30 seconds, 65°C for 30 seconds, 72°C for 1 minute followed by a 5 minute extension at 72°C.

**[0206]** A fragment of BCMA cDNA was isolated using PCR that includes the polynucleotide sequence from nucleotide 219 to nucleotide 362 of SEQ ID NO:7. The two primers used in the production of the BCMA fragment were an oligonucleotide primer containing 40 bps of the 5' vector flanking sequence and 17 bps corresponding to the amino terminus of the BCMA fragment (SEQ ID NO:54); and an oligonucleotide primer containing 40 bps of the 3' end corresponding to the flanking Fc4 sequence and 17 bps corresponding to the carboxyl terminus of the BCMA fragment (SEQ ID NO:55). To, a 100 µl final volume was added 10 ng BCMA template, 10 µl 10X Taq polymerase Reaction Buffer (Perkin Elmer), 8 µl 2.5 mM dNTPs, 78 µl H<sub>2</sub>O, 2 µl each of 20 mM stock solutions of oligonucleotide primers SEQ ID NO:54 and SEQ ID NO:55. An equal volume of mineral oil was added and the reaction was heated to 94°C for 2 minutes, followed by 25 cycles at 94°C for 30 seconds, 65°C for 30 seconds, 72°C for 1 minute followed by a 5 minute extension at 72°C.

**[0207]** The fragment containing the cDNA encoding the Fc4 fragment was constructed in a similar manner, one for each of the TACI and BCMA fusion constructs. For TACI the two primers used in the production of the Fc4 fragment were (upstream and downstream), an oligonucleotide primer containing 40 bps of the 5' TACI flanking sequence and 17 bps corresponding to the amino terminus of the Fc4 fragment (SEQ ID NO:56); and an oligonucleotide primer containing 40 bps of the 3' end corresponding to the flanking vector sequence and 17 bps corresponding to the carboxyl terminus of the Fc4 fragment (SEQ ID NO:57). For BCMA, the upstream primer in the production of the Fc4 fragment was an oligonucleotide primer containing 40 bps of the 5' BCMA flanking sequence and 17 bps corresponding to the amino terminus of the Fc4 fragment (SEQ ID NO:58). The downstream primer for the Fc4 for the BCMA construct was the same as that described above for TACI-Fc4 (SEQ ID NO:57).

**[0208]** To a 100 µl final volume was added 10 ng Fc4 template described above, 10 µl 10X Taq polymerase Reaction Buffer (Perkin Elmer), 8 µl 2.5 mM dNTPs, 78 µl dH<sub>2</sub>O, 2 µl each of 20 mM stocks of oligonucleotides SEQ ID NO:56 and SEQ ID NO:57 for TACI and oligonucleotides SEQ ID NO:58 and SEQ ID NO:57 for BCMA, and taq polymerase (2.5 units, Life Technology). An equal volume of mineral oil was added and the reaction was heated to 94°C for 2 minutes, then 25 cycles at 94°C, for 30 seconds, 65°C for 30 seconds, 72°C for 1 minute followed by a 5 minute extension at 72°C.

**[0209]** ten microliters of each of the 100 µl PCR reactions described above was run on a 0.8% LMP agarose gel (Seaplaque GTG) with 1 x TBE buffer for analysis. The remaining 90 µl of each PCR reaction was precipitated with the addition of 5 µl 1 M NaCl and .250 µl of absolute ethanol. The plasmid pZMP6 was cut with SmaI to linearize it at the polylinker. Plasmid pZMP6 was derived from the plasmid pCZR199 (American Type Culture Collection, Manassas, VA, ATCC# 98668) and is a mammalian expression vector containing an expression cassette having the CMV immediate early promoter, a consensus intron from the variable region of mouse immunoglobulin heavy chain locus, multiple restriction sites for insertion of coding sequences, a stop codon and a human growth hormone terminator. The plasmid' also has an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene and the SV40 terminator. The vector pZMP6 was constructed from pCZR199 by replacement of the metallothionein promoter with the CMV immediate early promoter, and the Kozac

sequences at the 5' end of the open reading frame.

[0210] One hundred microliters of competent yeast cells (*S. cerevisiae*) were combined with 10 µl containing approximately 1 µg each of either the TACI or the BCMA extracellular domain and the Fc4 PCR fragments appropriate for recombination with each, and 100 ng of SmaI digested pZMP6 vector and transferred to a 0.2 cm electroporation

5 cuvette. The yeast/DNA mixtures were electropulsed at 0.75 kV (5 kV/cm). ∞ ohms, 25 µF. To each cuvette was added 600 µl of 1.2 M sorbitol and the yeast were plated in two 300 µl aliquots onto to URA-D plates and incubated at 30 °C. [0211] After about 48 hours, the Ura+ yeast transformants from a single plate were resuspended in 1 ml H<sub>2</sub>O and spun briefly to pellet the yeast cells. The cell pellet was resuspended in 1 ml of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture was added to an Eppendorf

10 tube containing 300 µl acid washed glass beads and 200 µl phenol-chloroform, vortexed for 1 minute intervals two or three times, followed by a 5 minute spin in a Eppendorf centrifuge at maximum speed. Three hundred microliters of the aqueous phase was transferred to a fresh tube, and the DNA precipitated with 600 µl ethanol (EtOH), followed by centrifugation for 10 minutes at 4°C. The DNA pellet was resuspended in 100 µl H<sub>2</sub>O. [0212] Transformation of electrocompetent *E. coli* cells (DH10B, GibcoBRL) was done with 0.5-2 ml yeast DNA prep and 40 µl of DH10B cells. The cells were electropulsed at 2.0 kV, 25 mF and 400 ohms. Following electroporation, 1 ml SOC (2% Bacto Tryptone (Difco, Detroit, MI), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl<sub>2</sub>, 10 mM MgSO<sub>4</sub>, 20 mM glucose) was plated in 250 µl aliquots on four LB AMP plates (LB broth (Lennox), 1.8% Bacto

Agar (Difco), 100 mg/L Ampicillin). [0213] Individual clones harboring the correct expression construct for TACI-Fc4 or BCMA-Fc4 were identified by restriction digest to verify the presence of the insert and to confirm that the various DNA sequences have been joined correctly to one another. The insert of positive clones were subjected to sequence analysis. Larger scale plasmid DNA is isolated using the Qiagen Maxi kit (Qiagen) according to manufacturer's instruction

#### Example 7 Mammalian Expression of TACI-Fc4 and BCMA-Fc4

25 [0214] BHK 570 cells (ATCC NO: CRL-10314) were plated in 10 cm tissue culture dishes and allowed to grow to approximately 50 to 70% confluency overnight at 37°C, 5% CO<sub>2</sub>, in DMEM/FBS media (DMEM, Gibco/BRL High Glucose, (Gibco BRL, Gaithersburg, MD), 5% fetal bovine serum (Hyclone, Logan, UT), 1 mM L-glutamine (JRH Biosciences, Lenexa, KS), 1 mM sodium pyruvate (Gibco BRL)). The cells were then transfected with either the plasmid TACI-Fc4/pZMP6 or BCMA-Fc4/pZMP6, using Lipofectamine™ (Gibco BRL), in serum free (SF) media formulation (DMEM, 10 mg/ml transferrin, 5 mg/ml insulin, 2 mg/ml fetuin, 1% L-glutamine and 1% sodium pyruvate). TACI-Fc4/pZMP6 or BCMA-Fc4/pZMP6 was diluted into 15 ml tubes to a total final volume of 640 µl with SF media. 35 µl of Lipofectamine™ (Gibco BRL) was mixed with 605 µl of SF medium. The Lipofectamine™ mix was added to the DNA mix and allowed to incubate approximately 30 minutes at room temperature. Five milliliters of SF media was

#### Example 9 Transgenic Expression of Ztnf4

45 [0215] Transgenic animals expressing ztnf4 genes were made using adult, fertile males (B6C3f1), prepubescent fertile females (B6C3f1), vasectomized males (B6D2f1), and adult fertile females (B6D2f1) (all from Taconic Farms, Germantown, NY). The prepubescent fertile females were superovulated using Pregnant Mare's Serum gonadotrophin (Sigma, St. Louis, MO) and human Chorionic Gonadotropin (hCG (Sigma)). The superovulated females were subsequently mated with adult, fertile males, and copulation was confirmed by the presence of vaginal plugs.

50 [0216] Fertilized eggs were collected under a surgical scope (Leica MZ12 Stereo Microscope, Leica, Wetzlar, Germany). The eggs were then washed in hyaluronidase and Whitten's W640 medium (Table 8; all reagents available from Sigma Chemical Co.) that has been incubated with 5% CO<sub>2</sub>, 5% O<sub>2</sub>, and 90% N<sub>2</sub> at 37°C. The eggs were stored in a 37°C/5% CO<sub>2</sub> incubator until microinjection.

Table 8

WHITTEN'S 640 MEDIA		
	mg/200 ml	mg/500 ml
NaCl	1280	3200
KCl	72	180
KH <sub>2</sub> PO <sub>4</sub>	32	80
MgSO <sub>4</sub> ·7H <sub>2</sub> O	60	150
Glucose	200	500
Ca <sup>2+</sup> Lactate	106	265
Benzylpenicillin	15	37.5
Streptomycin SO <sub>4</sub>	10	25
NaHCO <sub>3</sub>	380	950
Na Pyruvate	5	12.5
H <sub>2</sub> O	200 ml	500 ml
500 mM EDTA	100 µl	250 µl
5% Phenol Red	200 µl	500 µl
BSA	600	1500

[0217] The 858 bp open reading frame encoding full length human TACI ligand Blys (SEQ ID NO:35) was amplified by PCR so as to introduce an optimized initiation codon and flanking 5' PmeI and 3' AscI sites using the oligonucleotide primers of SEQ ID NO:36 and SEQ ID NO:37. This PmeI/AscI fragment was subcloned into pKF024, a B and/or T cell-restricted transgenic vector containing the Ig Em enhancer (690bp *NotI/XbaI* from pEmSR; (Bodrug et al., *EMBO J.* 13:2124-30, 1994), the Ig V<sub>H</sub> promoter (536 bp *HincIII/XhoI* fragment from pJH1X(-); Hu et al., *J. Exp. Med.* 177:1681-90, 1993), the SV40 16S intron (171 bp *XhoI/HindIII* fragment from pEmSR), a *PmeI/AscI* polylinker, and the human growth hormone gene polyadenylation signal (627 bp *SmaI/EcoRI* fragment; Seeburg, *DNA* 1:239-49, 1982). The transgene insert was separated from plasmid backbone by *NotI* digestion and agarose gel purification, and fertilized ova from matings of B6C3F1Tac mice described above were microinjected and implanted into pseudopregnant females essentially as previously described (Malik et al., *Molec. Cell. Biol.* 15:2349-58, 1995).

[0218] The recipients were returned to cages in pairs, and allowed 19-21 days gestation. After birth, 19-21 days postpartum was allowed before sexing and weaning, and a 0.5 cm biopsy (used for genotyping) was snipped off the tail with clean scissors.

[0219] Genomic DNA was prepared from the tail snips using a commercially available kit (DNeasy 96 Tissue Kit; Qiagen, Valencia, CA) following the manufacturer's instructions. Genomic DNA was analyzed by PCR using primers designed to the human growth hormone (hGH) 3' UTR portion of the transgenic vector. Primers ZC17251 (SEQ ID NO: 38) and ZC17252 (SEQ ID NO:39) amplify a 368-base-pair fragment of hGH. The use of a region unique to the human sequence (identified from an alignment of the human and mouse growth hormone 3' UTR DNA sequences) ensured that the PCR reaction did not amplify the mouse sequence. In addition, primers ZC17156 (SEQ ID NO:40) and ZC17157 (SEQ ID NO:41), which hybridize to vector sequences and amplify the cDNA insert, may be used along with the hGH primers. In these experiments, DNA from animals positive for the transgene generated two bands, a 368-base-pair band corresponding to the hGH 3' UTR fragment and a band of variable size corresponding to the cDNA insert.

[0220] Once animals were confirmed to be transgenic (TG), they are back-crossed into an inbred strain by placing a TG female with a wild-type male, or a TG male with one or two wild-type female(s). As pups were born and weaned, the sexes were separated, and their tails snipped for genotyping.

[0221] To check for expression of a transgene in a live animal, a survival biopsy is performed. Analysis of the mRNA expression level of each transgene was done using an RNA solution hybridization assay or real-time PCR on an ABI Prism 7700 (PE Applied Biosystems, Inc., Foster City, CA) following the manufacturer's instructions.

#### Cell Preparation and Flow Cytometry

[0222] Founder mice were analyzed at various ages. For flow cytometric (FACS) analysis of lymphoid tissues, bone marrow (BM) cells were isolated from femurs and tibias by careful disruption in phosphate-buffered saline (PBS) using a mortar and pestle. Cells were resuspended, depleted of bone fragments by passive sedimentation, and pelleted at 1000 x g. Splenocytes, thymocytes, or lymph node cells were obtained by crushing intact tissues between glass slides, then resuspending and pelleting the cells as for BM. Cells were resuspended in FACS wash buffer (FACS WB) (Hank's

balanced salt solution, 1% BSA, 10mM Hepes, pH 7.4) at a concentration of  $20 \times 10^6$  cells/ml prior to staining. To stain,  $1 \times 10^6$  cells were transferred to 5 ml tubes and washed with 1 ml of FACS WB, then pelleted at  $1000 \times g$ . Cells were then incubated on ice for 20 minutes in the presence of saturating amounts of the appropriate FITC-, PE- and/or TriColor (TC)-conjugated mAbs in a total volume of 100  $\mu$ l in FACS WB. Cells were washed with 1.5 ml of WB, pelleted, then resuspended in 400  $\mu$ l WB and analyzed on a FACSCalibur flow cytometer using CellQuest software (Becton Dickinson, Mountain View, CA). Detectors for forward (FSC) and side (SSC) light scatter were set on a linear scale, whereas logarithmic detectors were used for all three fluorescence channels (FL-1, FL-2, and FL-3).

[0223] Compensation for spectral overlap between FL channels was performed for each experiment using single color stained cell populations. All cells were collected ungated to disk and data were analyzed using CellQuest software. RBC and dead cells were excluded by electronically gating data on the basis of FSC vs. SSC profiles.

#### Antibodies

[0224] Fluorescein isothiocyanate (FITC)-conjugated anti-CD8 monoclonal antibody (mAb) (clone 53-6.7) and phycoerythrin (PE)-conjugated anti-CD4 (clone RM4-5), anti-CD5 (clone 53-7.3), anti-CD19 (clone 1D3), and anti-syndecan (clone 281-2) mAbs were purchased from PharMingen (San Diego, CA). TriColor(TC)-conjugated anti-CD45R/B220 mAb (clone RA3-6B2) was purchased from Caltag.

[0225] Transgenic mice over expressing ztnf4 in the lymphoid compartment develop increased numbers of peripheral B cells, increased plasma cells and elevated levels of serum immunoglobulin. These transgenic animals have an increased number of B220+ cells in the spleen, lymph nodes and thymus. The increased number of splenic B cells includes both conventional B-2 cells, and the normally rare population of B-1 cells. In general, B-1 cells are largely confined to the peritoneal and other body cavities, produce low affinity self-reactive antibodies, and have often been associated with the development of autoimmune diseases such as systemic lupus erythematosus SLE.

[0226] Older transgenic animals produce autoantibodies, develop proteinuria and sclerotic glomeruli, characteristics of systemic lupus erythematosus.

[0227] Figure 5A shows single cell suspensions of spleen (top panel), mesenteric lymph node (middle panel), and bone marrow (lower panel) prepared as described below, stained with anti-B220-TC and analyzed by flow cytometry. The number of B220+ cells in each tissue was calculated by multiplying the percent B220+ cells by the total number of live (trypan blue excluding) cells counted on a hemocytometer. Each bar represents data from individual ztnf4 transgenic (Tg, shaded bars) or nonTG littermate (open bars) control mice.

[0228] Figure 5B shows cells isolated from ztnf4 TG (right-hand panels) or nonTG littermate (left-hand panels) lymph node (top row), spleen (middle rows), and thymus (bottom row) were stained with mAbs to the molecules indicated (DC5, CD4 and CD8), then analyzed by flow cytometry. Data shown were gated to exclude dead cells and RBCs.

[0229] Figure 5C shows total IgG, IgM, and IgE levels in serum from ztnf4 transgenic mice ranging in age from 6 to 23 weeks old.

[0230] Figure 5D shows the amyloid deposition and thickened mesangium of the glomeruli identified in H&E stained kidney sections from ztnf4 transgenic mice compared to normal glomeruli from control littermates.

[0231] Figure 5E shows an increase in effector T cells in ztnf4 transgenic mice, similar to that reported by Mackay et al. (J. Exp. Med. 190:1697-1710, 1999).

[0232] Soluble TACI(BR43x2) or BCMA-Ig fusions are injected (IP, IM or IV) into ztnf4 over expressing transgenic animals. Flow cytometric (FACS) analysis of lymphoid tissues will be used to identify any change in the number of B220+ B cells in the spleen, lymph nodes and thymus.

#### Example 10 Direct Binding ELISA

[0233] A direct binding ELISA was developed to characterize the ability of either soluble TACI-Ig or soluble BCMA-Ig to bind and inhibit the biological activity of ztnfr4 *in vitro*.

[0234] A 96 well plate was coated with 1  $\mu$ g/ml Goat-anti-Human Ig (Jackson Labs, Bar Harbor, MA) in ELISA A buffer (0.1 M  $\text{Na}_2\text{HCO}_3$ , pH 9.6, 0.02%  $\text{NaN}_3$ ) and incubated overnight at 4°C. TACI, BCMA, and an unrelated TNF receptor such as ztnfr10 (SEQ ID NO:42) as a control were titrated from 10  $\mu$ g/ml through 5 fold dilutions to 320 ng/ml plus a zero and co-incubated with 2.5, 0.5, or 0.1  $\mu$ g/ml biotinylated ztnf4 or ovalbumin as a negative control, and incubated 1 hour at room temperature.

[0235] The co-incubated receptor-biotinylated ligand mixture was then added to the goat-anti-human Ig coated 96 well plates. The plates were then washed (ELISA C, 500  $\mu$ l Tween 20 (Sigma Chemical Co., St. Louis, Mo.), 200 mg  $\text{NaN}_3$

[0236] PBS to a final volume of 1 liter) and blocked with Superblock (Pierce, Rockford, IL). The plates were then incubated at 37°C for 2 hours.

[0237] The plates are once again washed with ELISA C followed by the addition of 100  $\mu$ l/well of neutr-avidin-HRP

at 1:10,000 in ELISA B (5 or 10 µg BSA (Sigma) for 1% or 2% BSA, respectively, 250 µl Tween 20 (Sigma), 100 mg Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, phosphate-buffered saline pH 7.2 (PBS, Sigma) to a final volume of 500 ml. Alternatively, the buffer may be made up as 1% or 2% BSA in ELISA C Buffer). The plates are then developed with OPD for 10 minutes at room temperature and read at 492.

#### Example 11

##### Biological Activity Assay

**[0238]** A biological activity assay was developed to measure soluble TACI-FC inhibition of human B cell the stimulation by soluble ztnf4. B cells were isolated from peripheral blood mononuclear cells (PBMNC) using CD19 magnetic beads and the VarioMacs magnetic separation system (Miltenyi Biotec Auburn, CA) according to the manufacturer's instructions. Purified B cells were mixed with soluble ztnf4 (25 ng/ml) and recombinant human IL-4 (10 ng/ml Pharmingen) and were plated (in triplicate) on to round bottom 96 well plates at  $1 \times 10^5$  cells per well.

**[0239]** Soluble TACI-FC was diluted from 5 µg/ml to 6 ng/ml and incubated with the B cell for 5 days, pulsing overnight on day 4 with 1 µCi <sup>3</sup>H Thymidine (Amersham) per well. As a control soluble TACI-FC was also incubated with B cells and IL-4 without ztnf4 present.

**[0240]** Plates were harvested using Packard plate harvester and counted using the Packard reader. The TACI-Ig soluble receptor inhibited the ability of soluble ztnf4 to stimulate B' cell proliferation *in vitro* in a dose-dependent manner. A 10-fold molar excess TACI-Ig completely inhibits the proliferation of human B cells in response to soluble ztnf4 in the presence of IL-4.

##### Example 12 ORIGIN Assay

**[0241]** Levels of ztnf4 in individuals with a disease condition (such as SLE, rheumatoid arthritis for example) relative to normal individuals were determined using an electrochemiluminescence assay. A standard curve prepared from soluble, human ztnf4 at 10 ng/ml, 1 ng/ml, 0.1 ng/ml, 0.01 ng/ml and 0 ng/ml was prepared in ORIGIN buffer (Igen, Gaithersburg, MD). Serum samples were diluted in ORIGIN buffer. The standards and samples were incubated at room temperature for 2 hours with biotinylated rabbit anti-human ztnf4-NF BV antibody diluted to 1 µg/ml in Origin Assay Buffer (IGEN) and ruthenylated rabbit anti-human ztnf4-NF BV polyclonal antibody diluted to 1 µg/ml in Origin Assay Buffer (IGEN). Following the incubation the samples were vortexed and 0.4 mg/ml streptavidin Dynabeads (Dyna, Oslo, Norway) were added to each of the standards and samples at 50 µl/tube and incubated for 30 minutes at room temperature. Samples were then vortexed and samples were read on an Origin Analyzer (Igen) according to manufacturer's instructions. The Origin assay is based on electrochemiluminescence and produces a readout in ECL- what is this, how does it work and what does this tell you.

**[0242]** An elevated level of ztnf4 was detected in the serum samples from both NZBWF1/J, and MRL/MpJ-Fas<sup>1Pr</sup> mice which have progressed to advanced stages of glomerulonephritis and autoimmune disease.

##### Example 13 Soluble TACI-Ig in a Spontaneous Model of SLE

**[0243]** NZBW mice become symptomatic for spontaneous SLE at approximately 7-9 months of age. TACI-Fc was administered to NZBW mice to monitor its suppressive effect on B cells over the 5 week period when, on average, B-cell autoantibody production is thought to be at high levels in NZBW mice.

**[0244]** One hundred, 8-week old female (NZB x NZW)<sub>F1</sub> mice (Jackson Labs) were divided into 6 groups of 15 mice. Prior to treatment the mice were monitored once a month for urine protein and blood was drawn for CBC and serum banking. Serum will be screened for the presence of autoantibodies. Because proteinuria is the hallmark sign of glomerulonephritis, urine protein levels were monitored by dipstick at regular intervals over the course of the study. Prior to treatment the animals were weighed. Dosing was started when mice were approximately 5 months of age. The mice received intraperitoneal injections of vehicle only (PBS) or human IgG-FC (control protein) or TACI-FC4 (test protein) three times a week for 5 weeks.

Group (5 mice each)	Treatment	Dose
1	untreated control	
2	vehicle only	
3	human IgG-FC	20 µg

(continued)

Group (5 mice each)	Treatment	Dose
4	human IgG-FC	100 µg
5	human TACI-FC4	20 µg
6	human TACI-FC4	100 µg

[0245] Blood was collected twice during dosing and will be collected at least twice following dosing. Urine dipstick values for proteinuria and body weights were made every two weeks after dosing begins. Blood, urine dipstick value and body weight were collected at the time of euthanasia. Weight of spleen, thymus, liver with gall bladder, left kidney and brain were taken. The spleen and thymus were divided for FACS analysis and histology. Submandibular salivary glands, mesenteric lymph node chain, liver lobe with gall bladder, cecum and large intestine, stomach, small intestine, pancreas, right kidney, adrenal gland, tongue with trachea and esophagus, heart and lungs will also be collected for histology.

[0246] Figure 6 shows an elevated level of *ztnf4* in serum from NZBWF1 and MRL/lpr/lpr mice that correlates with the development of SLE. Figure 6A upper panel shows the correlation of *ztnf4* serum levels with age, 68 NZBWF1 mice ranging from 10 to 40 weeks old and 10 week and 30 week old NZB/B control mice. The middle panel shows the correlation with proteinuria at three ranges, trace to 20 mg/dl (T-30), 100-300 ng/dl and 2000 mg/dl in NZBWF1 mice compared to control NZB/B mice. The lower panel shows *ztnf4* levels with various titers of anti-ds DNA antibody in NZBWF1 mice compared to control NZB/B mice.

[0247] Figure 6B shows the same correlations made on 23 MRL/lpr/lpr mice ranging from 18-24 weeks old and 10 control 11 week old MRL/MpJ mice.

[0248] Figure 7 shows urinalysis results. Mice were considered to have proteinuria if the dipstick reading was  $\geq 100$  mg/dl. (A) PBS, (B) human IgG FC, 100 mg, (C) human IgG FC, 20 mg, (D) human TACI-IgG, 100 mg, and (E) human TACI-IgG, 20 mg. Mice treated with the soluble TACI-IgG fusion showed a reduction in proteinuria.

[0249] Analysis of peripheral blood from treated animals revealed that white blood cell and lymphocyte counts were reduced in TACI-FC treated mice (20 and 100 mg) when compared to FC (20 and 100 mg) and PBS treated mice, 2 weeks after the start of treatment. FACS analysis (lymphocyte gate) of peripheral blood drawn six weeks after treatment began (two weeks after last treatment was administered) and showed a dramatic decrease in percentage of B cells present in the samples. B cell levels were still in decline at five weeks after last treatment was administered, but not as dramatic. Table 9 provides the average (and standard deviation) for the mice in each treatment group (Table 9). The decline in the percent of B cells in peripheral blood was also observed two weeks into treatment.

Table 9

Treatment	Week 2		Week 5
	% B cells	% T cells	% B cells
PBS	26.05 (6.52)	67.05 (6.80)	20.83 (3.14)
100 mg FC	23.34 (5.77)	68.23 (7.30)	25.04 (8.07)
20 mg FC	24.09 (6.26)	65.27 (7.18)	18.96 (6.42)
100 mg TACI FC	11.07 (5.03)	79.06 (6.71)	14.79 (4.76)
20 mg TACI-FC	16.37 (7.27)	69.72 (8.90)	19.14 (5.27)

#### Example 14 Soluble TACI-Ig in normal mice

[0250] TACI-FC was administered to Balb/C mice to monitor its effect on normal mice. Sixty, 8-week old female Balb/C mice (HSD) were divided into 12 groups of 5 mice. Prior to treatment the mice were weighed and blood was drawn for CBC and serum banking. Groups 1-9 received intraperitoneal injections (IP) of vehicle only (PBS) or human IgG-FC (control protein) or TACI-FC4 (test protein) daily for 12 days and were sacrificed on day 14. Groups 10 and 11 received IP injections three times per week for two weeks and were sacrificed on day 14.

Group (5 mice each)	Treatment	Dose
1	human TACI-FC4	200 mg
2	human TACI-FC4	100 mg

(continued)

Group (5 mice each)	Treatment	Dose
3	human TACI-FC4	20 µg
4	human TACI-FC4	5 µg
5	human FC4	200 µg
6	human FC4	100 mg
7	human FC4	20 mg
8	human FC4	5 mg
9	vehicle only	as used
10	human TACI-FC4	100 mg
11	human FC4	100 mg
12	untreated control	

**[0251]** Blood was collected on days 7 and 12. Blood and body weight were collected at the time of euthanasia. Weight of spleen, thymus, and brain were taken. The spleen and thymus were divided for FACS analysis and histology. Skin, spleen, mesenteric LN chain, submandibular salivary glands, ovary, uterus, cervix, bladder, mesenteric lymph node chain, liver lobe with gall bladder, cecum and large intestine, stomach, small intestine, pancreas, right kidney, adrenal gland, tongue with trachea and esophagus, heart, thymus, thigh muscle, left and right femur, brain will also be collected for histology.

**[0252]** As described above in Example 13, a significant reduction in percent B cells was seen on days 7 (by CBC) and 12 (using FACS) in peripheral blood cells taken from all TACI-FC4 treated samples compared to those treated with FC4 or PBS alone and analyzed by CBC or FACS. Additionally, there was nearly a 50% decrease in B cells in the spleens taken from animals treated with TACI-FC4 as compared to those from FC4 treated mice day 14.

#### Example 15 Anti-dsDNA ELISA

**[0253]** Autoimmunity is characterized by high levels of anti-double stranded DNA antibodies. To measure the levels anti-dsDNA antibodies in both the over expressing *ztnf4* transgenic mice and the NZBW mice an ELISA assay was developed. A 96 well microtiter plate (Nunc) was coated with poly-L-lysine (Sigma) (20 µl/ml in 0.1 M Tris buffer pH 7.3) at 75 µl/well and incubated overnight at room temperature. The plates were then washed in dH<sub>2</sub>O and coated with poly dAdT (Sigma) (20 µl/ml in 0.1 M Tris buffer pH 7.3) at 75 µl/well and incubated at room temperature for 60 minutes. The plates were then washed with dH<sub>2</sub>O and blocked with 2%BSA (Sigma) in Tris Buffer for 30 minutes at room temperature followed by a final wash in dH<sub>2</sub>O.

**[0254]** Serum samples were taken from the *ztnf4* transgenic mice described in Example 10 and the NZBW mice described in Example 11. The serum samples were diluted 1:50 in 1% BSA/2% BGG (Calbiochem) in Tris Buffer. The diluted samples were then titrated into the coated plate at 1:50, 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200 and 1:6400 (50 µl/well) and incubated for 90 minutes at room temperature.

**[0255]** Plates were then washed in dH<sub>2</sub>O and goat antimouse IgG-Fc-HRP (Cappel) diluted to 1:1000 in 1% BSA/2% BGG was added at 50µl/well. The plates were incubated for 60 minutes at room temperature. The plates were washed 5X in dH<sub>2</sub>O. and developed with OPD, 1 tablet/10 ml Novo D and plated at 100 µl/well. The developer was stopped with 1N H<sub>2</sub>SO<sub>4</sub>, 100 µl/well, and the OD read at 492 nm.

**[0256]** Figure 8 shows the anti-ds DNA levels in two *ztnf4* transgenic mice (23 week'old), two non-transgenic litter mates compared with the levels detected in serum from NZBWF1 (32 week old) and MRL/lpr/lpr (19 week old) mice.

#### Example 16 Soluble TACI-Ig in a Spontaneous Model of ELE

**[0257]** Twenty five female PLxSJL F1 mice (12 weeks old, Jackson Labs) are given a subcutaneous injection of 125 µg/mouse of antigen (myelin Proteolipid Protein, PLP, residues 139-151), formulated in complete Freund's Adjuvant. The mice are divided into 5 groups of 5 mice. Intraperitoneal injections of pertussis toxin (400 ng) are given on Day 0 and 2. The groups will be given a 1x, 10x, or 100x dose of TACI, BCMA or BR43x2, one group will receive vehicle only and one group will receive no treatment. Prevention therapy will begin on Day 0, intervention therapy will begin on day 7, or at onset of clinical signs. Signs of disease, weight loss, and paralysis manifest in approximately 10-14 days, and



last for about 1 week. Animals are assessed daily by collecting body weights and assigning a clinical score to correspond to the extent of their symptoms. Clinical signs of EAE appear within 10-14 days of inoculation and persist for approximately 1 week. At the end of the study all animals are euthanized by gas overdose, and necropsied. The brain and spinal column are collected for histology or frozen for mRNA analysis. Body weight and clinical score data is plotted by individual and by group. Clinical Score

0	Normal	
0.5	Weak, tail tone may be reduced but not absent	
1	Limp tail (cannot lift tail when mouse is	picked up at base of tail)
2	Limp tail, weak legs (cannot lift tail, can	stay upright on hind legs but legs are shaky)
3	Paresis (cannot sit with legs under body,	walk in a paddling motion with legs behind)
4	Paralysis (cannot move back legs, drags legs	when trying to walk)
5	Quadriplegia (paralysis in front legs or	walking in a circular pattern, may have head tilt)
6	Moribund (completely paralyzed, cannot reach	food or water, sacrifice animal)

#### Example 17 TACI-FC and the CIA model for Rheumatoid Arthritis

**[0258]** Eight week old male DBA/1J mice (Jackson Labs) are divided into groups of 5 mice/group and are given two subcutaneous injections of 50-100µl of 1mg/ml collagen (chick or bovine origin), at 3 week intervals. One control will not receive collagen injections. The first injection is formulated in Complete Freund's Adjuvant and the second injection is formulated in Incomplete Freund's Adjuvant. TACI-FC will be administered prophylactically at or prior to the second injection, or after the animal develops a clinical score of 2 or more that persists at least 24 hours. Animals begin to show symptoms of arthritis following the second collagen injection, usually within 2-3 weeks. Extent of disease is evaluated in each paw by using a caliper to measure paw thickness and assigning a clinical score (0-3) to each paw. Clinical Score, 0 Normal, 1 Toe(s) inflamed, 2 Mild paw inflammation, 3 Moderate paw inflammation, and 4 Severe paw inflammation. Animals will be euthanized after having established disease for a set period of time, usually 7 days. Paws are collected for histology or mRNA analysis, and serum is collected for immunoglobulin and cytokine assays.

#### Example 18 Neutralizing TACI antibodies

**[0259]** Polyclonal anti-peptide antibodies were prepared by immunizing 2 female New Zealand white rabbits with the peptide, huztnf4-1 SAGIAKLEEGPELQLAIPRE (SEQ ID NO:59) or huztnf4-2 SFKRGSALEEKENKELVKET (SEQ ID NO:60). The peptides were synthesized using an Applied Biosystems Model 431A peptide synthesizer (Applied Biosystems, Inc., Foster City, CA) according to manufacturer's instructions. The peptides were then conjugated to the carrier protein keyhole limpet hemocyanin (KLH) with maleimide-activation. The rabbits were each given an initial intraperitoneal (ip) injection of 200 µg of peptide in Complete Freund's Adjuvant followed by booster ip injections of 100 µg peptide in Incomplete Freund's Adjuvant every three weeks. Seven to ten days after the administration of the second booster injection (3 total injections), the animals were bled and the serum was collected. The animals were then boosted and bled every three weeks.

**[0260]** The ztnf4 peptide-specific rabbit seras were characterized by an ELISA titer check using 1 µg/ml of the peptides used to make the antibody (SEQ ID NOs:59 and 60) as an antibody target. The 2 rabbit seras to the huztnf4-1 peptide (SEQ ID NO:59) have titer to their specific peptide at a dilution of 1:1E5 (1:100000). The 2 rabbit seras to the huztnf4-2 peptide (SEQ ID NO:60) had titer to their specific peptide at a dilution of 1:5E6 and to recombinant full-length proteins (N-terminal FLAG-tagged ztnf4 made in baculovirus (huztnf4s-NF-Bv) and C-terminally FLAG-tagged ztnf4 made in BHK cells) at a dilution of 1:5E6.

**[0261]** The ztnf4 peptide-specific polyclonal antibodies were affinity purified from the rabbit serum using CN-BR-SEPHAROSE 4B protein columns (Pharmacia LKB) that were prepared using 10 mgs of the specific peptides (SEQ. ID. NOs.59 or 60) per gram CNBr-SEPHAROSE, followed by 20X dialysis in PBS overnight. Ztnf4-specific antibodies were characterized by an ELISA titer check using 1 µg/ml of the appropriate peptide antigen or recombinant full-length protein (huztnf4s-NF-Bv) as antibody targets. The lower limit of detection (LLD) of the rabbit anti-huztnf4-1 affinity purified antibody on its specific antigen (huztnf4-1 peptide, SEQ ID NO:59) is a dilution of 5 ng/ml. The lower limit of detection (LLD) of the rabbit anti-huztnf4-2 affinity purified antibody on its specific antigen (huztnf4-2 peptide, SEQ ID NO:60) is a dilution of 0.5 ng/ml. The lower limit of detection (LLD) of the rabbit anti-huztnf4-2 affinity purified antibody on the recombinant protein huztnf4s-NF-Bv is a dilution of 5 ng/ml.

**[0262]** Mouse monoclonal antibodies were also generated and selected for inhibition of inhibition of biotinlabeled soluble ztnf4. None of the TACI monoclonal antibodies (248.14, 248.23, 248.24, or 246.3) block ztnf4 binding on BCMA. Monoclonal 248.23 reduces binding of 10 ng/ml ztnf4-biotin to about 50% when conditioned media is diluted to 1:243 and reduces binding to about 2X in undiluted media. Monoclonal 246.3 reduces binding of 10 ng/ml ztnf4-biotin to

about 50% between a 1:243 and 1:181 dilution of conditioned media and reduces binding 5X in undiluted media.

**[0263]** From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

5

10

15

20

25

30

35

40

45

50

55

## SEQUENCE LISTING

<110> ZymoGenetics, Inc.

<120> SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING

<130> 98-75

<150> 09/226,533

<151> 1999-01-07

<160> 60

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1192

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (6)...(746)

<400> 1

gagta atg agt ggc ctg ggc cgg agc agg cga ggt ggc cgg agc cgt gtg 50

Met Ser Gly Leu Gly Arg Ser Arg Arg Gly Gly Arg Ser Arg Val

1 5 10 15

gac cag gag gag cgc tgg tca ctc agc tgc cgc aag gag caa ggc aag 98

Asp Gln Glu Glu Arg Trp Ser Leu Ser Cys Arg Lys Glu Gln Gly Lys

20 25 30

ttc tat gac cat ctc ctg agg gac tgc atc agc tgt gcc tcc atc tgt 146

Phe Tyr Asp His Leu Leu Arg Asp Cys Ile Ser Cys Ala Ser Ile Cys

35 40 45

gga cag cac cct aag caa tgt gca tac ttc tgt gag aac aag ctc agg 194

Gly Gln His Pro Lys Gln Cys Ala Tyr Phe Cys Glu Asn Lys Leu Arg

50 55 60

agc cca gtg aac cttcca cca gag ctc agg aga cag cgg agt gga gaa 242

Ser Pro Val Asn Leu Pro Pro Glu Leu Arg Arg Gln Arg Ser Gly Glu

65 70 75

5 gtt gaa aac aat tca gac aac tcg gga agg tac caa gga ttg gag cac 290  
 Val Glu Asn Asn Ser Asp Asn Ser Gly Arg Tyr Gln Gly Leu Glu His  
 80 85 90 95

10 aga ggc tca gaa gca agt cca gct ctc ccg ggg ctg aag ctg agt gca 338  
 Arg Gly Ser Glu Ala Ser Pro Ala Leu Pro Gly Leu Lys Leu Ser Ala  
 100 105 110

15 gat cag gtg gcc ctg gtc tac agc acg ctg ggg ctc tgc ctg tgt gcc 386  
 Asp Gln Val Ala Leu Val Tyr Ser Thr Leu Gly Leu Cys Leu Cys Ala  
 115 120 125

20 gtc ctc tgc tgc ttc ctg gtg gcg gtg gcc tgc ttc ctc aag aag agg 434  
 Val Leu Cys Cys Phe Leu Val Ala Val Ala Cys Phe Leu Lys Lys Arg  
 130 135 140

25 ggg gat ccc tgc tcc tgc cag ccc cgc tca agg ccc cgt caa agt ccg 482  
 Gly Asp Pro Cys Ser Cys Gln Pro Arg Ser Arg Pro Arg Gln Ser Pro  
 145 150 155

30 gcc aag tct tcc cag gat cac gcg atg gaa gcc ggc agc cct gtg agc 530  
 Ala Lys Ser Ser Gln Asp His Ala Met Glu Ala Gly Ser Pro Val Ser  
 160 165 170 175

35 aca tcc ccc gag cca gtg gag acc tgc agc ttc tgc ttc cct gag tgc 578  
 Thr Ser Pro Glu Pro Val Glu Thr Cys Ser Phe Cys Phe Pro Glu Cys  
 180 185 190

40 agg gcg ccc acg cag gag agc gca gtc acg cct ggg acc ccc gac ccc 626  
 Arg Ala Pro Thr Gln Glu Ser Ala Val Thr Pro Gly Thr Pro Asp Pro  
 195 200 205

45 act tgt gct gga agg tgg ggg tgc cac acc agg acc aca gtc ctg cag 674  
 Thr Cys Ala Gly Arg Trp Gly Cys His Thr Arg Thr Thr Val Leu Gln  
 210 215 220

50 cct tgc cca cac atc cca gac agt ggc ctt ggc att gtg tgt gtg cct 722  
 Pro Cys Pro His Ile Pro Asp Ser Gly Leu Gly Ile Val Cys Val Pro  
 225 230 235

55 gcc cag gag ggg ggc cca ggt gca taaatggggg tcagggaggg aaaggaggag 776  
 Ala Gln Glu Gly Gly Pro Gly Ala  
 240 245

ggagagagat ggagaggagg ggagagagaa agagaggtgg ggagagggga gagagatatg 836  
 aggagagaga gacagaggag gcagagaggg agagaaacag aggagacaga gaggagaga 896  
 5 gagacagagg gagagagaga cagaggggaa gagaggcaga gagggaaga ggcagagaag 956  
 gaaagaggca gagagggaga gaggcagaga gggagagagg cagagagaca gagagggaga 1016  
 gaggacaga gagagataga gcaggaggtc ggggcactct ggtcccagt tcccagtga 1076  
 gctgtaggtc gtcacacct aaccacacgt gcaataaagt cctcgtgcct gctgctaca 1136  
 10 gccccgaga gccctcctc ctggagaata aaacctttgg cagctgccct tctca 1192

<210> 2

<211> 247

<212> PRT

<213> Homo sapiens

<400> 2

Met Ser Gly Leu Gly Arg Ser Arg Arg Gly Gly Arg Ser Arg Val Asp  
 1 5 10 15  
 20 Gln Glu Glu Arg Trp Ser Leu Ser Cys Arg Lys Glu Gln Gly Lys Phe  
 20 25 30  
 Tyr Asp His Leu Leu Arg Asp Cys Ile Ser Cys Ala Ser Ile Cys Gly  
 35 40 45  
 25 Gln His Pro Lys Gln Cys Ala Tyr Phe Cys Glu Asn Lys Leu Arg Ser  
 50 55 60  
 Pro Val Asn Leu Pro Pro Glu Leu Arg Arg Gln Arg Ser Gly Glu Val  
 65 70 75 80  
 30 Glu Asn Asn Ser Asp Asn Ser Gly Arg Tyr Gln Gly Leu Glu His Arg  
 85 90 95  
 Gly Ser Glu Ala Ser Pro Ala Leu Pro Gly Leu Lys Leu Ser Ala Asp  
 100 105 110  
 35 Gln Val Ala Leu Val Tyr Ser Thr Leu Gly Leu Cys Leu Cys Ala Val  
 115 120 125  
 Leu Cys Cys Phe Leu Val Ala Val Ala Cys Phe Leu Lys Lys Arg Gly  
 130 135 140  
 Asp Pro Cys Ser Cys Gln Pro Arg Ser Arg Pro Arg Gln Ser Pro Ala  
 145 150 155 160  
 40 Lys Ser Ser Gln Asp His Ala Met Glu Ala Gly Ser Pro Val Ser Thr  
 165 170 175  
 Ser Pro Glu Pro Val Glu Thr Cys Ser Phe Cys Phe Pro Glu Cys Arg  
 180 185 190  
 45 Ala Pro Thr Gln Glu Ser Ala Val Thr Pro Gly Thr Pro Asp Pro Thr  
 195 200 205  
 Cys Ala Gly Arg Trp Gly Cys His Thr Arg Thr Thr Val Leu Gln Pro  
 210 215 220  
 50 Cys Pro His Ile Pro Asp Ser Gly Leu Gly Ile Val Cys Val Pro Ala  
 225 230 235 240  
 Gln Glu Gly Gly Pro Gly Ala

245

5           <210> 3  
           <211> 360  
           <212> DNA  
           <213> Homo sapiens  
  
 10          <220>  
           <221> CDS  
           <222> (1)...(360)  
  
 15          <400> 3  
   atg agt ggc ctg ggc cgg agc agg cga ggt ggc cgg agc cgt gtg gac       48  
   Met Ser Gly Leu Gly Arg Ser Arg Arg Gly Gly Arg Ser Arg Val Asp  
    1                   5                   10                   15  
  
 20          cag gag gag cgc tgg tca ctc agc tgc cgc aag gag caa ggc aag ttc       96  
         Gln Glu Glu Arg Trp Ser Leu Ser Cys Arg Lys Glu Gln Gly Lys Phe  
                   20                   25                   30  
  
 25          tat gac cat ctc ctg agg gac tgc atc agc tgt gcc tcc atc tgt gga       144  
         Tyr Asp His Leu Leu Arg Asp Cys Ile Ser Cys Ala Ser Ile Cys Gly  
                   35                   40                   45  
  
 30          cag cac cct aag caa tgt gca tac ttc tgt gag aac aag ctc agg agc       192  
         Gln His Pro Lys Gln Cys Ala Tyr Phe Cys Glu Asn Lys Leu Arg Ser  
           50                   55                   60  
  
 35          cca gtg aac ctt cca cca gag ctc agg aga cag cgg agt gga gaa gtt       240  
         Pro Val Asn Leu Pro Pro Glu Leu Arg Arg Gln Arg Ser Gly Glu Val  
           65                   70                   75                   80  
  
 40          gaa aac aat tca gac aac tcg gga agg tac caa gga ttg gag cac aga       288  
         Glu Asn Asn Ser Asp Asn Ser Gly Arg Tyr Gln Gly Leu Glu His Arg  
                   85                   90                   95  
  
 45          ggc tca gaa gca agt cca gct ctc ccg ggg ctg aag ctg agt gca gat       336  
         Gly Ser Glu Ala Ser Pro Ala Leu Pro Gly Leu Lys Leu Ser Ala Asp  
           100                   105                   110  
  
 50          cag gtg gcc ctg gtc tac agc acg       360  
         Gln Val Ala Leu Val Tyr Ser Thr  
           115                   120  
  
 55

<210> 4  
 <211> 120  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 10 Met Ser Gly Leu Gly Arg Ser Arg Arg Gly Gly Arg Ser Arg Val Asp  
     1                    5                    10                    15  
   Gln Glu Glu Arg Trp Ser Leu Ser Cys Arg Lys Glu Gln Gly Lys Phe  
                     20                    25                    30  
 15 Tyr Asp His Leu Leu Arg Asp Cys Ile Ser Cys Ala Ser Ile Cys Gly  
                     35                    40                    45  
   Gln His Pro Lys Gln Cys Ala Tyr Phe Cys Glu Asn Lys Leu Arg Ser  
                     50                    55                    60  
 20 Pro Val Asn Leu Pro Pro Glu Leu Arg Arg Gln Arg Ser Gly Glu Val  
     65                    70                    75                    80  
   Glu Asn Asn Ser Asp Asn Ser Gly Arg Tyr Gln Gly Leu Glu His Arg  
                     85                    90                    95  
   Gly Ser Glu Ala Ser Pro Ala Leu Pro Gly Leu Lys Leu Ser Ala Asp  
                     100                    105                    110  
 25 Gln Val Ala Leu Val Tyr Ser Thr  
     115                    120

<210> 5  
 <211> 1377  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (14)...(895)

<400> 5  
 40 agcatcctga gta atg agt ggc ctg ggc cgg agc agg cga ggt ggc cgg 49  
     Met Ser Gly Leu Gly Arg Ser Arg Arg Gly Gly Arg  
                     1                    5                    10  
 45 agc cgt gtg gac cag gag gag cgc ttt cca cag ggc ctg tgg acg ggg 97  
   Ser Arg Val Asp Gln Glu Glu Arg Phe Pro Gln Gly Leu Trp Thr Gly  
                     15                    20                    25  
 50 gtg gct atg aga tcc tgc ccc gaa gag cag tac tgg gat cct ctg ctg 145  
   Val Ala Met Arg Ser Cys Pro Glu Glu Gln Tyr Trp Asp Pro Leu Leu  
                     30                    35                    40

5 ggt acc tgc atg tcc tgc aaa acc att tgc aac cat cag agc cag cgc 193  
 Gly Thr Cys Met Ser Cys Lys Thr Ile Cys Asn His Gln Ser Gln Arg  
 45 50 55 60

10 acc tgt gca gcc ttc tgc agg tca ctc agc tgc cgc aag gag caa ggc 241  
 Thr Cys Ala Ala Phe Cys Arg Ser Leu Ser Cys Arg Lys Glu Gln Gly  
 65 70 75

15 aag ttc tat gac cat ctc ctg agg gac tgc atc agc tgt gcc tcc atc 289  
 Lys Phe Tyr Asp His Leu Leu Arg Asp Cys Ile Ser Cys Ala Ser Ile  
 80 85 90

20 tgt gga cag cac cct aag caa tgt gca tac ttc tgt gag aac aag ctc 337  
 Cys Gly Gln His Pro Lys Gln Cys Ala Tyr Phe Cys Glu Asn Lys Leu  
 95 100 105

25 agg agc cca gtg aac ctt cca cca gag ctc agg aga cag cgg agt gga 385  
 Arg Ser Pro Val Asn Leu Pro Pro Glu Leu Arg Arg Gln Arg Ser Gly  
 110 115 120

30 gaa gtt gaa aac aat tca gac aac tcg gga agg tac caa gga ttg gag 433  
 Glu Val Glu Asn Asn Ser Asp Asn Ser Gly Arg Tyr Gln Gly Leu Glu  
 125 130 135 140

35 cac aga ggc tca gaa gca agt cca gct ctc ccg ggg ctg aag ctg agt 481  
 His Arg Gly Ser Glu Ala Ser Pro Ala Leu Pro Gly Leu Lys Leu Ser  
 145 150 155

40 gca gat cag gtg gcc ctg gtc tac agc acg ctg ggg ctc tgc ctg tgt 529  
 Ala Asp Gln Val Ala Leu Val Tyr Ser Thr Leu Gly Leu Cys Leu Cys  
 160 165 170

45 gcc gtc ctc tgc tgc ttc ctg gtg gcg gtg gcc tgc ttc ctc aag aag 577  
 Ala Val Leu Cys Cys Phe Leu Val Ala Val Ala Cys Phe Leu Lys Lys  
 175 180 185

50 agg ggg gat ccc tgc tcc tgc cag ccc cgc tca agg ccc cgt caa agt 625  
 Arg Gly Asp Pro Cys Ser Cys Gln Pro Arg Ser Arg Pro Arg Gln Ser  
 190 195 200

55 ccg gcc aag tct tcc cag gat cac gcg atg gaa gcc ggc agc cct gtg 673  
 Pro Ala Lys Ser Ser Gln Asp His Ala Met Glu Ala Gly Ser Pro Val  
 205 210 215 220



5	agc aca tcc ccc gag cca gtg gag acc tgc agc ttc tgc ttc cct gag Ser Thr Ser Pro Glu Pro Val Glu Thr Cys Ser Phe Cys Phe Pro Glu 225 230 235	721
10	tgc agg gcg ccc acg cag gag agc gca gtc acg cct ggg acc ccc gag Cys Arg Ala Pro Thr Gln Glu Ser Ala Val Thr Pro Gly Thr Pro Asp 240 245 250	769
15	ccc act tgt gct gga agg tgg ggg tgc cac acc agg acc aca gtc ctg Pro Thr Cys Ala Gly Arg Trp Gly Cys His Thr Arg Thr Thr Val Leu 255 260 265	817
20	cag cct tgc cca cac atc cca gac agt ggc ctt ggc att gtg tgt gtg Gln Pro Cys Pro His Ile Pro Asp Ser Gly Leu Gly Ile Val Cys Val 270 275 280	865
25	cct gcc cag gag ggg ggc cca ggt gca taa atgggggtca gggagggaaa Pro Ala Gln Glu Gly Gly Pro Gly Ala *	915
30	ggaggaggga gagagatgga gaggagggga gagagaaaga gaggtgggga gaggggagag agatatgagg agagagagac agaggaggca gaaagggaga gaaacagagg agacagagag ggagagagag acagaggagg agagagacag aggggaagag aggcagagag ggaaagaggc agagaaggaa agagacaggc agagaaggag agaggcagag agggagagag gcagagaggg agagaggcag agagacagag agggagagag ggacagagag agatagagca ggaggtcggg gcactctgag tcccagttcc cagtgcagct gtaggtcgtc atcacctaac cacacgtgca ataaagtcct cgtgcctgct gctcacagcc cccgagagcc cctcctcctg gagaataaaa cctttggcag ctgcccttcc tcaaaaaaaaa aaaaaaaaaa aa	975 1035 1095 1155 1215 1275 1335 1377
35	<210> 6 <211> 293 <212> PRT <213> Homo sapiens	
40	<400> 6	
45	Met Ser Gly Leu Gly Arg Ser Arg Arg Gly Gly Arg Ser Arg Val Asp 1 5 10 15 Gln Glu Glu Arg Phe Pro Gln Gly Leu Trp Thr Gly Val Ala Met Arg 20 25 30 Ser Cys Pro Glu Glu Gln Tyr Trp Asp Pro Leu Leu Gly Thr Cys Met 35 40 45 Ser Cys Lys Thr Ile Cys Asn His Gln Ser Gln Arg Thr Cys Ala Ala 50 55 60 Phe Cys Arg Ser Leu Ser Cys Arg Lys Glu Gln Gly Lys Phe Tyr Asp 65 70 75 80	
55		

His Leu Leu Arg Asp Cys Ile Ser Cys Ala Ser Ile Cys Gly Gln His  
 85 90 95  
 5 Pro Lys Gln Cys Ala Tyr Phe Cys Glu Asn Lys Leu Arg Ser Pro Val  
 100 105 110  
 Asn Leu Pro Pro Glu Leu Arg Arg Gln Arg Ser Gly Glu Val Glu Asn  
 115 120 125  
 10 Asn Ser Asp Asn Ser Gly Arg Tyr Gln Gly Leu Glu His Arg Gly Ser  
 130 135 140  
 Glu Ala Ser Pro Ala Leu Pro Gly Leu Lys Leu Ser Ala Asp Gln Val  
 145 150 155 160  
 15 Ala Leu Val Tyr Ser Thr Leu Gly Leu Cys Leu Cys Ala Val Leu Cys  
 165 170 175  
 Cys Phe Leu Val Ala Val Ala Cys Phe Leu Lys Lys Arg Gly Asp Pro  
 180 185 190  
 Cys Ser Cys Gln Pro Arg Ser Arg Pro Arg Gln Ser Pro Ala Lys Ser  
 195 200 205  
 20 Ser Gln Asp His Ala Met Glu Ala Gly Ser Pro Val Ser Thr Ser Pro  
 210 215 220  
 Glu Pro Val Glu Thr Cys Ser Phe Cys Phe Pro Glu Cys Arg Ala Pro  
 225 230 235 240  
 25 Thr Gln Glu Ser Ala Val Thr Pro Gly Thr Pro Asp Pro Thr Cys Ala  
 245 250 255  
 Gly Arg Trp Gly Cys His Thr Arg Thr Thr Val Leu Gln Pro Cys Pro  
 260 265 270  
 30 His Ile Pro Asp Ser Gly Leu Gly Ile Val Cys Val Pro Ala Gln Glu  
 275 280 285  
 Gly Gly Pro Gly Ala  
 290

35 <210> 7  
 <211> 995  
 <212> DNA  
 <213> Homo sapiens

40 <220>  
 <221> CDS  
 <222> (219)...(773)

45 <400> 7  
 aagactcaaa ctagaaact tgaattagat gtggtattca aatccttacg tgccgcgaag 60  
 acacagacag ccccgtaag aaccacgaa gcaggcgaag ttcattgttc tcaacattct 120  
 agctgctctt gctgcatttg ctctggaatt cttgtagaga tattacttgt ccttcaggc 180  
 50 tgttctttct gtagctccct tgttttcttt ttgtgatc atg ttg cag atg gct ggg 236  
 Met Leu Gln Met Ala Gly  
 1 5

55

5	cag tgc tcc caa aat gaa tat ttt gac agt ttg ttg cat gct tgc ata Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser Leu Leu His Ala Cys Ile	284
	10 15 20	
10	cct tgt caa ctt cga tgt tct tct aat act cct cct cta aca tgt cag Pro Cys Gln Leu Arg Cys Ser Ser Asn Thr Pro Pro Leu Thr Cys Gln	332
	25 30 35	
15	cgt tat tgt aat gca agt gtg acc aat tca gtg aaa gga acg aat gcg Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser Val Lys Gly Thr Asn Ala	380
	40 45 50	
20	att ctc tgg acc tgt ttg gga ctg agc tta ata att tct ttg gca gtt Ile Leu Trp Thr Cys Leu Gly Leu Ser Leu Ile Ile Ser Leu Ala Val	428
	55 60 65 70	
25	ttc gtg cta atg ttt ttg cta agg aag ata agc tct gaa cca tta aag Phe Val Leu Met Phe Leu Leu Arg Lys Ile Ser Ser Glu Pro Leu Lys	476
	75 80 85	
30	gac gag ttt aaa aac aca gga tca ggt ctc ctg ggc atg gct aac att Asp Glu Phe Lys Asn Thr Gly Ser Gly Leu Leu Gly Met Ala Asn Ile	524
	90 95 100	
35	gac ctg gaa aag agc agg act ggt gat gaa att att ctt ccg aga ggc Asp Leu Glu Lys Ser Arg Thr Gly Asp Glu Ile Ile Leu Pro Arg Gly	572
	105 110 115	
40	ctc gag tac acg gtg gaa gaa tgc acc tgt gaa gac tgc atc aag agc Leu Glu Tyr Thr Val Glu Glu Cys Thr Cys Glu Asp Cys Ile Lys Ser	620
	120 125 130	
45	aaa ccg aag gtc gac tct gac cat tgc ttt cca ctc cca gct atg gag Lys Pro Lys Val Asp Ser Asp His Cys Phe Pro Leu Pro Ala Met Glu	668
	135 140 145 150	
50	gaa ggc gca acc att ctt gtc acc acg aaa acg aat gac tat tgc aag Glu Gly Ala Thr Ile Leu Val Thr Thr Lys Thr Asn Asp Tyr Cys Lys	716
	155 160 165	
55	agc ctg cca gct gct ttg agt gct acg gag ata gag aaa tca att tct Ser Leu Pro Ala Ala Leu Ser Ala Thr Glu Ile Glu Lys Ser Ile Ser	764
	170 175 180	

gct agg taa ttaaccattt cgactcgagc agtgccactt taaaaatctt  
Ala Arg \*

813

ttgtcagaat agatgatgtg tcagatctct ttaggatgac tgtatttttc agttgccgat  
acagcttttt gtcctctaac tgtggaaact ctttatgtta gatataattc tctaggttac  
tggtgggagc ttaatggtag aaacttcctt ggttcatga ttaaagtctt ttttttcct  
ga

873

933

993

995

&lt;210&gt; 8

&lt;211&gt; 184

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

Met Leu Gln Met Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser  
1. 5 10 15  
Leu Leu His Ala Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Thr  
20 25 30  
Pro Pro Leu Thr Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser  
25 35 40 45  
Val Lys Gly Thr Asn Ala Ile Leu Trp Thr Cys Leu Gly Leu Ser Leu  
50 55 60  
Ile Ile Ser Leu Ala Val Phe Val Leu Met Phe Leu Leu Arg Lys Ile  
30 65 70 75 80  
Ser Ser Glu Pro Leu Lys Asp Glu Phe Lys Asn Thr Gly Ser Gly Leu  
85 90 95  
Leu Gly Met Ala Asn Ile Asp Leu Glu Lys Ser Arg Thr Gly Asp Glu  
100 105 110  
Ile Ile Leu Pro Arg Gly Leu Glu Tyr Thr Val Glu Glu Cys Thr Cys  
35 115 120 125  
Glu Asp Cys Ile Lys Ser Lys Pro Lys Val Asp Ser Asp His Cys Phe  
130 135 140  
Pro Leu Pro Ala Met Glu Glu Gly Ala Thr Ile Leu Val Thr Thr Lys  
40 145 150 155 160  
Thr Asn Asp Tyr Cys Lys Ser Leu Pro Ala Ala Leu Ser Ala Thr Glu  
165 170 175  
Ile Glu Lys Ser Ile Ser Ala Arg  
45 180

&lt;210&gt; 9

&lt;211&gt; 245

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

5 Gly Arg Ser Arg Arg Gly Gly Arg Ser Arg Val Asp Gln Glu Glu Arg  
 1 5 10 15  
 Phe Pro Gln Gly Leu Trp Thr Gly Val Ala Met Arg Ser Cys Pro Glu  
 20 25 30  
 Glu Gln Tyr Trp Asp Pro Leu Leu Gly Thr Cys Met Ser Cys Lys Thr  
 35 40 45  
 10 Ile Cys Asn His Gln Ser Gln Arg Thr Cys Ala Ala Phe Cys Arg Ser  
 50 55 60  
 Leu Ser Cys Arg Lys Glu Gln Gly Lys Phe Tyr Asp His Leu Leu Arg  
 65 70 75 80  
 15 Asp Cys Ile Ser Cys Ala Ser Ile Cys Gly Gln His Pro Lys Gln Cys  
 85 90 95  
 Ala Tyr Phe Cys Glu Asn Lys Leu Arg Ser Pro Val Asn Leu Pro Pro  
 100 105 110  
 20 Glu Leu Arg Arg Gln Arg Ser Gly Glu Val Glu Asn Asn Ser Asp Asn  
 115 120 125  
 Ser Gly Arg Tyr Gln Gly Leu Glu His Arg Gly Ser Glu Ala Ser Pro  
 130 135 140  
 25 Ala Leu Pro Gly Leu Lys Leu Ser Ala Asp Gln Val Ala Leu Val Tyr  
 145 150 155 160  
 Ser Thr Leu Gly Leu Cys Leu Cys Ala Val Leu Cys Cys Phe Leu Val  
 165 170 175  
 30 Ala Val Ala Cys Phe Leu Lys Lys Arg Gly Asp Pro Cys Ser Cys Gln  
 180 185 190  
 Pro Arg Ser Arg Pro Arg Gln Ser Pro Ala Lys Ser Ser Gln Asp His  
 195 200 205  
 Ala Met Glu Ala Gly Ser Pro Val Ser Thr Ser Pro Glu Pro Val Glu  
 210 215 220  
 35 Thr Cys Ser Phe Cys Phe Pro Glu Cys Arg Ala Pro Thr Gln Glu Ser  
 225 230 235 240  
 Ala Val Thr Pro Gly  
 245

&lt;210&gt; 10

&lt;211&gt; 40

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Motif describing the cysteine-rich pseudo-repeat domain

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(2)

<223> Each Xaa is independently any amino acid residue except cysteine, or absent.

<221> VARIANT

<222> (4)...(4)

<223> Xaa is any amino acid residue except cysteine.

<221> VARIANT

<222> (5)...(5)

<223> Xaa is glutamine, glutamic acid, or lysine.

<221> VARIANT

<222> (6)...(6)

<223> Xaa is glutamine, glutamic acid, lysine, asparagine, arginine, aspartic acid, histidine, or serine.

<221> VARIANT

<222> (7)...(7)

<223> Xaa is glutamine or glutamic acid.

<221> VARIANT

<222> (8)...(9)

<223> Each Xaa is independently any amino acid residue except cysteine, or absent.

<221> VARIANT

<222> (10)...(11)

<223> Xaa is tyrosine, phenylalanine, or tryptophan.

<221> VARIANT

<222> (13)...(13)

<223> Xaa is any amino acid residue except cysteine.

<221> VARIANT

<222> (16)...(17)

<223> Each Xaa is independently any amino acid residue except cysteine.

<221> VARIANT

<222> (19)...(19)

<223> Xaa is isoleucine, methionine, leucine, or valine.

<221> VARIANT

<222> (20)...(20)

<223> Xaa is any amino acid residue except cysteine.

<221> VARIANT

<222> (22)...(24)

<223> Each Xaa is independently any amino acid residue except cysteine.

<221> VARIANT

<222> (26)...(31)

<223> Each Xaa is independently any amino acid residue except cysteine.

<221> VARIANT

<222> (32)...(33)

<223> Each Xaa is independently any amino acid residue except cysteine, or absent.

<221> VARIANT

<222> (35)...(36)

<223> Each Xaa is independently any amino acid residue except cysteine.

<221> VARIANT

<222> (37)...(37)

<223> Xaa is tyrosine or phenylalanine.

<221> VARIANT

<222> (39)...(40)

<223> Each Xaa is independently any amino acid residue except cysteine, or absent.

<400> 10

Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Leu Leu Xaa

1

5

10

15

Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa

20

25

30

Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa

35

40

<210> 11

<211> 360

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Degenerate oligonucleotide sequence encoding the polypeptide of SEQ ID NO:4

&lt;221&gt; variation

&lt;222&gt; (1)...(360)

&lt;223&gt; Each N is independently A, T, G, or C.

&lt;400&gt; 11

atgwsnggny	tnggmgnws	nmgnmgnggn	ggnmgwnsm	ngtngayca	rgargarmgn	60
tggsnytnw	sntgymgnaa	rgarcarggn	aarttytayg	aycaytnyt	nmngaytgy	120
athwsntgyg	cnwsnathtg	yggncarcay	ccnaarcart	gygcntaytt	ytgygaraay	180
aarytnmgnw	sncngtnaa	yytnccnccn	garytnmgm	gncarmgnws	ngngargtn	240
garaayaayw	sngayaayws	nggnmgntay	carggnytn	arcaymgngg	nwsngargcn	300
wsnccngcny	tnccnggnyt	naarytnwsn	gcngaycarg	tngcnytngt	ntaywsnacr	360

&lt;210&gt; 12

&lt;211&gt; 741

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Degenerate oligonucleotide sequence encoding a polypeptide of SEQ ID NO:2

&lt;221&gt; variation

&lt;222&gt; (1)...(741)

&lt;223&gt; Each N is independently A, T, G, or C.

&lt;400&gt; 12

atgwsnggny	tnggmgnws	nmgnmgnggn	ggnmgwnsm	ngtngayca	rgargarmgn	60
tggsnytnw	sntgymgnaa	rgarcarggn	aarttytayg	aycaytnyt	nmngaytgy	120
athwsntgyg	cnwsnathtg	yggncarcay	ccnaarcart	gygcntaytt	ytgygaraay	180
aarytnmgnw	sncngtnaa	yytnccnccn	garytnmgm	gncarmgnws	ngngargtn	240
garaayaayw	sngayaayws	nggnmgntay	carggnytn	arcaymgngg	nwsngargcn	300
wsnccngcny	tnccnggnyt	naarytnwsn	gcngaycarg	tngcnytngt	ntaywsnacr	360
ytnggnytn	gytntgygc	ngtntntgy	tgyttytn	tngcngtngc	ntgyttytn	420
aaraarmgng	ngayccntg	ywsntgyar	ccnmgnsm	gnccnmgnca	rwsnccngcn	480
aarwsnwsnc	argaycaygc	natggargcn	ggnwsnccng	tnwsnacrws	nccngarccn	540
gtngaracnt	gywsnttytg	yttyccngar	tgymngcnc	cnacncarga	rwsngcngtn	600
acnccnggna	cncngaycc	nacntgygc	ggnmgntggg	gntgyayac	nmgnacnacn	660
gtnytnarc	cntgyccnca	yathccngay	wsnggnytn	gnathgtntg	ygtncngcn	720
cargarggng	gnccnggngc	n				741

&lt;210&gt; 13



5  
 <211> 8  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> FLAG tag

10  
 <400> 13  
 Asp Tyr Lys Asp Asp Asp Lys  
 1 5

15  
 <210> 14  
 <211> 7  
 <212> PRT  
 <213> Artificial Sequence

20  
 <220>  
 <223> Glu-Glu tag

25  
 <400> 14  
 Glu Glu Tyr Met Pro Met Glu  
 1 5

30  
 <210> 15  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

35  
 <220>  
 <223> Oligonucleotide ZC19980

40  
 <400> 15  
 cgaagagcag tactgggatc ctct 24

<210> 16  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

45  
 <220>  
 <223> Oligonucleotide ZC19981

50  
 <400> 16  
 gccaaaggcca ctgtctggga tgt 23

55

<210> 17.  
 <211> 1149  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (236)...(1027)

<400> 17

gaattcggca cgaggcagaa aggagaaaat tcaggataac tctcctgagg ggtgagccaa 60  
 gccctgccat gtagtgacg caggacatca acaaacacag ataacaggaa atgatccatt 120  
 ccctgtggtc acttattcta aaggcccaa ccttcaaagt tcaagtagtg atatggatga 180  
 ctccacagaa agggagcagt cagccttac ttctgcctt aagaaaagag aagaa atg 238  
 Met  
 1

aaa ctg aag gag tgt gtt tcc atc ctc cca cgg aag gaa agc ccc tct 286  
 Lys Leu Lys Glu Cys Val Ser Ile Leu Pro Arg Lys Glu Ser Pro Ser  
 5 10 15

gtc cga tcc tcc aaa gac gga aag ctg ctg gct gca acc ttg ctg ctg 334  
 Val Arg Ser Ser Lys Asp Gly Lys Leu Leu Ala Ala Thr Leu Leu Leu  
 20 25 30

gca ctg ctg tct tgc tgc ctc acg gtg gtg tct ttc tac cag gtg gcc 382  
 Ala Leu Leu Ser Cys Cys Leu Thr Val Val Ser Phe Tyr Gln Val Ala  
 35 40 45

gcc ctg caa ggg gac ctg gcc agc ctc cgg gca gag ctg cag ggc cac 430  
 Ala Leu Gln Gly Asp Leu Ala Ser Leu Arg Ala Glu Leu Gln Gly His  
 50 55 60 65

cac gcg gag aag ctg cca gca gga gca gga gcc ccc aag gcc ggc ctg 478  
 His Ala Glu Lys Leu Pro Ala Gly Ala Gly Ala Pro Lys Ala Gly Leu  
 70 75 80

gag gaa gct cca gct gtc acc gcg gga ctg aaa atc ttt gaa cca cca 526  
 Glu Glu Ala Pro Ala Val Thr Ala Gly Leu Lys Ile Phe Glu Pro Pro  
 85 90 95

gct cca gga gaa ggc aac tcc agt cag aac agc aga aat aag cgt gcc 574  
 Ala Pro Gly Glu Gly Asn Ser Ser Gln Asn Ser Arg Asn Lys Arg Ala  
 100 105 110

5	gtt cag ggt cca gaa gaa aca gtc act caa gac tgc ttg caa ctg att Val Gln Gly Pro Glu Glu Thr Val Thr Gln Asp Cys Leu Gln Leu Ile 115 120 125	622
10	gca gac agt gaa aca cca act ata caa aaa gga tct tac aca ttt gtt Ala Asp Ser Glu Thr Pro Thr Ile Gln Lys Gly Ser Tyr Thr Phe Val 130 135 140 145	670
15	cca tgg ctt ctc agc ttt aaa agg gga agt gcc cta gaa gaa aaa gag Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser Ala Leu Glu Glu Lys Glu 150 155 160	718
20	aat aaa ata ttg gtc aaa gaa act ggt tac ttt ttt ata tat ggt cag Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr Phe Phe Ile Tyr Gly Gln 165 170 175	766
25	gtt tta tat act gat aag acc tac gcc atg gga cat cta att cag agg Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met Gly His Leu Ile Gln Arg 180 185 190	814
30	aag aag gtc cat gtc ttt ggg gat gaa ttg agt ctg gtg act ttg ttt Lys Lys Val His Val Phe Gly Asp Glu Leu Ser Leu Val Thr Leu Phe 195 200 205	862
35	cga tgt att caa aat atg cct gaa aca cta ccc aat aat tcc tgc tat Arg Cys Ile Gln Asn Met Pro Glu Thr Leu Pro Asn Asn Ser Cys Tyr 210 215 220 225	910
40	tca gct ggc att gca aaa ctg gaa gaa gga gat gaa ctc caa ctt gca Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly Asp Glu Leu Gln Leu Ala 230 235 240	958
45	ata cca aga gaa aat gca caa ata tca ctg gat gga gat gtc aca ttt Ile Pro Arg Glu Asn Ala Gln Ile Ser Leu Asp Gly Asp Val Thr Phe 245 250 255	1006
50	ttt ggt gca ttg aaa-ctg ctg tgacctactt acaccatgtc tgtagctatt Phe Gly Ala Leu Lys Leu Leu 260	1057
55	ttcctccctt tctctgtacc tctaagaaga aagaatctaa ctgaaaatac caaaaaaaaa aaaaaaaaaa aaaaaaccct cgagcgcccg cc	1117 1149
	<210> 18 <211> 264	

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

Met Lys Leu Lys Glu Cys Val Ser Ile Leu Pro Arg Lys Glu Ser Pro  
 1 5 10 15  
 Ser Val Arg Ser Ser Lys Asp Gly Lys Leu Leu Ala Ala Thr Leu Leu  
 20 25 30  
 Leu Ala Leu Leu Ser Cys Cys Leu Thr Val Val Ser Phe Tyr Gln Val  
 35 40 45  
 Ala Ala Leu Gln Gly Asp Leu Ala Ser Leu Arg Ala Glu Leu Gln Gly  
 50 55 60  
 His His Ala Glu Lys Leu Pro Ala Gly Ala Gly Ala Pro Lys Ala Gly  
 65 70 75 80  
 Leu Glu Glu Ala Pro Ala Val Thr Ala Gly Leu Lys Ile Phe Glu Pro  
 85 90 95  
 Pro Ala Pro Gly Glu Gly Asn Ser Ser Gln Asn Ser Arg Asn Lys Arg  
 100 105 110  
 Ala Val Gln Gly Pro Glu Glu Thr Val Thr Gln Asp Cys Leu Gln Leu  
 115 120 125  
 Ile Ala Asp Ser Glu Thr Pro Thr Ile Gln Lys Gly Ser Tyr Thr Phe  
 130 135 140  
 Val Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser Ala Leu Glu Glu Lys  
 145 150 155 160  
 Glu Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr Phe Phe Ile Tyr Gly  
 165 170 175  
 Gln Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met Gly His Leu Ile Gln  
 180 185 190  
 Arg Lys Lys Val His Val Phe Gly Asp Glu Leu Ser Leu Val Thr Leu  
 195 200 205  
 Phe Arg Cys Ile Gln Asn Met Pro Glu Thr Leu Pro Asn Asn Ser Cys  
 210 215 220  
 Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly Asp Glu Leu Gln Leu  
 225 230 235 240  
 Ala Ile Pro Arg Glu Asn Ala Gln Ile Ser Leu Asp Gly Asp Val Thr  
 245 250 255  
 Phe Phe Gly Ala Leu Lys Leu Leu  
 260

&lt;210&gt; 19

&lt;211&gt; 1430

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (102)...(848)

5

&lt;400&gt; 19

ttggcgcagg agcgtgcgta ggattgctcg ctcacaacag gcacctgact ggtattgaaa 60  
 gccgagtctt cccttcctct ttaaaggatt ggtgaccagg c atg gct atg gca ttc 116  
 Met Ala Met Ala Phe  
 1 5

10

tgc ccc aaa gat cag tac tgg gac tcc tca agg aaa tcc tgt gtc tcc 164  
 Cys Pro Lys Asp Gln Tyr Trp Asp Ser Ser Arg Lys Ser Cys Val Ser  
 10 15 20

15

tgt gca ctg acc tgc agc cag agg agc cag cgc acc tgt aca gac ttc 212  
 Cys Ala Leu Thr Cys Ser Gln Arg Ser Gln Arg Thr Cys Thr Asp Phe  
 25 30 35

20

tgc aaa ttc atc aat tgc cga aaa gag caa ggc agg tac tac gac cat 260  
 Cys Lys Phe Ile Asn Cys Arg Lys Glu Gln Gly Arg Tyr Tyr Asp His  
 40 45 50

25

ctc ctg ggg gcc tgc gtc agc tgt gac tcc acc tgc aca cag cac cct 308  
 Leu Leu Gly Ala Cys Val Ser Cys Asp Ser Thr Cys Thr Gln His Pro  
 55 60 65

30

cag cag tgt gcc cac ttc tgt gag aaa agg ccc aga agc cag gcg aac 356  
 Gln Gln Cys Ala His Phe Cys Glu Lys Arg Pro Arg Ser Gln Ala Asn  
 70 75 80 85

35

ctc cag ccc gag ctc ggg aga cca cag gcc ggg gag gtg gaa gtc agg 404  
 Leu Gln Pro Glu Leu Gly Arg Pro Gln Ala Gly Glu Val Glu Val Arg  
 90 95 100

40

tca gac aac tca gga agg cac cag gga tct gag cat ggt cca gga ttg 452  
 Ser Asp Asn Ser Gly Arg His Gln Gly Ser Glu His Gly Pro Gly Leu  
 105 110 115

45

agg cta agt agc gac cag ctg act ctc tac tgc aca ctg ggg gtc tgc 500  
 Arg Leu Ser Ser Asp Gln Leu Thr Leu Tyr Cys Thr Leu Gly Val Cys  
 120 125 130

50

ctc tgc gcc atc ttc tgc tgt ttc ttg gtg gcc ttg gcc tcc ttc ctc 548  
 Leu Cys Ala Ile Phe Cys Cys Phe Leu Val Ala Leu Ala Ser Phe Leu  
 135 140 145

55

5	agg cgt aga gga gag cca cta ccc agc cag cct gcc ggg cca cgt ggg Arg Arg Arg Gly Glu Pro Leu Pro Ser Gln Pro Ala Gly Pro Arg Gly 150 155 160 165	596
10	tca caa gca aac tct ccc cac gcc cae cgc ccc gtg aca gag gct tgc Ser Gln Ala Asn Ser Pro His Ala His Arg Pro Val Thr Glu Ala Cys 170 175 180	644
15	gac gag gtg acc gcg tca ccc cag cct gtg gaa acg tgt agc ttc tgc Asp Glu Val Thr Ala Ser Pro Gln Pro Val Glu Thr Cys Ser Phe Cys 185 190 195	692
20	ttc ccg gag cgc agt tct ccc act cag gag agc gcg ccg cgt tcg ctc Phe Pro Glu Arg Ser Ser Pro Thr Gln Glu Ser Ala Pro Arg Ser Leu 200 205 210	740
25	ggg ata cac ggc ttc gcg ggc act gcc gcc ccg cag ccc tgt atg cgt Gly Ile His Gly Phe Ala Gly Thr Ala Ala Pro Gln Pro Cys Met Arg 215 220 225	788
30	gca aca gta ggc ggc ctg ggt gtc ctg cgc gca tcc act ggg gac gct Ala Thr Val Gly Gly Leu Gly Val Leu Arg Ala Ser Thr Gly Asp Ala 230 235 240 245	836
35	cgt ccg gca act tgacagcccg aaaaataaaa aagacaattt agaggatgga Arg Pro Ala Thr	888
40	gtgacagagg gggaaaggga tggagaagag acagatgaag acacgataaa ggaagcccgg ctgcacccac gcagagcaac aaagcaacca cctgcagcgc ccacgttccc agcaccgcct gtgcctgccg ctgtgtccta tactttccag agcagtcac ctgtgccitt tttctttagt cgagaaagat ggagaatgac cggcacctag cattaccctt acaattctta caaacaagtg gtctttccta tggccttagg cagatagctg agtgcagtgt ggatgtattt gtgatttaag taacttgtat gtgtatgtgc agattcgggg ttatgtcata tgtgcatgta tacgtgagtt gtgtgtctgt atgagttgtg tgtatatgtg cgcctataaa tatgtgtgtg aattctgtgc atgcagatgt gtgtgtacat atgtgtctgg ctgatgtggt atagccagaa agatgagggc ccttctaggt gaaggccaaa catctaaaaa ccatctaggt gatgggtgct cgtgccgaat tc	948 1008 1068 1128 1188 1248 1308 1368 1428 1430
45		

<210> 20  
<211> 249  
<212> PRT  
<213> Mus musculus

<400> 20

5 Met Ala Met Ala Phe Cys Pro Lys Asp Gln Tyr Trp Asp Ser Ser Arg  
 1 5 10 15  
 Lys Ser Cys Val Ser Cys Ala Leu Thr Cys Ser Gln Arg Ser Gln Arg  
 20 25 30  
 Thr Cys Thr Asp Phe Cys Lys Phe Ile Asn Cys Arg Lys Glu Gln Gly  
 35 40 45  
 10 Arg Tyr Tyr Asp His Leu Leu Gly Ala Cys Val Ser Cys Asp Ser Thr  
 50 55 60  
 Cys Thr Gln His Pro Gln Gln Cys Ala His Phe Cys Glu Lys Arg Pro  
 65 70 75 80  
 15 Arg Ser Gln Ala Asn Leu Gln Pro Glu Leu Gly Arg Pro Gln Ala Gly  
 85 90 95  
 Glu Val Glu Val Arg Ser Asp Asn Ser Gly Arg His Gln Gly Ser Glu  
 100 105 110  
 20 His Gly Pro Gly Leu Arg Leu Ser Asp Gln Leu Thr Leu Tyr Cys  
 115 120 125  
 Thr Leu Gly Val Cys Leu Cys Ala Ile Phe Cys Cys Phe Leu Val Ala  
 130 135 140  
 25 Leu Ala Ser Phe Leu Arg Arg Arg Gly Glu Pro Leu Pro Ser Gln Pro  
 145 150 155 160  
 Ala Gly Pro Arg Gly Ser Gln Ala Asn Ser Pro His Ala His Arg Pro  
 165 170 175  
 Val Thr Glu Ala Cys Asp Glu Val Thr Ala Ser Pro Gln Pro Val Glu  
 180 185 190  
 30 Thr Cys Ser Phe Cys Phe Pro Glu Arg Ser Ser Pro Thr Gln Glu Ser  
 195 200 205  
 Ala Pro Arg Ser Leu Gly Ile His Gly Phe Ala Gly Thr Ala Ala Pro  
 210 215 220  
 35 Gln Pro Cys Met Arg Ala Thr Val Gly Gly Leu Gly Val Leu Arg Ala  
 225 230 235 240  
 Ser Thr Gly Asp Ala Arg Pro Ala Thr  
 245

40 <210> 21

<211> 473

<212> DNA

<213> Artificial Sequence

45 <220>

<223> Northern Blot Probe

50 <400> 21

ctgtggacgg gggtagctat gagatcctgc cccgaagagc agtactggga tcctctgctg	60
ggtagctgca tgcctgcaa aaccatttgc aaccatcaga gccagcgac ctgtgcagcc	120
ttctgcaggt cactcagctg ccgcaaggag caaggcaagt tctatgacca tctcctgagg	180

gactgcatca gctgtgcctc catctgtgga cagcacccta agcaatgtgc atacttctgt 240  
 gagaacaagc tcaggagccc agtgaacctt ccaccagagc tcaggagaca gcggagtgga 300  
 5 gaagttagaa acaattcaga caactcggga aggtaccaag gattggagca cagaggctca 360  
 gaagcaagtc cagctctccc ggggctgaag ctgagtgcag atcaggtggc cctgggtctac 420  
 agcacgctgg ggcctgcct gtgtgccgtc ctctgctgct tcctggtggc ggt 473

10 <210> 22  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

15 <220>  
 <223> ZC20061

20 <400> 22  
 ctgtggacag ggggtggctat gagat 25

25 <210> 23  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <223> Oligonucleotide ZC20062

35 <400> 23  
 accgccacca ggaagcacag aggac 25

40 <210> 24  
 <211> 256  
 <212> DNA  
 <213> Artificial Sequence

45 <220>  
 <223> Northern Blot probe

50 <400> 24  
 tgcgattctc tggacctgtt tgggactgag cttataaatt tctttggcag ttttcgtgct 60  
 aatgtttttg ctaaggaaga taagctctga accattaaag gacgagttta aaaacacagg 120  
 atcaggtctc ctgggcatgg ctaacattga cctggaaaag agcaggactg gtgatgaaat 180  
 tattcttccg agaggcctcg agtacacggt ggaagaatgc acctgtgaag actgcatcaa 240  
 gagcaaaccg aaggtc 256

55 <210> 25  
 <211> 22



<212> DNA  
 <213> Artificial Sequence

5

<220>  
 <223> Oligonucleotide ZC21065

10

<400> 25  
 tgcgattctc tggacctgtt tg 22

<210> 26  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

15

<220>  
 <223> Oligonucleotide ZC21067

20

<400> 26  
 gaccttcggt ttgctcttga tg 22

25

<210> 27  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

30

<220>  
 <223> Oligonucleotide ZC24200

35

<400> 27  
 acactggggg tctgcctctg 20

<210> 28  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

40

<220>  
 <223> Oligonucleotide ZC24201

45

<400> 28  
 gcgaagccgt gtatccc 17

50

<210> 29  
 <211> 17  
 <212> DNA

55

<213> Artificial Sequence

5

<220>

<223> Oligonucleotide ZC24198

<400> 29

10

tctacagcac gctgggg

17

<210> 30

<211> 16

<212> DNA

15

<213> Artificial Sequence

<220>

<223> Oligonucleotide ZC24199

20

<400> 30

gcacaagtgg ggtcgg

16

<210> 31

25

<211> 19

<212> DNA

<213> Artificial Sequence

30

<220>

<223> Oligonucleotide ZC24271

<400> 31

35

ttattgtaat gcaagtgtg

19

<210> 32

<211> 17

<212> DNA

40

<213> Artificial Sequence

<220>

<223> Oligonucleotide ZC24272

45

<400> 32

tagctgggag tggaag

17

<210> 33

50

<211> 20

<212> DNA

<213> Artificial Sequence

55

<223> Oligonucleotide ZC24495

tccaagcgtg accagttcag

20

**<211> 18**

<212> DNA

### <213> Artificial Sequence

<223> Oligonucleotide ZC24496

agttggcttc tccatccc

18

<211> 1090

<212> DNA

<213> Homo sapiens

taactctcct	gaggggtgag	ccaagccctg	ccatgtagtg	cacgcaggac	atcaacaaac	60
acagataaca	ggaatgatc	cattccctgt	ggctacttat	tctaaaggcc	ccaaccttca	120
aagttcaagt	agtgatatgg	atgactccac	agaaagggag	cagtcacgcc	ttacttcttg	180
ccttaagaaa	agagaagaaa	tgaaactgaa	ggagtgtgtt	tccatcctcc	cacggaagga	240
aagccctct	gtccgatcct	ccaaagacgg	aaagctgctg	gctgcaacct	tgctgctggc	300
actgtgtct	tgtgcctca	cggtggtgtc	tttctaccag	gtggccgccc	tgcaagggga	360
cctggccagc	ctccgggcag	agctgcaggg	ccaccacgcg	gagaagctgc	cagcaggagc	420
aggagcccc	aaggccggcc	tggaggaagc	tccagctgtc	accgcgggac	tgaaaatctt	480
tgaaccacca	gctccaggag	aaggcaactc	cagtcagaac	agcagaaata	agcgtgccgt	540
tcagggtcca	gaagaaacag	tactcaaga	ctgcttgcaa	ctgattgcag	acagtgaaac	600
accaactata	caaaaaggat	cttacacatt	tgttccatgg	cttctcagct	ttaaaagggg	660
aagtgccta	gaagaaaaag	agaataaaat	attgggtcaa	gaaactggtt	acttttttat	720
atatggtcag	gttttatata	ctgataagac	ctacgcatg	ggacatctaa	ttcagaggaa	780
gaaggcccat	gtctttgggg	atgaattgag	tctggtgact	ttgtttcgat	gtattcaaaa	840
tatgcctgaa	acactacca	ataattcctg	ctattcagct	ggcattgcaa	aactggaaga	900
aggagatgaa	ctccaacttg	caataccaag	agaaaatgca	caaatatcac	tggatggaga	960
tgtcacattt	tttggtgcat	tgaactgct	gtgacctact	tacaccatgt	ctgtagctat	1020
tttctcctct	ttctctgtac	ctctaagaag	aaagaatcta	actgaaaata	ccaaaaaaa	1080
aaaaaaaaaa						1090

**<210> 36**

5           <211> 35  
           <212> DNA  
           <213> Artificial Sequence  
  
           <220>  
           <223> Oligonucleotide  
 10           <400> 36  
           cgcgcggttt aaacgccacc atggatgact ccaca                               35  
  
 15           <210> 37  
           <211> 32  
           <212> DNA  
           <213> Artificial Sequence  
  
 20           <220>  
           <223> Oligonucleotide  
  
           <400> 37  
 25           gtatacggcg cgcctcacag cagtttcaat gc                               32  
  
           <210> 38  
           <211> 25  
           <212> DNA  
 30           <213> Artificial Sequence  
  
           <220>  
           <223> Oligonucleotide ZC17251  
 35           <400> 38  
           tctggacgtc ctctgctgg tatag                                       25  
  
 40           <210> 39  
           <211> 25  
           <212> DNA  
           <213> Artificial Sequence  
  
 45           <220>  
           <223> Oligonucleotide ZC17252  
  
           <400> 39  
 50           ggtatggagc aaggggcaag ttggg                                       25  
  
           <210> 40  
           <211> 27  
 55

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide ZC17156

&lt;400&gt; 40

gagtggcaac ttccagggcc aggagag

27

&lt;210&gt; 41

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide ZC17157

&lt;400&gt; 41

cttttgctag cctcaaccct gactatc

27

&lt;210&gt; 42

&lt;211&gt; 813

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

ggcacagcac	ggggcgatgg	gcgcgtttcg	ggccctgtgc	ggcctggcgc	tgtgtgcgc	60
gctcagcctg	ggtcagcgcc	ccaccggggg	tcccggtgc	ggccctgggc	gcctcctgct	120
tgggacggga	acggacgcgc	gctgctgccg	ggttcacacg	acgcgtgct	gccgcgatta	180
cccgggcgag	gagtgtgtt	ccgagtggga	ctgcatgtgt	gtccagcctg	aattccactg	240
cggagaccct	tgtgcacga	cctgccggca	ccacccttgt	ccccaggcc	agggggtaca	300
gtcccagggg	aaattcagtt	ttggcttcca	gtgtatcgac	tgtgcctcgg	ggaccttctc	360
cggggggcac	gaaggccact	gcaaaccctg	gacagactgc	acccagttcg	ggtttctcac	420
tgtgttccct	gggaacaaga	cccacaacgc	tgtgtgcgtc	ccagggtccc	cgccggcaga	480
gccgcttggg	tggctgaccg	tcgtcctcct	ggccgtggcc	gcctgcgtcc	tcctcctgac	540
ctcggcccag	cttgactgc	acatctggca	gctgaggagt	cagtgcattg	ggccccgaga	600
gaccagctg	ctgctggagg	tgccgccgct	gaccgaagac	gccagaagct	gccagttccc	660
cgagggaagag	cggggcgagc	gatcggcaga	ggagaagggg	cggctgggag	acctgtgggt	720
gtgagcctgg	ctgtcctccg	gggccaccga	ccgcagccag	cccctcccca	ggagctcccc	780
aggccgcagg	gctctgcgtt	ctgctctggg	ccg			813

&lt;210&gt; 43

&lt;211&gt; 44

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

5           <220>  
           <223> Oligonucleotide ZC10.134  
  
           <400> 43  
 atcagcggaa ttcagatctt cagacaaaac tcacacatgc ccac           44  
 10  
           <210> 44  
           <211> 35  
           <212> DNA  
           <213> Artificial Sequence  
 15  
           <220>  
           <223> Oligonucleotide ZC10135  
  
 20           <400> 44  
 ggagctctct agatcattta cccggagaca gggag           35  
  
           <210> 45  
           <211> 768  
 25           <212> DNA  
           <213> Homo sapiens  
  
           <220>  
 30  
           <221> CDS  
           <222> (7)...(759)  
           <223> Ig Fc sequence  
 35  
           <400> 45  
 ggatcc atg aag cac ctg tgg ttc ttc ctc ctg ctg gtg gcg gct ccc           48  
           Met Lys His Leu Trp Phe Phe Leu Leu Val Ala Ala Pro  
           1                   5                   10  
 40  
 aga tgg gtc ctg tcc gag ccc aga tct tca gac aaa act cac aca tgc           96  
 Arg Trp Val Leu Ser Glu Pro Arg Ser Ser Asp Lys Thr His Thr Cys  
           15                   20                   25                   30  
 45  
 cca ccg tgc cca gca cct gaa gcc gag ggg gca ccg tca gtc ttc ctc           144  
 Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu  
           35                   40                   45  
 50  
 ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag           192  
 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu  
           50                   55                   60  
 55

5	gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 65 70 75	240
10	ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 80 85 90	288
15	ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 95 100 105 110	336
20	acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 115 120 125	384
25	gtc tcc aac aaa gcc ctc cca tcc tcc atc gag aaa acc atc tcc aaa Val Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys 130 135 140	432
30	gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 145 150 155	480
35	cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 160 165 170	528
40	ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 175 180 185 190	576
45	ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 195 200 205	624
50	tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 210 215 220	672
55	cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 225 230 235	720

5      cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa taatctaga      768  
       His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
       240                      245                      250

10      <210> 46  
       <211> 52  
       <212> DNA  
       <213> Artificial Sequence

15      <220>  
       <223> Oligonucleotide ZC15345

20      <400> 46  
       ccgtgcccag cacctgaagc cgagggggcā ccgtcagtct tcctcttccc cc      52

25      <210> 47  
       <211> 31  
       <212> DNA  
       <213> Artificial Sequence

30      <220>  
       <223> Oligonucleotide ZC15347

35      <400> 47  
       ggattctaga ttttataccc ggagacaggg a      31

40      <210> 48  
       <211> 55  
       <212> DNA  
       <213> Artificial Sequence

45      <220>  
       <223> Oligonucleotide ZC15517

50      <400> 48  
       ggtggcggct cccagatggg tcctgtccga gccagatct tcagacaaaa ctcac      55

55      <210> 49  
       <211> 18  
       <212> DNA  
       <213> Artificial Sequence

      <220>  
       <223> Oligonucleotide ZC15530



<sup>5</sup> <400> 49  
tgggaaggct ttgttga 18

10           <210> 50  
              <211> 42  
              <212> DNA  
              <213> Artificial Sequence

15                   <220>  
                  <223> Oligonucleotide ZC15518

<400> 50  
 tccaacaaag ccctcccatc ctccatcgag aaaaccatct cc 42

20

<210>	51
<211>	57
<212>	DNA
<213>	Artificial Sequence

<220>  
<223> Oligonucleotide ZC15516

30                   <400> 51  
                  ggatggatcc atgaagcacc tgtggttctt cctcctgctg gtggcggctc ccagatg                   57

35           <210> 52  
              <211> 59  
              <212> DNA  
              <213> Artificial Sequence

<220>  
<223> oligonucleotide primer

<400> 52  
ctcagccagg aaatccatgc cgagttgaga cgcttccgta gaatgagtgg cctgggccg 59

45           <210> 53  
            <211> 48  
            <212> DNA  
            <213> Artificial Sequence

<220>  
<223> Oligonucleotide primer

5           <400> 53  
 gcatgtgtga gttttgtctg aagatctggg ctcttcagc cccgggag           48

10           <210> 54  
           <211> 59  
           <212> DNA  
           <213> Artificial Sequence

15           <220>  
           <223> Oligonucleotide primer

20           <400> 54  
 ctacagccagg aaatccatgc cgagttgaga cgcttcgta gaatgagtgg cctgggccg           59

25           <210> 55  
           <211> 59  
           <212> DNA  
           <213> Artificial Sequence

30           <220>  
           <223> Oligonucleotide primer

35           <400> 55  
 gcacggtggg catgtgtgag ttttgtctga agatctgggc tccttcagcc cccgggagag           59

40           <210> 56  
           <211> 60  
           <212> DNA  
           <213> Artificial Sequence

45           <220>  
           <223> Oligonucleotide primer

50           <400> 56  
 gcacagaggc tcagaagcaa gtccagctct cccggggctg aaggagccca gatcttcaga           60

55           <210> 57  
           <211> 56  
           <212> DNA  
           <213> Artificial Sequence

60           <220>  
           <223> Oligonucleotide primer

65           <400> 57

ggggtgggta caaccccaga gctgttttaa tctagattat ttacccggag acaggg 56

5 <210> 58  
 <211> 59  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <223> Oligonucleotide primer

15 <400> 58  
 ctaacatgtc agcgttattg taatgcaagt gtgaccaatt cagagcccag atcttcaga 59

<210> 59  
 <211> 20  
 20 <212> PRT  
 <213> Artificial Sequence

<220>  
 25 <223> Antibody peptide

<400> 59  
 Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly Pro Glu Leu Gln Leu Ala  
 1 5 10 15  
 30 Ile Pro Arg Glu  
 20

<210> 60  
 35 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 40 <223> Antibody peptide

<400> 60  
 Ser Phe Lys Arg Gly Ser Ala Leu Glu Glu Lys Glu Asn Lys Glu Leu  
 1 5 10 15  
 45 Val Lys Glu Thr  
 20

50

55

## Claims

## 1. Use of a compound selected from the group consisting of:

- a) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BR43x2 (SEQ ID NO:2);
- b) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of TACI;
- c) a polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BCMA;
- d) a polypeptide comprising a sequence substantially homologous to or an ortholog of SEQ ID NO:10;
- e) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:2;
- f) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:4;
- g) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:6;
- h) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:8;
- i) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:10;
- j) a polypeptide comprising a sequence substantially homologous to or an ortholog of SEQ ID NO:4;
- k) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-166 of SEQ ID NO:6;
- l) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 8-37 of SEQ ID NO:8;
- m) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-48 of SEQ ID NO:8;

in the manufacture of a medicament for inhibiting ztnf4 activity in a mammal.

## 2. Use of a compound selected from the group consisting of:

- a) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BR43x2 (SEQ ID NO:2);
- b) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of TACI;
- c) a polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BCMA;
- d) a polypeptide comprising a sequence substantially homologous to or an ortholog of SEQ ID NO:10;
- e) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:2;
- f) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:4;
- g) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:6;
- h) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:8;
- i) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:10;
- j) a polypeptide comprising a sequence substantially homologous to or an ortholog of SEQ ID NO:4;
- k) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-166 of SEQ ID NO:6;
- l) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 8-37 of SEQ ID NO:8;
- m) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-48 of SEQ ID NO:8;

in the manufacture of a medicament for the treatment of an autoimmune disease.

3. Use according to claims 1 and 2, wherein said compound is pegylated.

4. Use of a compound selected from the group consisting of:

- a) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BR43x2 (SEQ ID NO:2);
- b) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of TACI;
- c) a polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BCMA;
- d) a polypeptide comprising a sequence substantially homologous to or an ortholog of SEQ ID NO:10;
- e) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:2;
- f) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:4;
- g) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:6;
- h) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:8;
- i) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:10;
- j) a polypeptide comprising a sequence substantially homologous to or an ortholog of SEQ ID NO:4;
- k) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-166 of SEQ ID NO:6;
- l) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 8-37 of SEQ ID NO:8;
- m) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-48 of SEQ ID NO:8;

in the manufacture of a medicament for inhibiting BR43x2, TACI or BCMA receptor-ztnf4 engagement.

5. Use according to claims 1-4, wherein said compound is a fusion protein consisting of a first portion and a second portion joined by a peptide bond, said first portion comprising a polypeptide selected from the group consisting of:

- a) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BR43x2 (SEQ ID NO:2);
- b) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of TACI;
- c) a polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BCMA;
- d) a polypeptide comprising a sequence substantially homologous to or an ortholog of SEQ ID NO:10;
- e) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:2;
- f) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:4;
- g) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:6;
- h) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:8;
- i) an antibody or antibody fragment which specifically binds to a sequence substantially homologous to or an ortholog of SEQ ID NO:10;
- j) a polypeptide comprising a sequence substantially homologous to or an ortholog of SEQ ID NO:4;
- k) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-166 of SEQ ID NO:6;
- l) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 8-37 of SEQ ID NO:8;

m) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-48 of SEQ ID NO:8;

said second portion comprising another polypeptide.

6. Use according to claim 5, wherein said first portion further comprises a polypeptide selected from the group consisting of:

- a) a sequence substantially homologous to or an ortholog of amino acid residues 59-120 of SEQ ID NO:2;
- b) a sequence substantially homologous to or an ortholog of amino acid residues 105-166 of SEQ ID NO:6; and
- c) a sequence substantially homologous to or an ortholog of amino acid residues 89-150 of SEQ ID NO:8.

7. Use according to claim 5, wherein said first portion is selected from the group consisting of:

- a) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BR43x2 (SEQ ID NO:2);
- b) a soluble polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of TAC1; and
- c) a polypeptide comprising a sequence substantially homologous to or an ortholog of the extracellular domain of BCMA.

8. Use according to claim 5, wherein said first portion is selected from the group consisting of:

- a) a polypeptide comprising a sequence substantially homologous to or an ortholog of SEQ ID NO:4;
- b) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-154 of SEQ ID NO:6;
- c) a polypeptide comprising a sequence substantially homologous to or an ortholog of amino acid residues 1-48 of SEQ ID NO:8.

9. Use according to claims 5 to 8 wherein said second portion is an immunoglobulin heavy chain constant region.

10. Use according to claim 9, wherein said immunoglobulin heavy chain constant region is a human immunoglobulin heavy chain constant region of IgG1.

11. Use according to claim 10, wherein said medicament comprises an immunoglobulin heavy chain constant region which contains two constant region domains and lacks the variable region.

12. Use according to claims 5 to 11 wherein either said first portion, said second portion, or both portions of said fusion protein are pegylated.

13. Use according to claims 1 to 12 wherein the medicament is for treatment of B lymphocytes or T lymphocytes.

14. Use according to claim 13 wherein the said B lymphocytes are activated B lymphocytes.

15. Use according to claim 13 wherein the said B lymphocytes are resting lymphocytes.

16. Use according to claims 2-15 wherein said autoimmune disease is systemic lupus erythematosus, myasthenia gravis, multiple sclerosis, or rheumatoid arthritis.

17. Use according to claims 1 to 15 wherein the medicament is for treatment of systemic lupus erythematosus.

18. Use according to claims 1 to 15 wherein the medicament is for treatment of asthma, bronchitis, emphysema, and end stage renal failure.

19. Use according to claim 18 wherein said end stage renal failure is due to glomerulonephritis, vasculitis, nephritis, or pyelonephritis.

20. Use according to claims 1 to 15 wherein the medicament is for the treatment of renal neoplasms, multiple myelo-

mas, lymphomas, light chain therapy, or amyloidosis.

**21.** Use according to claims 1 to 15 wherein the medicament is for inhibiting effector T cells.

5 **22.** Use according to claim 21 wherein the medicament is for inhibiting immune response.

**23.** Use according to claim 22, wherein said inhibition further comprises immunosuppression.

10 **24.** Use according to claim 23, wherein said immunosuppressant is to treat graft rejection, graft versus host disease, autoimmune disease, or inflammation.

**25.** Use according to claims 2-15 wherein said autoimmune disease is insulin dependent diabetes mellitus or Crohn's disease.

15 **26.** Use according to claims 1 to 25 wherein said medicament is for the treatment of inflammation.

**27.** Use according to claim 26, wherein said inflammation is associated with joint pain, swelling anemia, or septic shock.

20

25

30

35

40

45

50

55

TacI	-----	-----	-----	-----	MSG LGRSRRG
BR43X1	-----	-----	-----	-----	----GRSRRG
BR43X2	-----	-----	-----	-----	MSG LGRSRRG
BCMA	-----	-----	-----	-----	-----

TacI	GRSRVDQEER	FPQGLWTGVA	MRSCPEEQYW	DPLL-GTCMS	CTICNHQSQ
BR43X1	GRSRVDQEER	FPQGLWTGVA	MRSCPEEQYW	DPLL-GTCMS	CTICNHQSQ
BR43X2	GRSRVDQEER	-----	-----	-----	-----
BCMA	-----	-----MLQM	AGQCSQNEYF	DSLL-HACIP	CQLRCSSNTP
			<--- 1st cys repeat	-----	

TacI	-RTCAAFCRS	L-----SC	RKEQGKFYDH	LL-RD-CISC	ASICGQHPKQ
BR43X1	-RTCAAFCRS	L-----SC	RKEQGKFYDH	LL-RD-CISC	ASICGQHPKQ
BR43X2	-----WS	L-----SC	RKEQGKFYDH	LL-RD-CISC	ASICGQHPKQ
BCMA	PLTCQRYCNA	SVTNSVKGTN	AILWTCGLGS	LIISLAVFVL	MFLLRKISSE
	----->		<----- 2nd cys repeat	-----	

TacI	CAYFCENKLR	SPVNLPELR	RQRSGEVENN	SDNSGRYQGL	EHRGSEASPA
BR43X1	CAYFCENKLR	SPVNLPELR	RQRSGEVENN	SDNSGRYQGL	EHRGSEASPA
BR43X2	CAYFCENKLR	SPVNLPELR	RQRSGEVENN	SDNSGRYQGL	EHRGSEASPA
BCMA	PLKDEFKNTG	SGLLGMANID	LEKSRTGDEI	ILPRGLETV	EECTCEDCIK
	----->				

TacI	LPGLKLSADQ	VALVYSTLGL	CLCAVLCCFL	VAVACFLKKR	GDPSCSQPRS
BR43X1	LPGLKLSADQ	VALVYSTLGL	CLCAVLCCFL	VAVACFLKKR	GDPSCSQPRS
BR43X2	LPGLKLSADQ	VALVYSTLGL	CLCAVLCCFL	VAVACFLKKR	GDPSCSQPRS
BCMA	SKPKVSDHC	FPLPAMEEGA	TILVTTKTND	YCKSLPAALS	ATEIEKSISA
			<--- TACI/BR43 TM	----->	

TacI	RPRQSPAKSS	QDHAMEAGSP	VSTSPEPVET	CSFCFPECRA	PTQESAVTPG
BR43X1	RPRQSPAKSS	QDHAMEAGSP	VSTSPEPVET	CSFCFPECRA	PTQESAVTPG
BR43X2	RPRQSPAKSS	QDHAMEAGSP	VSTSPEPVET	CSFCFPECRA	PTQESAVTPG
BCMA	R-----	-----	-----	-----	-----

TacI	TPDPTCAGRW	GCHTRTTVLQ	PCPHIPDSGL	GIVCVPAQEG	GPGA-----
BR43X1	TPDPTCAGRW	GCHTRTTVLQ	PCPHIPDSGL	GIVCVPAQEG	GPGA-----
BR43X2	TPDPTCAGRW	GCHTRTTVLQ	PCPHIPDSGL	GIVCVPAQEG	GPGA-----
BCMA	-----	-----	-----	-----	-----

FIGURE 1






Figure 2





Figure 3A






Figure 4




Figure 5A




Figure 5B





Figure 5C



**Figure 5E**



# NZBWF1







Figure 6A



**Figure 5A**




Figure 7




Figure 8



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 03 01 6020

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X,D	WO 98 39361 A (ST. JUDE CHILDREN'S RESEARCH HOSPITAL) 11 September 1998 (1998-09-11) * the whole document *	1-27	C12N15/11 C07K14/705 A61K38/17 A61K39/395
X,D	G-U VON BÜLOW AND R J BRAM: "NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily" SCIENCE., vol. 278, 3 October 1997 (1997-10-03), pages 138-141, XP002140938 AAAS. LANCASTER, PA., US * the whole document *	1-27	
A,D	WO 98 18921 A (HUMAN GENOME SCIENCES) 7 May 1998 (1998-05-07) * the whole document *	1-27	
A	EP 0 869 180 A (SMITH KLINE BEECHAM CORPORATION) 7 October 1998 (1998-10-07) * the whole document *	1-27	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
T	J A GROSS ET AL.: "TACI and BCMA are receptors for a TNF homologue implicated in 8-cell autoimmune disease" NATURE., vol. 404, 27 April 2000 (2000-04-27), pages 995-999, XP002140939 MACMILLAN JOURNALS LTD. LONDON., GB ISSN: 0028-0836 * the whole document *	1-27	C12N C07K A61K
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>29 September 2003</b>	Examiner <b>Masturzo, P</b>
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 02 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 01 6020

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-09-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9839361 A	11-09-1998	US 5969102 A	19-10-1999
		AU 732119 B2	12-04-2001
		AU 6685498 A	22-09-1998
		EP 0964874 A1	22-12-1999
		JP 2001518080 T	09-10-2001
		WO 9839361 A1	11-09-1998
		US 6316222 B1	13-11-2001
		US 2003082173 A1	01-05-2003
		US 6500428 B1	31-12-2002
WO 9818921 A	07-05-1998	WO 9818921 A1	07-05-1998
		AU 731553 B2	05-04-2001
		AU 7674596 A	22-05-1998
		BR 9612752 A	18-01-2000
		EP 0939804 A1	08-09-1999
		JP 2001503263 T	13-03-2001
		KR 2000052796 A	25-08-2000
		NZ 334309 A	25-08-2000
		US 6562579 B1	13-05-2003
EP 869180 A	07-10-1998	US 6403770 B1	11-06-2002
		CA 2232743 A1	02-10-1998
		EP 0869180 A1	07-10-1998
		JP 10323194 A	08-12-1998
		JP 2000060580 A	29-02-2000

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**